Form 10-Q

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

0001193125-17-339757.txt : 20171113 0001193125-17-339757.hdr.sgml : 20171113 20171113062555 ACCESSION NUMBER: 0001193125-17-339757 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 60 CONFORMED PERIOD OF REPORT: 20170930 FILED AS OF DATE: 20171113 DATE AS OF CHANGE: 20171113 FILER: COMPANY DATA: COMPANY CONFORMED NAME: InfuSystem Holdings, Inc CENTRAL INDEX KEY: 0001337013 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 203341405 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-35020 FILM NUMBER: 171192853 BUSINESS ADDRESS: STREET 1: 31700 RESEARCH PARK DRIVE CITY: MADISON HEIGHTS STATE: MI ZIP: 48071 BUSINESS PHONE: (248) 291-1210 MAIL ADDRESS: STREET 1: 31700 RESEARCH PARK DRIVE CITY: MADISON HEIGHTS STATE: MI ZIP: 48071 FORMER COMPANY: FORMER CONFORMED NAME: HAPC, Inc. DATE OF NAME CHANGE: 20060425 FORMER COMPANY: FORMER CONFORMED NAME: Healthcare Acquisition Partners Corp. DATE OF NAME CHANGE: 20050824 10-Q 1 d486354d10q.htm FORM 10-Q Form 10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

☒	Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

for the quarterly period ended September 30, 2017

☐	Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

for the transition period from to

Commission File Number: 001-35020

LOGO

INFUSYSTEM HOLDINGS, INC.

(Exact name of registrant as specified in its charter)


Delaware		20-3341405
(State or Other Jurisdiction of Incorporation or Organization)		(I.R.S. Employer Identification No.)

31700 Research Park Drive

Madison Heights, Michigan 48071

(Address of Principal Executive Offices)

(248) 291-1210

(Registrant’s Telephone Number, including Area Code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act during the past 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Securities Exchange Act.

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Securities Exchange Act). Yes ☐ No ☒

As of November 6, 2017, 22,780,738 shares of the registrant’s common stock, par value $0.0001 per share, were outstanding.

INFUSYSTEM HOLDINGS, INC. AND SUBSIDIARIES

Index to Form 10-Q


		PAGE
PART I - FINANCIAL INFORMATION

Item 1.	Financial Statements		3

	-Condensed Consolidated Balance Sheets as of September 30, 2017 (Unaudited) and December 31, 2016		3

	-Unaudited Condensed Consolidated Statements of Operations for the three and nine months ended September 30, 2017 and 2016		4

	-Unaudited Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2017 and 2016		5

	-Notes to the Unaudited Condensed Consolidated Financial Statements		6

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations		16

Item 3.	Quantitative and Qualitative Disclosures About Market Risk		23

Item 4.	Controls and Procedures		23

PART II - OTHER INFORMATION

Item 1.	Legal Proceedings		23

Item 1A.	Risk Factors		23

Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds		23

Item 3.	Defaults Upon Senior Securities		24

Item 4.	Mine Safety Disclosures		24

Item 5.	Other Information		24

Item 6.	Exhibits		25

	Signatures		26

Item 1.

Financial Statements

INFUSYSTEM HOLDINGS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS


	As of
	September 30,			December 31,
*(in thousands, except share data)*	2017			2016
	(Unaudited)
ASSETS
Current Assets:
Cash and cash equivalents	$	803		$	3,398
Accounts receivable, less allowance for doubtful accounts of $6,847 and $4,989 at September 30, 2017 and December 31, 2016, respectively		10,971			11,581
Inventory		1,873			2,166
Other current assets		1,121			949
Deferred income taxes		—			2,675

Total Current Assets		14,768			20,769
Medical equipment held for sale or rental		1,200			1,642
Medical equipment in rental service, net of accumulated depreciation		24,301			28,036
Property & equipment, net of accumulated depreciation		1,711			1,997
Intangible assets, net		26,951			31,239
Deferred income taxes		16,334			12,436
Other assets		70			225

Total Assets	$	85,335		$	96,344

LIABILITIES AND STOCKHOLDERS’ EQUITY
Current Liabilities:
Accounts payable	$	4,093		$	5,315
Capital leases		584			2,938
Current portion of long-term debt		2,849			5,314
Other current liabilities		2,427			2,872

Total Current Liabilities		9,953			16,439
Long-term debt, net of current portion		26,535			26,577
Capital leases		101			2,573
Other long-term liabilities		—			66

Total Long-Term Liabilities		26,636			29,216
Total Liabilities	$	36,589		$	45,655

Stockholders’ Equity:
Preferred stock, $.0001 par value: authorized 1,000,000 shares; none issued		—			—
Common stock, $.0001 par value: authorized 200,000,000 shares; issued and outstanding 22,978,398 and 22,780,738, respectively, as of September 30, 2017 and 22,867,335 and 22,669,675, respectively, as of December 31, 2016		2			2
Additional paid-in capital		92,383			91,829
Retained deficit		(43,639	)		(41,142	)

Total Stockholders’ Equity		48,746			50,689

Total Liabilities and Stockholders’ Equity	$	85,335		$	96,344

See accompanying notes to unaudited condensed consolidated financial statements.

INFUSYSTEM HOLDINGS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(UNAUDITED)


*(in thousands, except share and per share data)*	Three Months Ended September 30						Nine Months Ended September 30
	2017			2016			2017			2016
Net revenues:
Rentals	$	15,322		$	14,640		$	45,228		$	47,370
Product Sales		2,266			2,586			6,956			6,273

Net revenues		17,588			17,226			52,184			53,643
Cost of revenues:
Cost of revenues — Product, service and supply costs		4,452			4,018			13,612			12,313
Cost of revenues — Pump depreciation and disposals		2,095			2,819			6,541			7,241

Gross profit		11,041			10,389			32,031			34,089

Selling, general and administrative expenses:
Provision for doubtful accounts		1,274			1,098			4,456			3,912
Amortization of intangibles		1,384			958			4,182			2,792
Selling and marketing		2,262			2,490			7,443			7,629
General and administrative		5,561			5,267			18,451			18,328

Total selling, general and administrative		10,481			9,813			34,532			32,661

Operating income (loss)		560			576			(2,501	)		1,428
Other (expense) income:
Interest expense		(354	)		(384	)		(1,015	)		(1,016	)
Other (expense) income		(8	)		(6	)		(111	)		21

Total other expense		(362	)		(390	)		(1,126	)		(995	)
Income (loss) before income taxes		198			186			(3,627	)		433
Income tax (expense) benefit		(327	)		(130	)		914			(183	)

Net (loss) income	$	(129	)	$	56		$	(2,713	)	$	250

Net (loss) income per share:
Basic	$	(0.01	)	$	0.00		$	(0.12	)	$	0.01
Diluted	$	(0.01	)	$	0.00		$	(0.12	)	$	0.01
Weighted average shares outstanding:
Basic		22,755,976			22,620,386			22,725,806			22,614,203
Diluted		22,755,976			22,995,643			22,725,806			23,059,794

See accompanying notes to unaudited condensed consolidated financial statements.

INFUSYSTEM HOLDINGS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)


	Nine Months Ended September 30
*(in thousands)*	2017			2016
NET CASH PROVIDED BY OPERATING ACTIVITIES	$	4,102		$	3,735

INVESTING ACTIVITIES
Acquisition of business		—			(200	)
Purchase of medical equipment and property		(2,829	)		(6,997	)
Proceeds from sale of medical equipment and property		3,518			2,511

NET CASH PROVIDED BY (USED IN) INVESTING ACTIVITIES		689			(4,686	)

FINANCING ACTIVITIES
Principal payments on revolving credit facility, term loans and capital lease obligations		(35,769	)		(44,197	)
Cash proceeds from revolving credit facility		28,317			45,327
Debt issuance costs		(38	)		—
Common stock repurchased to satisfy statutory withholding on employee stock based compensation plans		(27	)		(50	)
Cash proceeds from stock plans		131			125

NET CASH (USED IN) PROVIDED BY FINANCING ACTIVITIES		(7,386	)		1,205

Net change in cash and cash equivalents		(2,595	)		254
Cash and cash equivalents, beginning of period		3,398			818

Cash and cash equivalents, end of period	$	803		$	1,072

See accompanying notes to unaudited condensed consolidated financial statements.

INFUSYSTEM HOLDINGS, INC. AND SUBSIDIARIES

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

1.	Basis of Presentation, Nature of Operations and Summary of Significant Accounting Policies

The terms “InfuSystem”, “the Company”, “we”, “our” and “us” are used herein to refer to InfuSystem Holdings, Inc. and its subsidiaries. InfuSystem Holdings, Inc. is a leading provider of infusion pumps and related services. The Company services hospitals, oncology practices and other alternative site healthcare providers. Headquartered in Madison Heights, Michigan, the Company delivers local, field-based customer support, and also operates pump repair Centers of Excellence in Michigan, Kansas, California, Texas, Georgia and Ontario, Canada.

The accompanying unaudited condensed consolidated financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) for interim financial information. Accordingly, the unaudited condensed consolidated financial statements do not include all of the information and notes required by U.S. Generally Accepted Accounting Principles (“GAAP”) for complete financial statements. The accompanying unaudited condensed consolidated financial statements include all adjustments, composed of normal recurring adjustments, considered necessary by management to fairly state the Company’s results of operations, financial position and cash flows. The operating results for the interim periods are not necessarily indicative of results that may be expected for any other interim period or for the full year. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2016 as filed with the SEC.

The unaudited condensed consolidated financial statements are prepared in conformity with GAAP, which requires the use of estimates, judgments and assumptions that affect the amounts of assets and liabilities at the reporting date and the amounts of revenue and expenses in the periods presented. The Company believes that the accounting estimates employed are appropriate and the resulting balances are reasonable; however, due to the inherent uncertainties in making estimates, actual results could differ from the original estimates, requiring adjustments to these balances in future periods.

2.	Medical Equipment and Property

Medical equipment consisted of the following as of September 30, 2017 and December 31, 2016 (in thousands):


	September 30, 2017			December 31, 2016
Medical Equipment held for sale or rental	$	1,200		$	1,642
Medical Equipment in rental service		58,681			59,034
Medical Equipment in rental service—pump reserve		(519	)		(551	)
Accumulated depreciation		(33,861	)		(30,447	)

Medical Equipment in rental service—net		24,301			28,036

Total	$	25,501		$	29,678

Depreciation expense for medical equipment for the three and nine months ended September 30, 2017 was $1.7 million and $4.8 million, respectively, compared to $1.6 million and $4.7 million for the same prior year periods, which was recorded in cost of revenues – pump depreciation and disposals, for each period.

3.	Property and Equipment

Property and equipment is comprised of the following (in thousands):


	September 30, 2017							December 31, 2016
	Gross Assets		Accumulated Depreciation			Total		Gross Assets		Accumulated Depreciation			Total
Furniture, fixtures, and equipment	$	3,842	$	(3,253	)	$	589	$	3,809	$	(3,071	)	$	738
Automobiles		118		(82	)		36		129		(83	)		46
Leasehold improvements		2,177		(1,091	)		1,086		2,177		(964	)		1,213

Total	$	6,137	$	(4,426	)	$	1,711	$	6,115	$	(4,118	)	$	1,997

Depreciation expense for property and equipment for the three and nine months ended September 30, 2017 was $0.1 million and $0.4 million, respectively, compared to $0.1 million and $0.4 million for the same prior year periods. This expense was recorded in general and administrative expenses.

4.	Intangible Assets

The carrying amount and accumulated amortization of intangible assets as of September 30, 2017 and December 31, 2016, are as follows (in thousands):


	September 30, 2017
	Gross Assets		Accumulated Amortization		Net
Nonamortizable intangible assets
Trade names	$	2,000	$	—	$	2,000
Amortizable intangible assets
Trade names		23		23		—
Physician and customer relationships		36,534		21,207		15,327
Non-competition agreements		1,136		1,120		16
Software		13,635		4,027		9,608

Total nonamortizable and amortizable intangible assets	$	53,328	$	26,377	$	26,951


	December 31, 2016
	Gross Assets		Accumulated Amortization		Net
Nonamortizable intangible assets
Trade names	$	2,000	$	—	$	2,000
Amortizable intangible assets
Trade names		23		23		—
Physician and customer relationships		36,534		19,427		17,107
Non-competition agreements		1,136		1,064		72
Software		13,745		1,685		12,060

Total nonamortizable and amortizable intangible assets	$	53,438	$	22,199	$	31,239

Amortization expense for the three and nine months ended September 30, 2017 was $1.4 million and $4.2 million, respectively, compared to $1.0 million and $2.8 million, respectively, for the three and nine months ended September 30, 2016. Expected annual amortization expense for intangible assets recorded as of September 30, 2017, is as follows (in thousands):


	10/1-12/31/2017		2018		2019		2020		2021		2022 and thereafter
Amortization expense	$	1,382	$	5,216	$	4,783	$	4,347	$	3,975	$	5,248

Debt

On March 23, 2015, the Company and its direct and indirect subsidiaries (the “Borrowers”) entered into a credit agreement (the “Chase Credit Agreement”) with JPMorgan Chase Bank, N.A., as lender (the “Lender”). The Chase Credit Agreement originally provided for a $27.0 million Term Loan A, up to an $8.0 million Term Loan B and a $10.0 million revolving credit facility (the “Revolver”) and a maturity date of March 23, 2020, collectively (the “Credit Facility”). The Borrowers drew $27.0 million under the Term Loan A to repay and terminate the previously existing Credit Facility under the credit agreement dated November 30, 2012, as amended, by and among the Company, its direct and indirect subsidiaries, Wells Fargo Bank, National Association, as administrative agent, and certain lenders party thereto (the “WF Facility”). Term Loan B was unfunded at closing and beginning on April 20, 2015, the closing date of the acquisition of the assets of Ciscura, the Borrowers drew $8.0 million on Term Loan B, in several installments, in accordance with the requirements of the asset purchase agreement governing the acquisition to fund the acquisition and associated expenses. The remaining available amount on Term Loan B expired on March 23, 2016.

On December 5, 2016, the Company entered into a First Amendment to the Chase Credit Agreement to waive certain events of default then existing thereunder, as well as to make certain amendments to the Credit Facility, including but not limited to: (i) restructuring of the Credit Facility that effectively consolidated Term Loan A and Term Loan B into a new single term loan (the “Term Loan”) resulting in a new total drawn amount of $32 million under the Term Loan with the approximately $5 million excess over the current aggregate drawn amounts under Term Loan A and Term Loan B to be available to reduce the Company’s drawings under the revolving credit line under the Credit Facility; (ii) extending the maturity date of the Term Loan and the revolving credit line to December 5, 2021; (iii) setting the quarterly mandatory principal payment due on the Term Loan to $1.3 million due on the last business day of each fiscal quarter with any remaining unpaid and outstanding amount due at maturity; and (iv) amending the leverage ratio covenant to provide for the following schedule of maximum permitted ratios: (a) 2.75 to 1.0 at any time on or after December 31, 2015 but prior to March 31, 2017, (b) 2.50 to 1.0 at any time on or after March 31, 2017 but prior to March 31, 2018 or (c) 2.25 to 1.00 at any time on or after March 31, 2018.

On March 22, 2017, the Company entered into a Second Amendment to the Chase Credit Agreement to make certain amendments to the Credit Facility, including but not limited to: (i) amending the definition of “Fixed Charges” to increase the Company’s ability to prepay its indebtedness under the Credit Facility without negatively impacting its financial covenants; and (ii) amending the leverage ratio covenant to provide for the following schedule of maximum permitted ratios: (a) 2.75 to 1.0 at any time on or after December 31, 2015 but prior to March 31, 2018, (b) 2.50 to 1.0 at any time on or after March 31, 2018 but prior to March 31, 2019 or (c) 2.25 to 1.00 at any time on or after March 31, 2019.

As of March 31, 2017, the Company breached a financial covenant under its Credit Facility, which resulted in an event of default under the Credit Facility. Specifically, the Company was not in compliance with the leverage ratio covenant under the Credit Facility. The required maximum leverage ratio under the Credit Facility as of March 31, 2017 was 2.75 compared to an actual ratio of 2.96. The Company subsequently received a waiver from this breach from the Lender on May 10, 2017, which provided a limited, specific and one-time waiver from this breach but did not otherwise modify the terms of the Credit Facility. No fee was paid to the Lender in connection with this waiver.

On June 28, 2017, the Company entered into a Third Amendment to the Chase Credit Agreement to make certain amendments to the Credit Facility, including but not limited to:

(i)

restates the chart within the definition of “Applicable Rate” in Section 1.01 of the Credit Agreement as follows:


Leverage Ratio	CBFR Spread			Eurodollar Spread			Commitment Fee Rate
Level I < 1.5:1.0		-1.00	%		2.00	%		0.25	%
Level II < 2.0:1.0 to 1.0 but ³ 1.5:1.0		-0.75	%		2.25	%		0.25	%
Level III < 2.5:1.0 to 1.0 but ³ 2.0:1.0		-0.50	%		2.50	%		0.25	%
Level IV < 3.0:1.0 to 1.0 but ³ 2.5:1.0		0.00	%		2.75	%		0.25	%
Level V ³ 3.0:1.0		0.25	%		3.00	%		0.25	%

and further amends the definition of “Applicable Rate” in Section 1.01 of the Credit Agreement by adding the following to the end thereof: “The Applicable Rate will be set at Level V as of the Third Amendment Effective Date, and adjusted for the first time thereafter based on the financial statements required to be delivered hereunder for the fiscal quarter ending June 30, 2017.”;

(ii)

amend the definition of “Fixed Charge Coverage Ratio” in Section 1.01 of the Credit Agreement by adding the phrase “(it is acknowledged that, at all times, such unfinanced portion is either a deduction to EBITDA or, if unfinanced portion is ever interpreted to be a negative number, then zero)” to follow the phrase therein that reads “means, for any period, the ratio of (a) EBITDA minus the unfinanced portion of Capital Expenditures.”;

(iii)

amend clause (f)(ii) in the definition of “Permitted Acquisition” in Section 1.01 of the Credit Agreement by (a) replacing the reference therein to “$10,000,000” with “$5,000,000” and (b) by replacing the reference therein to “$25,000,000” with “$12,500,000.”;

(iv)

add the following definition of “Excess Cash Flow” to Section 1.01 of the Credit Agreement as follows:

“Excess Cash Flow” means, for any fiscal year of the Company, (a) EBITDA for such fiscal year, minus (b) Capital Expenditures made or incurred during such fiscal year minus (c) Fixed Charges for such fiscal year.

(v)

restate Section 2.08(b) of the Credit Agreement as follows:

(b) The Borrowers hereby unconditionally agree that the Term A Loans and the Term B Loans shall be replaced and refinanced in full as of the First Amendment Effective Date with a Term Loan in an aggregate amount equal to $32,000,000 made under Section 2.01(d), the Borrowers acknowledge and agree that the principal balance of such Term Loan as of the Third Amendment Effective Date is $30,665,999.98, and the Borrowers hereby unconditionally promise to pay to the Lender the principal amount of the Term Loans made under Section 2.01(d) after the Third Amendment Effective Date as follows: (i) on June 30, 2017, September 30, 2017 and December 31, 2017 in principal installments each in the amount of $577,500 (as adjusted from time to time pursuant to Section 2.09(d) or 2.16(b)), (ii) commencing with the last Business Day of March, 2018 and on the last Business Day of each March, June, September and December thereafter, in consecutive quarterly principal installments each in the amount of $766,650 (as adjusted from time to time pursuant to Section 2.09(d) or 2.16(b)) and (iii) to the extent not previously paid, all unpaid Term Loans shall be paid in full in cash by the Borrowers on the Term Maturity Date.

(vi)

restate Section 2.09(d) of the Credit Agreement as follows:

(d) All prepayments required to be made pursuant to Section 2.09(c) shall be applied, first to prepay the Term Loans (and in the event Term Loans of more than one Class shall be outstanding at the time, shall be allocated among the Term Loans pro rata based on the aggregate principal amounts of outstanding Term Loans of each such Class), and such prepayments of the Term Loans shall be applied to reduce the remaining scheduled repayments of Term Loans of each Class in the inverse order of maturity (with any prepayments applied first to the payment at final maturity), second to prepay the Revolving Loans without a corresponding reduction in the

Revolving Commitment and third to cash collateralize outstanding LC Exposure. Within each such category, such prepayments shall be applied first to CBFR Loans and then to Eurodollar Loans in order of Interest Period maturities (beginning with the earliest to mature).

All prepayments required to be made pursuant to Section 2.09(f) shall be applied, first to prepay the Revolving Loans without a corresponding reduction in the Revolving Commitment, second to prepay the Term Loans (and in the event Term Loans of more than one Class shall be outstanding at the time, shall be allocated among the Term Loans pro rata based on the aggregate principal amounts of outstanding Term Loans of each such Class), and such prepayments of the Term Loans shall be applied to reduce the remaining scheduled repayments of Term Loans of each Class in the inverse order of maturity (with any prepayments applied first to the payment at final maturity), and third to cash collateralize outstanding LC Exposure. Within each such category, such prepayments shall be applied first to CBFR Loans and then to Eurodollar Loans in order of Interest Period maturities (beginning with the earliest to mature).

(vii)

add a new Section 2.09(f) to the Credit Agreement as follows:

(f) Until the latest of the Revolving Credit Maturity Date, the Term A Maturity Date, the Term B Maturity Date or the Term Maturity Date, as the case may be, the Borrowers shall prepay the Obligations as set forth in Section 2.09(d) on the date that is ten days after the earlier of (i) the date on which the Company’s annual audited financial statements for the immediately preceding fiscal year are delivered pursuant to Section 5.01 or (ii) the date on which such annual audited financial statements were required to be delivered pursuant to Section 5.01, in an amount equal to: (I) seventy-five percent (75%) of the Company’s Excess Cash Flow for the immediately preceding fiscal year if the Company’s Leverage Ratio is greater than or equal to 2.5 to 1.0 for the immediately preceding fiscal year, (II) fifty percent (50%) of the Company’s Excess Cash Flow for the immediately preceding fiscal year if the Company’s Leverage Ratio is less than 2.5 to 1.0 but greater than or equal to 2.0 to 1.0 for the immediately preceding fiscal year, or (III) zero percent (0%) of the Company’s Excess Cash Flow for the immediately preceding fiscal year if the Company’s Leverage Ratio is less than 2.0 to 1.0 for the immediately preceding fiscal year. Each Excess Cash Flow prepayment shall be accompanied by a certificate signed by a Financial Officer of the Company certifying the manner in which Excess Cash Flow and the resulting prepayment was calculated, which certificate shall be in form and substance satisfactory to the Lender.

(viii)

amend Section 6.04(c) of the Credit Agreement by replacing the reference therein to “$5,000,000” with “$2,500,000.”;

(ix)

restate Sections 6.12(a) and (b) of the Credit Agreement as follows:

(a) Leverage Ratio. The Borrowers will not permit the Leverage Ratio to exceed (i) 4.0 to 1.0 at any time on or after the Effective Date but prior to December 31, 2017, (ii) 3.75 to 1.0 at any time on or after December 31, 2017 but prior to June 30, 2018, (iii) 3.50 to 1.0 at any time on or after June 30, 2018 but prior to December 31, 2018, or (iv) 3.00 to 1.00 at any time on or after December 31, 2018.

(b) Fixed Charge Coverage Ratio. The Borrowers will not permit the Fixed Charge Coverage Ratio to be less than (i) 1.15:1.0 at any time on or after the Effective Date but prior to March 31, 2018, or (ii) 1.25:1.0 at any time on or after March 31, 2018.

As of September 30, 2017, the Borrowers were in compliance with all such covenants.

Simultaneous with the execution of Third Amendment, the Company entered into a Patent and Trademark Security Agreement, which replaces the Patent and Trademark Security Agreement entered into on March 23, 2015 at the time the Company entered into the Credit Agreement. The new Patent and Trademark Security Agreement was revised to make reference to the Third Amendment and the Company has provided the Lender with updated schedules listing the Company’s trademarks, patents, applications for trademarks and patents, and other intellectual properties owned or licensed.

As a result of the changes to the definition of ‘Leverage Ratio” and “Fixed Charge Coverage Ratio” within the Third Amendment, the Company will have increased flexibility. The change to the definition of “Applicable Rate” will effectively increase the Company’s interest rate under the Credit Agreement by 50 basis points in the near term, while allowing for the Company to reduce that rate as its Leverage Ratio declines.

To secure repayment of the obligations of the Borrowers, each Borrower has granted to the Lender, for the benefit of various secured parties, a first priority security interest in substantially all of the personal property assets of each of the Borrowers. In addition, the Company has pledged the shares of InfuSystem Holdings USA, Inc. (“Holdings USA”) and Holdings USA has pledged the shares of each of InfuSystem, Inc. and First Biomedical, Inc. and the equity interests of IFC, LLC to the Lender, for the benefit of the secured parties, to further secure the obligations under the Chase Credit Agreement.

The availability under the Revolver is based upon the Borrowers’ eligible accounts receivable and eligible inventory and is comprised as follows (in thousands):


	September 30, 2017			December 31, 2016
Revolver:
Gross Availability	$	9,810		$	10,000
Outstanding Draws		—			—
Letter of Credit		(750	)		—
Landlord Reserves		(45	)		(45	)

Availability on Revolver	$	9,015		$	9,955

The Company had approximate future maturities of loans as of September 30, 2017 as follows (in thousands):


	2017			2018			2019			2020			2021			Total
Term Loan	$	578		$	3,067		$	3,067		$	3,067		$	19,732		$	29,511
Unamortized value of the debt issuance costs (a)		(7	)		(30	)		(30	)		(30	)		(30	)		(127	)
Revolver		—			—			—			—			—			—

Total	$	571		$	3,037		$	3,037		$	3,037		$	19,702		$	29,384

(a)	Includes the reclassification of the debt issuance costs as a result of the Company adopting ASU 2015-03

The following is a breakdown of the Company’s current and long-term debt as of September 30, 2017 and December 31, 2016 (in thousands):


September 30, 2017										December 31, 2016
	Current Portion of Long-Term Debt			Long-Term Debt			Total				Current Portion of Long-Term Debt			Long-Term Debt			Total
Term Loan	$	2,877		$	26,634		$	29,511		Term Loans	$	5,336		$	26,664		$	32,000
Unamortized value of the debt issuance costs (a)	$	(28	)	$	(99	)		(127	)	Unamortized value of the debt issuance costs (a)	$	(22	)	$	(87	)		(109	)
Revolver		—			—			—		Revolver		—			—			—

Total	$	2,849		$	26,535		$	29,384		Total	$	5,314		$	26,577		$	31,891

(a)	Includes the reclassification of the debt issuance costs as a result of the Company adopting ASU 2015-03

As of September 30, 2017, interest on the Credit Facility is payable at our option as a (i) Eurodollar Loan, which bears interest at a per annum rate equal to LIBOR Plus a margin ranging from 2.00% to 3.00% or (ii) CBFR Loan, which bears interest at a per annum rate equal to the greater of (a) the lender’s prime rate or (b) LIBOR for a 30-day interest period plus 2.50%, in each case, plus a margin ranging from -1.00% to 0.25%. The actual rate at September 30, 2017 was 3.99% (LIBOR of 1.24% plus 2.75%).

6.	Income Taxes

During the three and nine months ended September 30, 2017, the Company recorded income tax expense of $0.3 million and an income tax benefit of $0.9 million, respectively. During the three and nine months ended September 30, 2016, the Company recorded an income tax expense of $0.1 million and $0.2 million, respectively. In computing its income tax provision, the Company estimates its effective tax rate for the full year and applies that rate to income earned through the reporting period. The Company’s effective income tax rate for the nine months ended September 30, 2017 was 25.2% compared to 42.3% for the same prior year period.

7.	Commitments, Contingencies and Litigation

From time to time in the ordinary course of its business, the Company may be involved in legal proceedings, the outcomes of which may not be determinable. The results of litigation are inherently unpredictable. Any claims against the Company, whether meritorious or not, could be time consuming, result in costly litigation, require significant amounts of management time and result in diversion of significant resources. The Company is not able to estimate an aggregate amount or range of reasonably possible losses for those legal matters for which losses are not probable and estimable, primarily for the following reasons: (i) many of the relevant legal proceedings are in preliminary stages, and until such proceedings develop further, there is often uncertainty regarding the relevant facts and circumstances at issue and potential liability; and (ii) many of these proceedings involve matters of which the outcomes are inherently difficult to predict. The Company has insurance policies covering potential losses where such coverage is cost effective.

As a result of the restatement of the Company’s consolidated financial statements as of December 31, 2015 and the first and second quarters of 2016, the Company is currently involved in a class-action lawsuit filed by shareholders. On November 8, 2016, a purported shareholder of the Company filed a putative class-action lawsuit in the U.S. District Court for the Central District of California (the “Court”) (Case No. 2:16-cv-08295-ODW) against the Company and two individual defendants: Eric Steen, the Company’s former Chief Executive Officer, President and Director; and Jonathan Foster, the Company’s former Chief Financial Officer. The complaint alleges that the defendants issued materially false and misleading statements in and/or omitted material facts from documents filed with the SEC between May 12, 2015 and November 7, 2016. The complaint asserts claims against all defendants under the antifraud provisions of the federal securities laws and against Messrs. Steen and Foster as control persons. The complaint seeks compensatory damages for the putative class, prejudgment and post-judgment interest, attorneys’ fees and other costs. Two other shareholders subsequently filed motions for appointment as lead plaintiff and for appointment of their attorneys as lead counsel for the putative class. On February 17, 2017, the Court appointed a lead plaintiff for the putative class. On April 18, 2017, the lead plaintiff filed an amended class-action complaint with the Court. On June 19, 2017, the Company and all defendants filed a Motion to Dismiss the amended complaint and that motion is now fully briefed and is pending before the Court.

The Company believes that the allegations against it and its officers are without merit and intends to vigorously defend against the claims asserted. The ultimate resolution of this matter cannot be predicted, however, and it is not possible at this time for the Company to estimate any probable loss or range of losses because of the preliminary nature of the matter.

8.	(Loss) Earnings Per Share

Basic (loss) income per share is computed by dividing net (loss) income by the weighted average number of common shares outstanding during the period. Diluted (loss) income per share assumes the issuance of potentially dilutive shares of common stock during the period. The following table reconciles the numerators and denominators of the basic and diluted (loss) income per share computations:


	Three Months Ended September 30					Nine Months Ended September 30
	2017			2016		2017			2016
Numerator:
Net (loss) income (in thousands)	$	(129	)	$	56	$	(2,713	)	$	250
Denominator:
Weighted average common shares outstanding:
Basic		22,755,976			22,620,386		22,725,806			22,614,203
Dilutive effect of non-vested awards		—			375,257		—			445,591

Diluted		22,755,976			22,995,643		22,725,806			23,059,794
Net (loss) income per share:
Basic	$	(0.01	)	$	0.00	$	(0.12	)	$	0.01
Diluted	$	(0.01	)	$	0.00	$	(0.12	)	$	0.01

For the three and nine months ended September 30, 2017, 0.7 million and 0.6 million of stock options were not included in the calculation because they would have an anti-dilutive effect, compared to less than 0.1 million for the same prior year periods.

9.	Leases

The Company leases office space, service facility centers and equipment under non-cancelable capital and operating lease arrangements. The Company periodically enters into capital leases to finance the purchase of ambulatory infusion pumps. The pumps are capitalized into medical equipment in rental service at their fair market value, which equals the value of the future minimum lease payments and are depreciated over the useful life of the pumps. The weighted average interest rate under capital leases was 3.6% as of September 30, 2017. The leases for office space and service facility centers used in the Company’s logistics operations are operating leases. In most cases, the Company expects its facility leases will be renewed or replaced by other leases in the ordinary course of business.

Future minimum rental payments pursuant to leases that have an initial or remaining non-cancelable lease term in excess of one year as of September 30, 2017 are as follows (in thousands):


	Capital Leases			Operating Leases		Total
2017	$	153		$	331	$	484
2018		514			1,324		1,838
2019		33			1,223		1,256
2020		—			419		419
2021		—			181		181
Thereafter		—			938		938

Total require payments	$	700		$	4,416	$	5,116

Less amounts representing interest (3.5%)		(15	)

Present value of minimum lease payments		685
Less current maturities		(584	)

Long-term capital lease liability	$	101

At September 30, 2017 and December 31, 2016, pump assets obtained under capital leases had an original cost of approximately $14.0 million and $13.9 million, respectively, and accumulated depreciation of $5.3 million and $3.9 million, respectively.

The Company had minimum future operating lease commitments, mainly related to its leased facilities. Related rental expense for facilities and other equipment from third parties under operating leases for the three and nine months ended September 30, 2017 was $0.2 million and $0.7 million, respectively, compared to $0.3 million and $0.8 million for the same three and nine months ended September 30, 2016.

10.

Subsequent Events

The Company has evaluated subsequent events through the date of issuance for the unaudited condensed consolidated financial statements as of September 30, 2017.

11.

Recent Accounting Pronouncements and Developments

In May 2017, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2017-09, “Stock Compensation—Scope of Modification Accounting”, which provides guidance on which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic 718. The new standard is effective for fiscal years beginning after December 15, 2017 (i.e. a January 1, 2018 effective date). The Company believes the adoption will not have a material impact on its consolidated financial statements.

In January 2017, the FASB issued ASU No. 2017-04, “Intangibles—Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment”, which changes the subsequent measurement of goodwill impairment by eliminating Step 2 from the impairment test. Under the new guidance, an entity will measure impairment using the difference between the carrying amount and the fair value of the reporting unit. The new standard is effective for fiscal years beginning after December 15, 2019 (i.e. a January 1, 2020 effective date), with early adoption permitted for goodwill impairment tests with measurement dates after January 1, 2017. The Company believes the adoption will not have a material impact on its consolidated financial statements.

In May 2014, the FASB issued ASU 2014-09, “Revenue from Contracts with Customers (Topic 606)”, which supersedes the revenue recognition requirements in ASC 605, “Revenue Recognition”, and most industry-specific guidance. ASU 2014-09, along with amendments in 2015 and 2016, focuses on creating a single source of revenue guidance for revenue arising from contracts with customers. Under the new standard, recognition of revenue occurs when a customer obtains control of promised goods or services in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. Additionally, the new standard requires that enhanced disclosures about the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers, including revenue recognition policies to identify performance obligations, assets recognized from costs incurred to obtain and fulfill a contract, and significant judgments in measurement and recognition. The standard, as amended, will be effective for annual periods beginning after December 15, 2017, including interim periods within that reporting period.

The Company is in the process of evaluating the impact of these changes, which includes a review of existing contracts with customers, an evaluation of the specific terms of those contracts and the appropriate treatment under the new standards, and a comparison of that new treatment to the Company’s existing accounting policies to identify differences.

The Company expects that the disclosures in the notes to its consolidated financial statements related to revenue recognition will be significantly expanded under the new standard, specifically regarding quantitative and qualitative information about performance obligations.

The Company anticipates the adoption of ASC 606 using the modified retrospective approach, under which the cumulative effect of the initial application of the new standard will be recognized as an adjustment to the opening balance of retained earnings in the first quarter of 2018. As the Company is still in the process of finalizing its evaluation of ASU 2014-09, along with the subsequent amendments, its initial assessment may change as it refines its systems, processes, controls and assumptions.

In February 2016, the FASB issued ASU No. 2016-02, “Leases (Topic 842)” (“ASU 2016-02”). Under ASU 2016-02, an entity will be required to recognize right-of-use assets and lease liabilities on its balance sheet and disclose key information about leasing arrangements. ASU 2016-02 offers specific accounting guidance for a lessee, a lessor and sale and leaseback transactions. Lessees and lessors are required to disclose qualitative and quantitative information about leasing arrangements to enable a user of the financial statements to assess the amount, timing and uncertainty of cash flows arising from leases. For public companies, ASU 2016-02 is effective for annual reporting periods beginning after December 15, 2018, including interim periods within that reporting period, and requires a modified retrospective adoption, with early adoption permitted. The Company is currently evaluating the impact, if any, that the adoption of this guidance will have on its financial position, results of operations, cash flows and/or disclosures.

In March 2016, the FASB issued ASU No. 2016-09, “Compensation— Stock Compensation (Topic 718)” (“ASU 2016-09”). The guidance changes how companies account for certain aspects of equity-based payments to employees. Entities will be required to recognize income tax effects of awards in the income statement when the awards vest or are settled. The guidance also allows an employer to repurchase more of an employee’s shares than it can under current guidance for tax withholding purposes providing for withholding at the employee’s maximum rate as opposed to the minimum rate without triggering liability accounting and to make a policy election to account for forfeitures as they occur. The updated guidance is effective for annual periods beginning after December 15, 2016. Effective January 1, 2017, the Company adopted the accounting guidance contained within ASU 2016-09. Thus, the Company recorded a $0.2 million deferred tax asset and a $0.2 million increase to retained earnings on January 1, 2017 to recognize the Company’s excess tax benefits that existed as of December 31, 2016 (modified retrospective application).

amortized cost basis of the financial asset to present the net carrying value at the amount expected to be collected on the financial asset. ASU 2016-13 is effective as of January 1, 2020. Early adoption is permitted. The Company is currently evaluating the impact of ASU 2016-13. The adoption of this standard is not expected to have a material impact on the Company’s consolidated financial position, results of operations, cash flows and/or disclosures.

In August 2016, the FASB issued ASU No. 2016-15, “Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments” (“ASU 2016-15”). The amendments in this ASU introduce clarifications to the presentation of certain cash receipts and cash payments in the statement of cash flows. The primary updates include additions and clarifications of the classification of cash flows related to certain debt repayment activities, contingent consideration payments related to business combinations, proceeds from insurance policies, distributions from equity method investees and cash flows related to securitized receivables. ASU 2016-15 is effective for annual periods beginning after December 15, 2017, including interim periods within those fiscal years. Early adoption is permitted, including in interim periods. ASU 2016-15 requires retrospective application to all prior periods presented upon adoption. The Company is currently evaluating the impact, if any, that the adoption of this guidance will have on its cash flows and/or disclosures, however, the Company does not anticipate that the adoption of this new standard will have a material impact on the Company’s financial position, results of operations or statements of cash flows upon adoption.

In November 2015, the FASB issued ASU No. 2015-17, “Income Taxes (Topic 740): Balance Sheet Classification of Deferred Taxes” (“ASU 2015-17”), simplifying the balance sheet classification of deferred taxes by requiring all deferred taxes, along with any related valuation allowance, to be presented as noncurrent. ASU 2015-17 is effective for the Company beginning in the first quarter of 2017 and may be applied either prospectively or retrospectively. The Company has chosen to apply this guidance prospectively, thus prior periods were not retrospectively adjusted. The adoption of this guidance resulted in the balance sheet reclassification of $2.7 million of current deferred tax assets to noncurrent.

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

The terms “InfuSystem”, “the Company”, “we”, “our” and “us” used herein refer to InfuSystem Holdings, Inc. and its subsidiaries.

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS

Certain statements contained in this quarterly report on Form 10-Q are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”) and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). The words “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “expect,” “strategy,” “future,” “likely,” variations of such words, and other similar expressions, as they relate to the Company, are intended to identify forward-looking statements. However, the absence of these words or similar expressions does not mean that a statement is not forward-looking. Forward-looking statements include statements relating to future actions, business plans, objectives and prospects, future operating or financial performance. In connection with the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, the Company is identifying certain factors that could cause actual results to differ, perhaps materially, from those indicated by these forward-looking statements. Those factors, risks and uncertainties include, but are not limited to, potential changes in overall healthcare reimbursement, including the Centers for Medicare and Medicaid Services (“CMS”) competitive bidding and fee schedule reductions, sequestration, concentration of customers, increased focus on early detection of cancer, competitive treatments, dependency on Medicare Supplier Number, availability of chemotherapy drugs, global financial conditions, changes and enforcement of state and federal laws, natural forces, competition, dependency on suppliers, risks in acquisitions & joint ventures, U.S. Healthcare Reform, relationships with healthcare professionals and organizations, technological changes related to infusion therapy, the Company’s ability to implement information technology improvements and to respond to technological changes, dependency on websites and intellectual property, the ability of the Company to successfully integrate acquired businesses, dependency on key personnel, dependency on banking relations and the ability to comply with Credit Facility covenants, and other risks associated with its common stock, as well as any litigation to which the Company may be involved in from time to time; and other risk factors as discussed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2016 and in other filings made by the Company from time to time with the Securities and Exchange Commission (“SEC”), including its quarterly reports on Form 10-Q. Our Annual Report on Form 10-K is available on the SEC’s EDGAR website at www.sec.gov, and a copy may also be obtained by contacting the Company. All forward-looking statements made in this Form 10-Q speak only as of the date of this report. We do not intend, and do not undertake any obligation, to update any forward-looking statements to reflect future events or circumstances after the date of such statements, except as required by law.

Overview

We are a leading provider of infusion pumps and related products and services for patients in the home, oncology clinics, ambulatory surgery centers, and other sites of care from five locations in the United States and Canada. We provide our products and services to hospitals, oncology practices and facilities and other alternate site health care providers. Headquartered in Madison Heights, Michigan, we deliver local, field-based customer support, and also operate pump service and repair Centers of Excellence in Michigan, Kansas, California, Texas, Georgia and Ontario, Canada. InfuSystem, Inc., our wholly owned subsidiary, is accredited by the Community Health Accreditation Program while First Biomedical, Inc., our wholly owned subsidiary, is ISO certified.

Our core service is to supply electronic ambulatory infusion pumps and associated disposable supply kits to oncology clinics, infusion clinics and hospital outpatient chemotherapy clinics to be utilized in the treatment of a variety of cancers including colorectal cancer and other disease states. Colorectal cancer is the third most prevalent form of cancer in the United States, according to the American Cancer Society, and the standard of care for the treatment of colorectal cancer relies upon continuous chemotherapy infusions delivered via ambulatory infusion pumps.

In addition, we sell or rent new and pre-owned pole mounted and ambulatory infusion pumps to, and provide biomedical recertification, maintenance and repair services for, oncology practices as well as other alternate site settings including home care and home infusion providers, skilled nursing facilities, pain centers and others. We also provide these products and services to customers in the small-hospital market.

We purchase new and pre-owned pole mounted and ambulatory infusion pumps from a variety of sources on a non-exclusive basis. We repair, refurbish and provide biomedical certification for the devices as needed. The pumps are then available for sale, rental or to be used within our ambulatory infusion pump management service.

We view our payor environment as changing. Management is intent on extending its considerable breadth of payor contracts as patients move into different insurance coverages, including Medicaid and Insurance Marketplace products. In some cases, this may slightly reduce our aggregate billed revenues payment rate but result in an overall increase in collected revenues.

InfuSystem Holdings, Inc. Results of Operations for the Three and Nine Months Ended September 30, 2017 compared to the Three and Nine Months Ended September 30, 2016

Net Revenues

Our net revenues for the quarter ended September 30, 2017 were $17.6 million, an increase of $0.4 million, or 2%, compared to $17.2 million for the quarter ended September 30, 2016. During the period, net revenues from rentals increased $0.7 million, or 5%, compared to the same prior year period. The increase in net revenues from rentals can be largely attributed to (i) an overall increase in rental volume of $0.5 million with new and existing sites of therapy and (ii) an increase in pricing and collection impacts of $0.2 million. Net revenues from product sales were $2.3 million, a decrease of $0.3 million compared to the same prior year period.

Our net revenues for the nine months ended September 30, 2017 were $52.2 million, a decrease of $1.5 million, or 3%, over the same prior year period. During the period, net revenues from rentals decreased $2.1 million, or 5%, compared to the same prior year period, largely attributed to (i) changed practices and reduced billing rates due to SE1609 regulatory change of approximately $2.6 million and (ii) pricing and collections impacts of $2.4 million. These were offset by an overall increase in rental volume of $2.9 million with new and existing sites of therapy. Net revenues from product sales were $7.0 million, an increase of $0.7 million, or 11% compared to the same prior year period.

Gross Profit

Gross profit for the quarter ended September 30, 2017 was $11.0 million, an increase of $0.6 million, or 6%, compared to $10.4 million for the quarter ended September 30, 2016. Gross profit, as a percentage of net revenues, for the quarter ended September 30, 2017 was 63%, up from 60% for the same prior year period. The increase in gross profit for the period was largely attributed to the increase in net revenues of $0.4 million for the period, as well as, a decrease of $0.7 million in the costs of pumps sold, which was offset by an increase of $0.5 million in product and supply costs.

Gross profit for the nine months ended September 30, 2017 was $32.0 million, a decrease of $2.1 million, or 6%, compared to the nine months ended September 30, 2016. Gross profit, as a percentage of net revenues, for the nine months ended September 30, 2017 was 61%, down from 64% for the same prior year period. The decrease in gross profit as a percentage of net revenues for the period was largely due to the decrease in net revenues in the period of $1.5 million plus an increase of $0.1 million in product and supply costs, $0.8 million in disposables sold and $0.3 million in service costs, which was offset by a decrease of $0.6 million in costs of pumps sold.

Provision for Doubtful Accounts

Provision for doubtful accounts for the quarter ended September 30, 2017 was $1.3 million, an increase of $0.2 million, or 16%, compared to the quarter ended September 30, 2016. The provision for doubtful accounts was 7% of net revenues at September 30, 2017, compared to 6% for the same prior year period. Bad debt is primarily associated with rental revenues. Provision for doubtful accounts for the nine months ended September 30, 2017 was $4.5 million, an increase of $0.5 million, or 14%, compared to $3.9 million for the nine months ended September 30, 2016. The provision for doubtful accounts was 9% of net revenues at September 30, 2017, compared to 7% for the same prior year period. The increase for both 2017 periods is largely due to a higher mix of patient payors in our rental business, which generally have higher uncollectible rates than commercial payors. This was offset by a decrease in reserves related to our revised billing practices for Medicare accounts as required by SE1609. We now directly bill providers and not third-party payors for SE1609 related services. Because this is a dramatic change from prior practices, we experienced a delay in providers acknowledging and paying under the new model. We continue to see improvements in collections from SE1609 providers since the initial implementation in July 2016, but nonetheless, we have adopted the practice of reserving for all SE1609 accounts receivable aged greater than 120 days. We believe the strategic shift to focusing additional resources on collection efforts will continue to deliver a positive impact with respect to these SE1609 accounts receivable.

Amortization of Intangible Assets

Amortization of intangible assets for the quarter ended September 30, 2017 was $1.4 million, an increase of $0.4 million compared to the same prior year period. Amortization of intangible assets for the nine months ended September 30, 2017 was $4.2 million, an increase of $1.4 million compared to the same prior year period. These increases were largely attributable to the completion of several IT projects that were placed into service and the resulting amortization.

Selling and Marketing Expenses

During the quarter ended September 30, 2017, selling and marketing expenses were $2.3 million, a decrease of $0.2 million, or 9%, compared to the same prior year period. During the nine months ended September 30, 2017, selling and marketing expenses were $7.4 million, a decrease of $0.2 million, compared to $7.6 million for the same prior year period. The decrease for the nine months ended September 30, 2017 versus the same prior year period was largely attributable to decreases in salaries and benefits of $0.3 million, advertising and promotions of $0.1 million and travel and related expenses of $0.2 million, which was offset by an increase in sales commissions of $0.4 million. Selling and marketing expenses during these periods consisted of sales personnel salaries, commissions and associated fringe benefit and payroll-related items, marketing, share-based compensation, travel and entertainment and other miscellaneous expenses.

General and Administrative Expenses

During the quarter ended September 30, 2017, General and Administrative (“G&A”) expenses were $5.6 million, an increase of $0.3 million, or 6%, compared to the quarter ended September 30, 2016. The increase in G&A expense versus the same prior year period was mainly attributable to increases in stock compensation expense of $0.2 million and outside services of $0.1 million.

During the nine months ended September 30, 2017, G&A expenses were $18.4 million, an increase of 1%, from $18.3 million for the nine months ended September 30, 2016. The increase in G&A expense versus the same prior year period was mainly attributable to an increase in stock compensation expense of $0.1 million and outside services of $0.5 million, offset by decreases in salaries and benefits of $0.4 million and depreciation expense of $0.1 million. Some additional items that added to the overall increase in G&A expense versus the same prior year period were $0.6 million of severance, $0.2 million of legal expenses related to a shareholder lawsuit and $0.3 million of early termination fees related to capital leases repaid in response to the Third Amendment to our Credit Agreement with Chase Bank finalized during the second quarter of 2017.

Other Income and Expenses

During the quarter ended September 30, 2017, we recorded interest expense of $0.4 million, a decrease of less than $0.1 million, or 8%, compared to the same prior year period. During the nine months ended September 30, 2017, we recorded interest expense of $1.0 million, which was consistent with the same prior year period.

Income Taxes

During the three and nine months ended September 30, 2017, we recorded income tax expense of $0.3 million and an income tax benefit of $0.9 million, respectively. During the three and nine months ended September 30, 2016, the Company recorded income tax expenses of $0.1 million and $0.2 million, respectively. Our effective income tax rate for the nine months ended September 30, 2017 was 25.2%.

Liquidity and Capital Resources

We finance our operations and capital expenditures with internally generated cash from operations and borrowings under our Credit Facility. As of September 30, 2017, we had cash and cash equivalents of $0.8 million and $9.0 million of net availability under the Revolver compared to $3.4 million of cash and cash equivalents and $9.9 million of net availability under our Revolver at December 31, 2016. Our liquidity and borrowing plans are established to align with our financial and strategic planning processes and to ensure we have the necessary funding to meet our operating commitments, which primarily include the purchase of pumps, inventory, payroll and general expenses. We also take into consideration our overall capital allocation strategy which includes investment for future growth and acquisitions.

Operating Cash Flow. Cash provided by operating activities for the nine months ended September 30, 2017 was $4.1 million compared to $3.7 million for the nine months ended September 30, 2016. This increase is due to higher amounts of non-cash expenses (such as amortization expenses) and other liabilities in the current period, which were offset by decreases in deferred income taxes and other current liabilities.

Investing Cash Flow. Cash provided by investing activities was $0.7 million for the nine months ended September 30, 2017 compared to cash used of $4.7 million for the nine months ended September 30, 2016. The increase in cash provided was due to a $2.9 million decrease in spending on non-pump assets, the majority of which was a direct result of a more significant investment in IT during the nine months ended September 30, 2016, $1.3 million decrease in cash used to purchase medical equipment and $1.0 million more in cash proceeds from the sales of medical equipment. We purchased $2.6 million of infusion pumps during the nine-month

period ended September 30, 2017 to serve new rental business anticipated for the remainder of 2017, compared to $3.8 million of infusion pumps during the nine-month period ended September 30, 2016. We anticipate this downward spend on infusion pumps for the remainder of 2017 to continue when compared to prior year.

Financing Cash Flow. Cash used in financing activities for the nine months ended September 30, 2017 was $7.4 million compared to cash proceeds of $1.2 million for the nine months ended September 30, 2016. This change is primarily attributable to the cash proceeds received as a result of our decision to borrow from the revolving credit line under our Credit Facility during the nine months ended September 30, 2016, as well as, our decision to pay down a majority of our capital lease obligations during the first half of 2017.

Credit Facility. On March 23, 2015, the Company and its direct and indirect subsidiaries entered into a credit agreement with JPMorgan Chase Bank, N.A., as lender (the “Chase Credit Agreement”). The Chase Credit Agreement originally provided for a Credit Facility consisting of a $27.0 million Term Loan A, up to $8.0 million Term Loan B and a $10.0 million revolving Credit Facility and a maturity date of March 23, 2020. The Credit Facility is collateralized by substantially all of our assets and shares of our subsidiaries and requires us to comply with certain covenants, including but not limited to, financial covenants relating to the satisfaction, on a quarterly and annual basis for the duration of the Credit Facility, of a total leverage ratio, a fixed charge coverage ratio and a net worth level.

On December 5, 2016, we entered into a First Amendment to the Chase Credit Agreement to waive certain events of default then existing thereunder, as well as to make certain amendments to the Credit Facility, including but not limited to: (i) restructuring of the Credit Facility that effectively consolidated Term Loan A and Term Loan B into a new single term loan (“Term Loan”) resulting in a new total drawn amount of $32 million under the Term Loan with the approximately $5 million excess over the current aggregate drawn amounts under Term Loan A and Term Loan B to be available to reduce the Company’s drawings under the revolving credit line under the Credit Facility; (ii) extending the maturity date of the Term Loan and the revolving credit line to December 5, 2021; (iii) setting the quarterly mandatory principal payment due on the Term Loan to $1.3 million due on the last business day of each fiscal quarter with any remaining unpaid and outstanding amount due at maturity; and (iv) amending the leverage ratio covenant to provide for the following schedule of maximum permitted ratios: (a) 2.75 to 1.0 at any time on or after December 31, 2015 but prior to March 31, 2017, (b) 2.50 to 1.0 at any time on or after March 31, 2017 but prior to March 31, 2018 or (c) 2.25 to 1.00 at any time on or after March 31, 2018.

On March 22, 2017, we entered into a Second Amendment to the Chase Credit Agreement to make certain amendments to the Credit Facility, including but not limited to: (i) amending the definition of “Fixed Charges” to increase the Company’s ability to prepay its indebtedness under the Credit Facility without negatively impacting its financial covenants; and (ii) amending the leverage ratio covenant to provide for the following schedule of maximum permitted ratios: (a) 2.75 to 1.0 at any time on or after December 31, 2015 but prior to March 31, 2018, (b) 2.50 to 1.0 at any time on or after March 31, 2018 but prior to March 31, 2019 or (c) 2.25 to 1.00 at any time on or after March 31, 2019.

As of March 31, 2017, we breached a financial covenant under our Credit Facility, which resulted in an event of default under the Credit Facility. Specifically, we were not in compliance with the leverage ratio covenant under the Credit Facility. The required maximum leverage ratio under the Credit Facility as of March 31, 2017 was 2.75 compared to an actual ratio of 2.96. We subsequently received a waiver from this breach from the lender on May 10, 2017, which provided a limited, specific and one-time waiver from this breach but did not otherwise modify the terms of the Credit Facility. No fee was paid to the lender in connection with this waiver.

On June 28, 2017, we entered into a Third Amendment to the Chase Credit Agreement to make certain amendments to the Credit Facility, including but not limited to:

(i)

restates the chart within the definition of “Applicable Rate” in Section 1.01 of the Credit Agreement as follows:


Leverage Ratio	CBFR Spread			Eurodollar Spread			Commitment Fee Rate
Level I < 1.5:1.0		-1.00	%		2.00	%		0.25	%
Level II < 2.0:1.0 to 1.0 but ³ 1.5:1.0		-0.75	%		2.25	%		0.25	%
Level III < 2.5:1.0 to 1.0 but ³ 2.0:1.0		-0.50	%		2.50	%		0.25	%
Level IV < 3.0:1.0 to 1.0 but ³ 2.5:1.0		0.00	%		2.75	%		0.25	%
Level V ³ 3.0:1.0		0.25	%		3.00	%		0.25	%

(ii)

(iii)

(iv)

add the following definition of “Excess Cash Flow” to Section 1.01 of the Credit Agreement as follows:

(v)

restate Section 2.08(b) of the Credit Agreement as follows:

(vi)

restate Section 2.09(d) of the Credit Agreement as follows:

principal amounts of outstanding Term Loans of each such Class), and such prepayments of the Term Loans shall be applied to reduce the remaining scheduled repayments of Term Loans of each Class in the inverse order of maturity (with any prepayments applied first to the payment at final maturity), and third to cash collateralize outstanding LC Exposure. Within each such category, such prepayments shall be applied first to CBFR Loans and then to Eurodollar Loans in order of Interest Period maturities (beginning with the earliest to mature).

(vii)

add a new Section 2.09(f) to the Credit Agreement as follows:

(viii)

amend Section 6.04(c) of the Credit Agreement by replacing the reference therein to “$5,000,000” with “$2,500,000.”;

(ix)

restate Sections 6.12(a) and (b) of the Credit Agreement as follows:

As of September 30, 2017, we were in compliance with all such covenants.

Simultaneous with the execution of Third Amendment, we entered into a Patent and Trademark Security Agreement, which replaces the Patent and Trademark Security Agreement entered into on March 23, 2015 at the time we entered into the Credit Agreement. The new Patent and Trademark Security Agreement was revised to make reference to the Third Amendment and we have provided the Lender with updated schedules listing our trademarks, patents, applications for trademarks and patents, and other intellectual properties owned or licensed.

As a result of the changes to the definition of ‘Leverage Ratio” and “Fixed Charge Coverage Ratio” within the Third Amendment, we will have increased flexibility to effect the changes necessary to return us to a strong financial position. The change to the definition of “Applicable Rate” will effectively increase our interest rate under the Credit Agreement by 50 basis points in the near term, while allowing for us to reduce that rate as our Leverage Ratio declines. The addition of the provision that requires the prepayment of a percentage of our annual “Excess Cash Flow” will ensure our primary goal remains to reduce the total debt outstanding.

As of September 30, 2017, Term Loan A under the Credit Facility had a balance of $29.5 million. The availability under the revolving credit line under the Credit Facility is based upon our eligible accounts receivable and eligible inventory and is computed as follows (in thousands):


	September 30, 2017			December 31, 2016
Revolver:
Gross Availability	$	9,810		$	10,000
Outstanding Draws		—			—
Letter of Credit		(750	)		—
Landlord Reserves		(45	)		(45	)

Availability on Revolver	$	9,015		$	9,955

Critical Accounting Policies and Estimates

The unaudited condensed consolidated financial statements are prepared in conformity with U.S. GAAP, which require the use of estimates, judgments and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses in the periods presented. We believe that the accounting estimates employed are appropriate and resulting balances are reasonable; however, due to inherent uncertainties in making estimates, actual results could differ from the original estimates, requiring adjustments to these balances in future periods. The critical accounting estimates that affect the unaudited condensed consolidated financial statements and the judgments and assumptions used are consistent with those described in the MD&A section in our annual report on Form 10-K for the year ended December 31, 2016, with the exception of our adoption of ASU’s 2016-09 and 2015-17. See Note 11 for further details.

Item 3.

Quantitative and Qualitative Disclosures About Market Risk

InfuSystem is a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and is not required to provide the information required under this item.

Item 4.

Controls and Procedures

Evaluation of Disclosure Controls and Procedures and Changes in Internal Control over Financial Reporting

We maintain a set of disclosure controls and procedures designed to ensure that material information required to be disclosed in our filings under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and that material information is accumulated and communicated to our management, including our Principal Executive Officer (“PEO”) and Chief Financial Officer (“CFO”), as appropriate, to allow timely decisions regarding required disclosures. Our PEO and CFO have evaluated these disclosure controls and procedures as of the end of the period covered by this quarterly report on Form 10-Q and have determined that such disclosure controls and procedures were effective.

There has been no change in our internal control over financial reporting during our most recent calendar quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

PART II—OTHER INFORMATION

Item 1.

Legal Proceedings

From time to time in the ordinary course of our business, we may be involved in legal proceedings, the outcomes of which may not be determinable. The results of litigation are inherently unpredictable. Any claims against us, whether meritorious or not, could be time consuming, result in costly litigation, require significant amounts of management time and result in diversion of significant resources. We are not able to estimate an aggregate amount or range of reasonably possible losses for those legal matters for which losses are not probable and estimable, primarily for the following reasons: (i) many of the relevant legal proceedings are in preliminary stages, and until such proceedings develop further, there is often uncertainty regarding the relevant facts and circumstances at issue and potential liability; and (ii) many of these proceedings involve matters of which the outcomes are inherently difficult to predict. We have insurance policies covering potential losses where such coverage is cost effective.

As a result of the restatement of our financial statements as of December 31, 2015 and the first and second quarters of 2016, we are currently involved in a class-action lawsuit filed by shareholders. On November 8, 2016, a purported shareholder of the Company filed a putative class-action lawsuit in the U.S. District Court for the Central District of California (the “Court”) (Case No. 2:16-cv-08295-ODW) against us and two individual defendants: Eric Steen, our former Chief Executive Officer, President and Director; and Jonathan Foster, our former Chief Financial Officer. The complaint alleges that the defendants issued materially false and misleading statements in and/or omitted material facts from documents filed with the SEC between May 12, 2015 and November 7, 2016. The complaint asserts claims against all defendants under the antifraud provisions of the federal securities laws and against Messrs. Steen and Foster as control persons. The complaint seeks compensatory damages for the putative class, prejudgment and post-judgment interest, attorneys’ fees and other costs. Two other shareholders subsequently filed motions for appointment as lead plaintiff and for appointment of their attorneys as lead counsel for the putative class. On February 17, 2017, the Court appointed a lead plaintiff for the putative class. On April 18, 2017, the lead plaintiff filed an amended class-action complaint with the Court. On June 19, 2017, the Company and all defendants filed a Motion to Dismiss the amended complaint, and that motion is now fully briefed and is pending before the Court.

We believe that the allegations against us and our officers are without merit and intend to vigorously defend against the claims asserted. The ultimate resolution of this matter cannot be predicted, however, and it is not possible at this time for us to estimate any probable loss or range of losses because of the preliminary nature of the matter.

Item 1A.

Risk Factors

For information regarding factors that could affect our results of operations, financial condition and liquidity, refer to the section entitled “Risk Factors” in Part I, Item 1A in our Annual Report on Form 10-K for the year ended December 31, 2016.

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

None.

Item 3.

Defaults Upon Senior Securities

None.

Item 4.

Mine Safety Disclosures

Not applicable.

Item 5.

Other Information

None.

Item 6.

Exhibits


Exhibits

31.1*		Certification of Principle Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

31.2*		Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

32.1*		Certification of the Principle Executive Officer pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002**

32.2*		Certification of the Chief Financial Officer pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002**

101.INS*		XBRL Instance Document

101.SCH*		XBRL Taxonomy Extension Schema Document

101.CAL*		XBRL Taxonomy Extension Calculation Linkbase Document

101.DEF*		XBRL Taxonomy Extension Definition Linkbase Document

101.LAB*		XBRL Taxonomy Extension Label Linkbase Document

101.PRE*		XBRL Taxonomy Extension Presentation Linkbase Document

*		Filed herewith
**		Pursuant to Item 601(b)(32) of Regulation S-K, this Exhibit is furnished rather than filed with the Form 10-Q.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


				INFUSYSTEM HOLDINGS, INC.

Date: November 10, 2017				/s/ Gregg Lehman
				Gregg Lehman
				Executive Chairman of the Board Director
				(Principal Executive Officer)

Date: November 10, 2017				/s/ Christopher Downs
				Christopher Downs
				Chief Financial Officer (Interim)
				(Principal Financial Officer)

Date: November 10, 2017				/s/ Trent N. Smith
				Trent N. Smith
				Chief Accounting Officer
				(Principal Accounting Officer)

EX-31.1 2 d486354dex311.htm EX-31.1 EX-31.1

Exhibit 31.1

CERTIFICATION BY PRINCIPLE EXECUTIVE OFFICER

I, Gregg Lehman, certify that:

1. I have reviewed this quarterly report on Form 10-Q of InfuSystem Holdings, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and we have:

a. designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b. designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c. evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d. disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting.

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a. all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b. any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: November 10, 2017

/s/ Gregg Lehman

Gregg Lehman

Executive Chairman of the Board Director

(Principal Executive Officer)

EX-31.2 3 d486354dex312.htm EX-31.2 EX-31.2

Exhibit 31.2

CERTIFICATION BY CHIEF FINANCIAL OFFICER

I, Christopher Downs, certify that:

1. I have reviewed this quarterly report on Form 10-Q of InfuSystem Holdings, Inc.

b. any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: November 10, 2017

/s/ Christopher Downs

Christopher Downs

Chief Financial Officer (Interim)

EX-32.1 4 d486354dex321.htm EX-32.1 EX-32.1

Exhibit 32.1

CERTIFICATION OF PRINICPLE EXECUTIVE OFFICER

Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

(Subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code)

Pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of title 18, United States Code), the undersigned officer of InfuSystem Holdings, Inc., a Delaware corporation (the “Company”), does hereby certify, to such officer’s knowledge, that:

The quarterly report on Form 10-Q for the quarter ended September 30, 2017 (the “Form 10-Q”) of the Company fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, and information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: November 10, 2017

/s/ Gregg Lehman

Gregg Lehman

Executive Chairman of the Board Director

(Principal Executive Officer)

EX-32.2 5 d486354dex322.htm EX-32.2 EX-32.2

Exhibit 32.2

CERTIFICATION OF CHIEF FINANCIAL OFFICER

Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

(Subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code)

Date: November 10, 2017

/s/ Christopher Downs

Christopher Downs

Chief Financial Officer (Interim)

EX-101.INS 6 infu-20170930.xml XBRL INSTANCE DOCUMENT

32000000

5000000

32000000

0.0275 0.0250 0.0225 22780738

10000000

8000000

27000000

0.0275 0.0250 0.0225

25000000

10000000

5000000

12500000

5000000

2500000

1072000

6847000

14768000

10971000

4426000

92383000

4093000

85335000

584000

101000

700000

33000

685000

153000

803000

200000000

22780738

15000

0.035

514000

0.0001

22978398

2000

0.0399

16334000

4347000

5248000

3975000

4783000

5216000

1382000

26951000

1873000

53328000

36589000

85335000

26636000

9953000

29384000

2849000

3037000

571000

19702000

26535000

938000

1121000

1223000

2427000

4416000

1324000

70000

181000

419000

331000

0.0001

1000000

1711000

6137000

-43639000

48746000

127000

1200000 938000 25501000 5300000 5116000 30000 30000 7000 30000 30000 484000 24301000 1838000 33861000 28000 58681000 1256000 419000 26377000 181000 519000 99000

2700000

750000

9810000

9015000

45000

30665999.98

0.75 0.50 0.00

4027000

13635000

9608000

1120000

1136000

16000

23000

21207000

36534000

15327000

2000000

0.036

29511000

2877000

3067000

578000

19732000

26634000

82000

36000

118000

3253000

589000

3842000

1091000

1086000

2177000

0.0124

0.0275

818000

4989000

20769000

11581000

4118000

91829000

5315000

96344000

2938000

2573000

3398000

200000000

22669675

0.0001

22867335

2000

2675000

12436000

31239000

2166000

53438000

45655000

96344000

29216000

16439000

31891000

5314000

26577000

949000

2872000

66000

225000

0.0001

1000000

1997000

6115000

-41142000

50689000

109000

1642000 29678000 3900000 28036000 30447000 22000 59034000 22199000 551000 87000

10000000

9955000

45000

1685000

13745000

12060000

1064000

1136000

72000

23000

19427000

36534000

17107000

2000000

32000000

5336000

26664000

83000

46000

129000

3071000

738000

3809000

964000

1213000

2177000

200000

1300000

0.0025

0.0200

-0.0100

0.0025

0.0225

-0.0075

0.0025

0.0250

-0.0050

0.0025

0.0275

0.0000

0.0025

0.0300

0.0025

200000

false

4182000

-2595000

13612000

--12-31

<div> <table style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr style="break-inside: avoid"> <td valign="top" width="4%" align="left">5.</td> <td valign="top" align="left">Debt</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"> On March 23, 2015, the Company and its direct and indirect subsidiaries (the “Borrowers”) entered into a credit agreement (the “Chase Credit Agreement”) with JPMorgan Chase Bank, N.A., as lender (the “Lender”). The Chase Credit Agreement originally provided for a $27.0 million Term Loan A, up to an $8.0 million Term Loan B and a $10.0 million revolving credit facility (the “Revolver”) and a maturity date of March 23, 2020, collectively (the “Credit Facility”). The Borrowers drew $27.0 million under the Term Loan A to repay and terminate the previously existing Credit Facility under the credit agreement dated November 30, 2012, as amended, by and among the Company, its direct and indirect subsidiaries, Wells Fargo Bank, National Association, as administrative agent, and certain lenders party thereto (the “WF Facility”). Term Loan B was unfunded at closing and beginning on April 20, 2015, the closing date of the acquisition of the assets of Ciscura, the Borrowers drew $8.0 million on Term Loan B, in several installments, in accordance with the requirements of the asset purchase agreement governing the acquisition to fund the acquisition and associated expenses. The remaining available amount on Term Loan B expired on March 23, 2016. <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"> On December 5, 2016, the Company entered into a First Amendment to the Chase Credit Agreement to waive certain events of default then existing thereunder, as well as to make certain amendments to the Credit Facility, including but not limited to: (i) restructuring of the Credit Facility that effectively consolidated Term Loan A and Term Loan B into a new single term loan (the “Term Loan”) resulting in a new total drawn amount of $32 million under the Term Loan with the approximately $5 million excess over the current aggregate drawn amounts under Term Loan A and Term Loan B to be available to reduce the Company’s drawings under the revolving credit line under the Credit Facility; (ii) extending the maturity date of the Term Loan and the revolving credit line to December 5, 2021; (iii) setting the quarterly mandatory principal payment due on the Term Loan to $1.3 million due on the last business day of each fiscal quarter with any remaining unpaid and outstanding amount due at maturity; and (iv) amending the leverage ratio covenant to provide for the following schedule of maximum permitted ratios: (a) 2.75 to 1.0 at any time on or after December 31, 2015 but prior to March 31, 2017, (b) 2.50 to 1.0 at any time on or after March 31, 2017 but prior to March 31, 2018 or (c) 2.25 to 1.00 at any time on or after March 31, 2018. <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"> On March 22, 2017, the Company entered into a Second Amendment to the Chase Credit Agreement to make certain amendments to the Credit Facility, including but not limited to: (i) amending the definition of “Fixed Charges” to increase the Company’s ability to prepay its indebtedness under the Credit Facility without negatively impacting its financial covenants; and (ii) amending the leverage ratio covenant to provide for the following schedule of maximum permitted ratios: (a) 2.75 to 1.0 at any time on or after December 31, 2015 but prior to March 31, 2018, (b) 2.50 to 1.0 at any time on or after March 31, 2018 but prior to March 31, 2019 or (c) 2.25 to 1.00 at any time on or after March 31, 2019. <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"> As of March 31, 2017, the Company breached a financial covenant under its Credit Facility, which resulted in an event of default under the Credit Facility. Specifically, the Company was not in compliance with the leverage ratio covenant under the Credit Facility. The required maximum leverage ratio under the Credit Facility as of March 31, 2017 was 2.75 compared to an actual ratio of 2.96. The Company subsequently received a waiver from this breach from the Lender on May 10, 2017, which provided a limited, specific and one-time waiver from this breach but did not otherwise modify the terms of the Credit Facility. No fee was paid to the Lender in connection with this waiver. <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">   <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"> On June 28, 2017, the Company entered into a Third Amendment to the Chase Credit Agreement to make certain amendments to the Credit Facility, including but not limited to: <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">   <table style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr style="break-inside: avoid"> <td width="8%"> </td> <td valign="top" width="5%" align="left">(i)</td> <td valign="top" align="left">restates the chart within the definition of “Applicable Rate” in Section 1.01 of the Credit Agreement as follows:</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">   <table style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="55%" align="center" border="0"> <tr> <td width="72%"></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="bottom" nowrap="nowrap" align="center"> Leverage Ratio </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">CBFR  Spread</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Eurodollar Spread</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Commitment Fee Rate</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid" bgcolor="#CCEEFF"> <td valign="top" align="center"> Level I < 1.5:1.0 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">-1.00</td> <td valign="bottom" nowrap="nowrap">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2.00</td> <td valign="bottom" nowrap="nowrap">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0.25</td> <td valign="bottom" nowrap="nowrap">% </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="top" align="center"> Level II < 2.0:1.0 to 1.0 but ³ 1.5:1.0 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">-0.75</td> <td valign="bottom" nowrap="nowrap">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2.25</td> <td valign="bottom" nowrap="nowrap">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0.25</td> <td valign="bottom" nowrap="nowrap">% </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid" bgcolor="#CCEEFF"> <td valign="top" align="center"> Level III < 2.5:1.0 to 1.0 but ³ 2.0:1.0 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">-0.50</td> <td valign="bottom" nowrap="nowrap">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2.50</td> <td valign="bottom" nowrap="nowrap">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0.25</td> <td valign="bottom" nowrap="nowrap">% </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="top" align="center"> Level IV < 3.0:1.0 to 1.0 but ³ 2.5:1.0 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0.00</td> <td valign="bottom" nowrap="nowrap">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2.75</td> <td valign="bottom" nowrap="nowrap">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0.25</td> <td valign="bottom" nowrap="nowrap">% </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid" bgcolor="#CCEEFF"> <td valign="top" align="center"> Level V ³ 3.0:1.0 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0.25</td> <td valign="bottom" nowrap="nowrap">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3.00</td> <td valign="bottom" nowrap="nowrap">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0.25</td> <td valign="bottom" nowrap="nowrap">% </td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 203px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"> and further amends the definition of “Applicable Rate” in Section 1.01 of the Credit Agreement by adding the following to the end thereof: “The Applicable Rate will be set at Level V as of the Third Amendment Effective Date, and adjusted for the first time thereafter based on the financial statements required to be delivered hereunder for the fiscal quarter ending June 30, 2017.”; <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">   <table style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr style="break-inside: avoid"> <td width="8%"> </td> <td valign="top" width="5%" align="left">(ii)</td> <td valign="top" align="left">amend the definition of “Fixed Charge Coverage Ratio” in Section 1.01 of the Credit Agreement by adding the phrase “(it is acknowledged that, at all times, such unfinanced portion is either a deduction to EBITDA or, if unfinanced portion is ever interpreted to be a negative number, then zero)” to follow the phrase therein that reads “means, for any period, the ratio of (a) EBITDA minus the unfinanced portion of Capital Expenditures.”;</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">   <table style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr style="break-inside: avoid"> <td width="8%"> </td> <td valign="top" width="5%" align="left">(iii)</td> <td valign="top" align="left">amend clause (f)(ii) in the definition of “Permitted Acquisition” in Section 1.01 of the Credit Agreement by (a) replacing the reference therein to “$10,000,000” with “$5,000,000” and (b) by replacing the reference therein to “$25,000,000” with “$12,500,000.”;</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">   <table style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr style="break-inside: avoid"> <td width="8%"> </td> <td valign="top" width="5%" align="left">(iv)</td> <td valign="top" align="left">add the following definition of “Excess Cash Flow” to Section 1.01 of the Credit Agreement as follows:</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 266px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"> “Excess Cash Flow” means, for any fiscal year of the Company, (a) EBITDA for such fiscal year, minus (b) Capital Expenditures made or incurred during such fiscal year minus (c) Fixed Charges for such fiscal year. <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">   <table style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr style="break-inside: avoid"> <td width="8%"> </td> <td valign="top" width="5%" align="left">(v)</td> <td valign="top" align="left">restate Section 2.08(b) of the Credit Agreement as follows:</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 266px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"> (b) The Borrowers hereby unconditionally agree that the Term A Loans and the Term B Loans shall be replaced and refinanced in full as of the First Amendment Effective Date with a Term Loan in an aggregate amount equal to $32,000,000 made under Section 2.01(d), the Borrowers acknowledge and agree that the principal balance of such Term Loan as of the Third Amendment Effective Date is $30,665,999.98, and the Borrowers hereby unconditionally promise to pay to the Lender the principal amount of the Term Loans made under Section 2.01(d) after the Third Amendment Effective Date as follows: (i) on June 30, 2017, September 30, 2017 and December 31, 2017 in principal installments each in the amount of $577,500 (as adjusted from time to time pursuant to Section 2.09(d) or 2.16(b)), (ii) commencing with the last Business Day of March, 2018 and on the last Business Day of each March, June, September and December thereafter, in consecutive quarterly principal installments each in the amount of $766,650 (as adjusted from time to time pursuant to Section 2.09(d) or 2.16(b)) and (iii) to the extent not previously paid, all unpaid Term Loans shall be paid in full in cash by the Borrowers on the Term Maturity Date. <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">   <table style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr style="break-inside: avoid"> <td width="8%"> </td> <td valign="top" width="5%" align="left">(vi)</td> <td valign="top" align="left">restate Section 2.09(d) of the Credit Agreement as follows:</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 266px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"> (d) All prepayments required to be made pursuant to Section 2.09(c) shall be applied, first to prepay the Term Loans (and in the event Term Loans of more than one Class shall be outstanding at the time, shall be allocated among the Term Loans pro rata based on the aggregate principal amounts of outstanding Term Loans of each such Class), and such prepayments of the Term Loans shall be applied to reduce the remaining scheduled repayments of Term Loans of each Class in the inverse order of maturity (with any prepayments applied first to the payment at final maturity), second to prepay the Revolving Loans without a corresponding reduction in the Revolving Commitment and third to cash collateralize outstanding LC Exposure. Within each such category, such prepayments shall be applied first to CBFR Loans and then to Eurodollar Loans in order of Interest Period maturities (beginning with the earliest to mature). <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 266px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"> All prepayments required to be made pursuant to Section 2.09(f) shall be applied, first to prepay the Revolving Loans without a corresponding reduction in the Revolving Commitment, second to prepay the Term Loans (and in the event Term Loans of more than one Class shall be outstanding at the time, shall be allocated among the Term Loans pro rata based on the aggregate principal amounts of outstanding Term Loans of each such Class), and such prepayments of the Term Loans shall be applied to reduce the remaining scheduled repayments of Term Loans of each Class in the inverse order of maturity (with any prepayments applied first to the payment at final maturity), and third to cash collateralize outstanding LC Exposure. Within each such category, such prepayments shall be applied first to CBFR Loans and then to Eurodollar Loans in order of Interest Period maturities (beginning with the earliest to mature). <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">   <table style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr style="break-inside: avoid"> <td width="8%"> </td> <td valign="top" width="5%" align="left">(vii)</td> <td valign="top" align="left">add a new Section 2.09(f) to the Credit Agreement as follows:</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 266px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"> (f) Until the latest of the Revolving Credit Maturity Date, the Term A Maturity Date, the Term B Maturity Date or the Term Maturity Date, as the case may be, the Borrowers shall prepay the Obligations as set forth in Section 2.09(d) on the date that is ten days after the earlier of (i) the date on which the Company’s annual audited financial statements for the immediately preceding fiscal year are delivered pursuant to Section 5.01 or (ii) the date on which such annual audited financial statements were required to be delivered pursuant to Section 5.01, in an amount equal to: (I) seventy-five percent (75%) of the Company’s Excess Cash Flow for the immediately preceding fiscal year if the Company’s Leverage Ratio is greater than or equal to 2.5 to 1.0 for the immediately preceding fiscal year, (II) fifty percent (50%) of the Company’s Excess Cash Flow for the immediately preceding fiscal year if the Company’s Leverage Ratio is less than 2.5 to 1.0 but greater than or equal to 2.0 to 1.0 for the immediately preceding fiscal year, or (III) zero percent (0%) of the Company’s Excess Cash Flow for the immediately preceding fiscal year if the Company’s Leverage Ratio is less than 2.0 to 1.0 for the immediately preceding fiscal year. Each Excess Cash Flow prepayment shall be accompanied by a certificate signed by a Financial Officer of the Company certifying the manner in which Excess Cash Flow and the resulting prepayment was calculated, which certificate shall be in form and substance satisfactory to the Lender. <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">   <table style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr style="break-inside: avoid"> <td width="8%"> </td> <td valign="top" width="5%" align="left">(viii)</td> <td valign="top" align="left">amend Section 6.04(c) of the Credit Agreement by replacing the reference therein to “$5,000,000” with “$2,500,000.”;</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">   <table style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr style="break-inside: avoid"> <td width="8%"> </td> <td valign="top" width="5%" align="left">(ix)</td> <td valign="top" align="left">restate Sections 6.12(a) and (b) of the Credit Agreement as follows:</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 266px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"> (a) Leverage Ratio. The Borrowers will not permit the Leverage Ratio to exceed (i) 4.0 to 1.0 at any time on or after the Effective Date but prior to December 31, 2017, (ii) 3.75 to 1.0 at any time on or after December 31, 2017 but prior to June 30, 2018, (iii) 3.50 to 1.0 at any time on or after June 30, 2018 but prior to December 31, 2018, or (iv) 3.00 to 1.00 at any time on or after December 31, 2018. <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 266px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"> (b) Fixed Charge Coverage Ratio. The Borrowers will not permit the Fixed Charge Coverage Ratio to be less than (i) 1.15:1.0 at any time on or after the Effective Date but prior to March 31, 2018, or (ii) 1.25:1.0 at any time on or after March 31, 2018. <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"> As of September 30, 2017, the Borrowers were in compliance with all such covenants. <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"> Simultaneous with the execution of Third Amendment, the Company entered into a Patent and Trademark Security Agreement, which replaces the Patent and Trademark Security Agreement entered into on March 23, 2015 at the time the Company entered into the Credit Agreement. The new Patent and Trademark Security Agreement was revised to make reference to the Third Amendment and the Company has provided the Lender with updated schedules listing the Company’s trademarks, patents, applications for trademarks and patents, and other intellectual properties owned or licensed. <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"> As a result of the changes to the definition of ‘Leverage Ratio” and “Fixed Charge Coverage Ratio” within the Third Amendment, the Company will have increased flexibility. The change to the definition of “Applicable Rate” will effectively increase the Company’s interest rate under the Credit Agreement by 50 basis points in the near term, while allowing for the Company to reduce that rate as its Leverage Ratio declines. <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">   <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"> To secure repayment of the obligations of the Borrowers, each Borrower has granted to the Lender, for the benefit of various secured parties, a first priority security interest in substantially all of the personal property assets of each of the Borrowers. In addition, the Company has pledged the shares of InfuSystem Holdings USA, Inc. (“Holdings USA”) and Holdings USA has pledged the shares of each of InfuSystem, Inc. and First Biomedical, Inc. and the equity interests of IFC, LLC to the Lender, for the benefit of the secured parties, to further secure the obligations under the Chase Credit Agreement. <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"> The availability under the Revolver is based upon the Borrowers’ eligible accounts receivable and eligible inventory and is comprised as follows (in thousands): <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">   <table style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="73%"></td> <td valign="bottom" width="8%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="8%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">September 30, 2017</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">December 31, 2016</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid" bgcolor="#CCEEFF"> <td valign="top"> Revolver: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="top"> Gross Availability </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">9,810</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">10,000</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid" bgcolor="#CCEEFF"> <td valign="top"> Outstanding Draws </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="top"> Letter of Credit </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(750</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid" bgcolor="#CCEEFF"> <td valign="top"> Landlord Reserves </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(45</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(45</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="top"> Availability on Revolver </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">9,015</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">9,955</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"> The Company had approximate future maturities of loans as of September 30, 2017 as follows (in thousands): <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">   <table style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="100%" align="center" border="0"> <tr> <td width="63%"></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2017</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2018</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2019</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2020</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2021</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Total</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid" bgcolor="#CCEEFF"> <td valign="top"> Term Loan </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">578</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">3,067</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">3,067</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">3,067</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">19,732</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">29,511</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="top"> Unamortized value of the debt issuance costs (a) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(7</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(30</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(30</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(30</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(30</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(127</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid" bgcolor="#CCEEFF"> <td valign="top"> Revolver </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="top"> Total </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">571</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">3,037</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">3,037</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">3,037</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">19,702</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">29,384</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">   <table style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr style="break-inside: avoid"> <td valign="top" width="4%" align="left">(a)</td> <td valign="top" align="left">Includes the reclassification of the debt issuance costs as a result of the Company adopting ASU 2015-03</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"> The following is a breakdown of the Company’s current and long-term debt as of September 30, 2017 and December 31, 2016 (in thousands): <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">   <table style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="100%" align="center" border="0"> <tr> <td width="30%"></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td width="28%"></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="12" nowrap="nowrap" align="center"> September 30, 2017 </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="12" align="center"> December 31, 2016 </td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Current Portion of Long-Term Debt</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Long-Term Debt</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Total</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Current Portion of Long-Term Debt</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Long-Term Debt</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Total</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid" bgcolor="#CCEEFF"> <td valign="top"> Term Loan </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,877</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">26,634</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">29,511</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"> Term Loans </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">5,336</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">26,664</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">32,000</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="top">Unamortized value of the debt issuance costs (a)</td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(28</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(99</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(127</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom">Unamortized value of the debt issuance costs (a)</td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(22</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(87</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(109</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid" bgcolor="#CCEEFF"> <td valign="top"> Revolver </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"> Revolver </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="top"> Total </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,849</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">26,535</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">29,384</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"> Total </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">5,314</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">26,577</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">31,891</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">   <table style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr style="break-inside: avoid"> <td valign="top" width="4%" align="left">(a)</td> <td valign="top" align="left">Includes the reclassification of the debt issuance costs as a result of the Company adopting ASU 2015-03</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"> As of September 30, 2017, interest on the Credit Facility is payable at our option as a (i) Eurodollar Loan, which bears interest at a per annum rate equal to LIBOR Plus a margin ranging from 2.00% to 3.00% or (ii) CBFR Loan, which bears interest at a per annum rate equal to the greater of (a) the lender’s prime rate or (b) LIBOR for a 30-day interest period plus 2.50%, in each case, plus a margin ranging from -1.00% to 0.25%. The actual rate at September 30, 2017 was 3.99% (LIBOR of 1.24% plus 2.75%). </div>

400000

0.252

Q3 2017 10-Q

-0.12

2017-09-30

-0.12

InfuSystem Holdings, Inc 0001337013 Smaller Reporting Company

32031000

18451000

-3627000

<div> <table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" border="0" cellpadding="0" cellspacing="0" width="100%"> <tr style="page-break-inside:avoid"> <td width="4%" valign="top" align="left">6.</td> <td align="left" valign="top">Income Taxes</td> </tr> </table> During the three and nine months ended September 30, 2017, the Company recorded income tax expense of $0.3 million and an income tax benefit of $0.9 million, respectively. During the three and nine months ended September 30, 2016, the Company recorded an income tax expense of $0.1 million and $0.2 million, respectively. In computing its income tax provision, the Company estimates its effective tax rate for the full year and applies that rate to income earned through the reporting period. The Company’s effective income tax rate for the nine months ended September 30, 2017 was 25.2% compared to 42.3% for the same prior year period. </div>

-914000

1015000

<div> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr style="PAGE-BREAK-INSIDE: avoid"> <td valign="top" width="4%" align="left">4.</td> <td valign="top" align="left">Intangible Assets</td> </tr> </table> The carrying amount and accumulated amortization of intangible assets as of September 30, 2017 and December 31, 2016, are as follows (in thousands):   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"> <tr> <td width="70%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="10" align="center">September 30, 2017</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Gross Assets</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Accumulated Amortization</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Net</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Nonamortizable intangible assets </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Trade names </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,000</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,000</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Amortizable intangible assets </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Trade names </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">23</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">23</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Physician and customer relationships </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">36,534</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">21,207</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">15,327</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Non-competition agreements </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,136</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,120</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">16</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Software </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">13,635</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4,027</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">9,608</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Total nonamortizable and amortizable intangible assets </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">53,328</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">26,377</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">26,951</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="16"></td> <td height="16" colspan="12"></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="10" align="center">December 31, 2016</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Gross Assets</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Accumulated Amortization</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Net</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Nonamortizable intangible assets </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Trade names </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,000</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,000</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Amortizable intangible assets </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Trade names </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">23</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">23</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Physician and customer relationships </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">36,534</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">19,427</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">17,107</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Non-competition agreements </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,136</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,064</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">72</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Software </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">13,745</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,685</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">12,060</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Total nonamortizable and amortizable intangible assets </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">53,438</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">22,199</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">31,239</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table>   Amortization expense for the three and nine months ended September 30, 2017 was $1.4 million and $4.2 million, respectively, compared to $1.0 million and $2.8 million, respectively, for the three and nine months ended September 30, 2016. Expected annual amortization expense for intangible assets recorded as of September 30, 2017, is as follows (in thousands):   <table style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0"> <tr> <td width="58%"></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">10/1-12/31/2017</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2018</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2019</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2020</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2021</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2022 and thereafter</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Amortization expense </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,382</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">5,216</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">4,783</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">4,347</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">3,975</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">5,248</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> </table> </div>

689000

4102000

34532000

-7386000

-2713000

-2501000

<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"> In May 2017, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2017-09, “Stock Compensation—Scope of Modification Accounting”, which provides guidance on which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic 718. The new standard is effective for fiscal years beginning after December 15, 2017 (i.e. a January 1, 2018 effective date). The Company believes the adoption will not have a material impact on its consolidated financial statements. <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"> In January 2017, the FASB issued ASU No. 2017-04, “Intangibles—Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment”, which changes the subsequent measurement of goodwill impairment by eliminating Step 2 from the impairment test. Under the new guidance, an entity will measure impairment using the difference between the carrying amount and the fair value of the reporting unit. The new standard is effective for fiscal years beginning after December 15, 2019 (i.e. a January 1, 2020 effective date), with early adoption permitted for goodwill impairment tests with measurement dates after January 1, 2017. The Company believes the adoption will not have a material impact on its consolidated financial statements. <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"> In May 2014, the FASB issued ASU 2014-09, “Revenue from Contracts with Customers (Topic 606)”, which supersedes the revenue recognition requirements in ASC 605, “Revenue Recognition”, and most industry-specific guidance. ASU 2014-09, along with amendments in 2015 and 2016, focuses on creating a single source of revenue guidance for revenue arising from contracts with customers. Under the new standard, recognition of revenue occurs when a customer obtains control of promised goods or services in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. Additionally, the new standard requires that enhanced disclosures about the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers, including revenue recognition policies to identify performance obligations, assets recognized from costs incurred to obtain and fulfill a contract, and significant judgments in measurement and recognition. The standard, as amended, will be effective for annual periods beginning after December 15, 2017, including interim periods within that reporting period. <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"> The Company is in the process of evaluating the impact of these changes, which includes a review of existing contracts with customers, an evaluation of the specific terms of those contracts and the appropriate treatment under the new standards, and a comparison of that new treatment to the Company’s existing accounting policies to identify differences. <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"> The Company expects that the disclosures in the notes to its consolidated financial statements related to revenue recognition will be significantly expanded under the new standard, specifically regarding quantitative and qualitative information about performance obligations. <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"> The Company anticipates the adoption of ASC 606 using the modified retrospective approach, under which the cumulative effect of the initial application of the new standard will be recognized as an adjustment to the opening balance of retained earnings in the first quarter of 2018. As the Company is still in the process of finalizing its evaluation of ASU 2014-09, along with the subsequent amendments, its initial assessment may change as it refines its systems, processes, controls and assumptions. <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"> In February 2016, the FASB issued ASU No. 2016-02, “Leases (Topic 842)” (“ASU 2016-02”). Under ASU 2016-02, an entity will be required to recognize right-of-use assets and lease liabilities on its balance sheet and disclose key information about leasing arrangements. ASU 2016-02 offers specific accounting guidance for a lessee, a lessor and sale and leaseback transactions. Lessees and lessors are required to disclose qualitative and quantitative information about leasing arrangements to enable a user of the financial statements to assess the amount, timing and uncertainty of cash flows arising from leases. For public companies, ASU 2016-02 is effective for annual reporting periods beginning after December 15, 2018, including interim periods within that reporting period, and requires a modified retrospective adoption, with early adoption permitted. The Company is currently evaluating the impact, if any, that the adoption of this guidance will have on its financial position, results of operations, cash flows and/or disclosures. <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"> In March 2016, the FASB issued ASU No. 2016-09, “Compensation— Stock Compensation (Topic 718)” (“ASU 2016-09”). The guidance changes how companies account for certain aspects of equity-based payments to employees. Entities will be required to recognize income tax effects of awards in the income statement when the awards vest or are settled. The guidance also allows an employer to repurchase more of an employee’s shares than it can under current guidance for tax withholding purposes providing for withholding at the employee’s maximum rate as opposed to the minimum rate without triggering liability accounting and to make a policy election to account for forfeitures as they occur. The updated guidance is effective for annual periods beginning after December 15, 2016. Effective January 1, 2017, the Company adopted the accounting guidance contained within ASU 2016-09. Thus, the Company recorded a $0.2 million deferred tax asset and a $0.2 million increase to retained earnings on January 1, 2017 to recognize the Company’s excess tax benefits that existed as of December 31, 2016 (modified retrospective application). <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"> In June 2016, the FASB issued ASU No. 2016-13, “Financial Instruments (Topic 326) Credit Losses” (“ASU 2016-13”). ASU 2016-13 changes the impairment model for most financial assets and certain other instruments. Under the new standard, entities holding financial assets and net investment in leases that are not accounted for at fair value through net income are to be presented at the net amount expected to be collected. An allowance for credit losses will be a valuation account that will be deducted from the amortized cost basis of the financial asset to present the net carrying value at the amount expected to be collected on the financial asset. ASU 2016-13 is effective as of January 1, 2020. Early adoption is permitted. The Company is currently evaluating the impact of ASU 2016-13. The adoption of this standard is not expected to have a material impact on the Company’s consolidated financial position, results of operations, cash flows and/or disclosures. <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"> In August 2016, the FASB issued ASU No. 2016-15, “Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments” (“ASU 2016-15”). The amendments in this ASU introduce clarifications to the presentation of certain cash receipts and cash payments in the statement of cash flows. The primary updates include additions and clarifications of the classification of cash flows related to certain debt repayment activities, contingent consideration payments related to business combinations, proceeds from insurance policies, distributions from equity method investees and cash flows related to securitized receivables. ASU 2016-15 is effective for annual periods beginning after December 15, 2017, including interim periods within those fiscal years. Early adoption is permitted, including in interim periods. ASU 2016-15 requires retrospective application to all prior periods presented upon adoption. The Company is currently evaluating the impact, if any, that the adoption of this guidance will have on its cash flows and/or disclosures, however, the Company does not anticipate that the adoption of this new standard will have a material impact on the Company’s financial position, results of operations or statements of cash flows upon adoption. <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"> In November 2015, the FASB issued ASU No. 2015-17, “Income Taxes (Topic 740): Balance Sheet Classification of Deferred Taxes” (“ASU 2015-17”), simplifying the balance sheet classification of deferred taxes by requiring all deferred taxes, along with any related valuation allowance, to be presented as noncurrent. ASU 2015-17 is effective for the Company beginning in the first quarter of 2017 and may be applied either prospectively or retrospectively. The Company has chosen to apply this guidance prospectively, thus prior periods were not retrospectively adjusted. The adoption of this guidance resulted in the balance sheet reclassification of $2.7 million of current deferred tax assets to noncurrent. </div>

-1126000

45228000

700000

-111000

38000

27000

2829000

<div> Property and equipment is comprised of the following (in thousands):   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0"> <tr> <td width="62%"></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="10" align="center">September 30, 2017</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="10" align="center">December 31, 2016</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Gross Assets</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Accumulated Depreciation</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Total</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Gross Assets</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Accumulated Depreciation</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Total</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Furniture, fixtures, and equipment </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">3,842</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(3,253</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">589</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">3,809</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(3,071</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">738</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Automobiles </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">118</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(82</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">36</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">129</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(83</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">46</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Leasehold improvements </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,177</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(1,091</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,086</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,177</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(964</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,213</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Total </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">6,137</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(4,426</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,711</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">6,115</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(4,118</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,997</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

3518000

131000

28317000

4456000

35769000

<div> The following is a breakdown of the Company’s current and long-term debt as of September 30, 2017 and December 31, 2016 (in thousands):   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0"> <tr> <td width="30%"></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td width="28%"></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="12" nowrap="nowrap" align="center"> September 30, 2017 </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="12" align="center"> December 31, 2016 </td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Current Portion of Long-Term Debt</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Long-Term Debt</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Total</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Current Portion of Long-Term Debt</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Long-Term Debt</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Total</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Term Loan </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,877</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">26,634</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">29,511</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"> Term Loans </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">5,336</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">26,664</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">32,000</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top">Unamortized value of the debt issuance costs (a)</td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(28</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(99</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(127</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom">Unamortized value of the debt issuance costs (a)</td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(22</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(87</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(109</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Revolver </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"> Revolver </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Total </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,849</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">26,535</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">29,384</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"> Total </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">5,314</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">26,577</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">31,891</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table>   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr style="PAGE-BREAK-INSIDE: avoid"> <td valign="top" width="4%" align="left">(a)</td> <td valign="top" align="left">Includes the reclassification of the debt issuance costs as a result of the Company adopting ASU 2015-03</td> </tr> </table> </div>

<div> The following table reconciles the numerators and denominators of the basic and diluted (loss) income per share computations:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="53%"></td> <td valign="bottom" width="8%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="8%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="8%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="8%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center">Three Months Ended September 30</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center">Nine Months Ended September 30</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2017</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2016</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2017</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2016</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Numerator: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Net (loss) income (in thousands) </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(129</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">56</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(2,713</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">250</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Denominator: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Weighted average common shares outstanding: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Basic </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">22,755,976</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">22,620,386</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">22,725,806</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">22,614,203</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Dilutive effect of non-vested awards </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">375,257</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">445,591</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Diluted </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">22,755,976</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">22,995,643</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">22,725,806</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">23,059,794</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Net (loss) income per share: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Basic </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(0.01</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.00</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(0.12</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.01</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Diluted </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(0.01</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.00</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(0.12</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.01</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

<div> Expected annual amortization expense for intangible assets recorded as of September 30, 2017, is as follows (in thousands):   <table style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0"> <tr> <td width="58%"></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">10/1-12/31/2017</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2018</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2019</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2020</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2021</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2022 and thereafter</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Amortization expense </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,382</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">5,216</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">4,783</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">4,347</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">3,975</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">5,248</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> </table> </div>

<div> The Company had approximate future maturities of loans as of September 30, 2017 as follows (in thousands):   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0"> <tr> <td width="63%"></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2017</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2018</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2019</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2020</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2021</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Total</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Term Loan </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">578</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">3,067</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">3,067</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">3,067</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">19,732</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">29,511</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Unamortized value of the debt issuance costs (a) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(7</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(30</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(30</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(30</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(30</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(127</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Revolver </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Total </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">571</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">3,037</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">3,037</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">3,037</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">19,702</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">29,384</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table>   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr style="PAGE-BREAK-INSIDE: avoid"> <td valign="top" width="4%" align="left">(a)</td> <td valign="top" align="left">Includes the reclassification of the debt issuance costs as a result of the Company adopting ASU 2015-03</td> </tr> </table> </div>

52184000

6956000

<div> The availability under the Revolver is based upon the Borrowers’ eligible accounts receivable and eligible inventory and is comprised as follows (in thousands):   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="73%"></td> <td valign="bottom" width="8%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="8%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">September 30, 2017</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">December 31, 2016</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Revolver: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Gross Availability </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">9,810</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">10,000</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Outstanding Draws </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Letter of Credit </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(750</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Landlord Reserves </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(45</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(45</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Availability on Revolver </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">9,015</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">9,955</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

7443000

INFU

22725806

6541000 4800000 14000000 <div> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr style="PAGE-BREAK-INSIDE: avoid"> <td valign="top" width="4%" align="left">2.</td> <td valign="top" align="left">Medical Equipment and Property</td> </tr> </table> Medical equipment consisted of the following as of September 30, 2017 and December 31, 2016 (in thousands):   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="72%"></td> <td valign="bottom" width="8%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="8%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">September 30, 2017</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">December 31, 2016</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Medical Equipment held for sale or rental </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,200</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,642</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Medical Equipment in rental service </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">58,681</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">59,034</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Medical Equipment in rental service—pump reserve </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(519</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(551</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Accumulated depreciation </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(33,861</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(30,447</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Medical Equipment in rental service—net </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">24,301</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">28,036</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Total </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">25,501</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">29,678</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> Depreciation expense for medical equipment for the three and nine months ended September 30, 2017 was $1.7 million and $4.8 million, respectively, compared to $1.6 million and $4.7 million for the same prior year periods, which was recorded in cost of revenues – pump depreciation and disposals, for each period. </div> <div> Medical equipment consisted of the following as of September 30, 2017 and December 31, 2016 (in thousands):   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="72%"></td> <td valign="bottom" width="8%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="8%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">September 30, 2017</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">December 31, 2016</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Medical Equipment held for sale or rental </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,200</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,642</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Medical Equipment in rental service </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">58,681</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">59,034</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Medical Equipment in rental service—pump reserve </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(519</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(551</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Accumulated depreciation </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(33,861</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(30,447</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Medical Equipment in rental service—net </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">24,301</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">28,036</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Total </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">25,501</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">29,678</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div> <div> The carrying amount and accumulated amortization of intangible assets as of September 30, 2017 and December 31, 2016, are as follows (in thousands):   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"> <tr> <td width="70%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="10" align="center">September 30, 2017</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Gross Assets</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Accumulated Amortization</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Net</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Nonamortizable intangible assets </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Trade names </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,000</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,000</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Amortizable intangible assets </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Trade names </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">23</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">23</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Physician and customer relationships </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">36,534</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">21,207</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">15,327</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Non-competition agreements </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,136</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,120</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">16</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Software </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">13,635</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4,027</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">9,608</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Total nonamortizable and amortizable intangible assets </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">53,328</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">26,377</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">26,951</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="16"></td> <td height="16" colspan="12"></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="10" align="center">December 31, 2016</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Gross Assets</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Accumulated Amortization</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Net</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Nonamortizable intangible assets </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Trade names </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,000</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,000</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Amortizable intangible assets </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Trade names </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">23</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">23</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Physician and customer relationships </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">36,534</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">19,427</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">17,107</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Non-competition agreements </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,136</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,064</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">72</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Software </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">13,745</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,685</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">12,060</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Total nonamortizable and amortizable intangible assets </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">53,438</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">22,199</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">31,239</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div> <div> Future minimum rental payments pursuant to leases that have an initial or remaining non-cancelable lease term in excess of one year as of September 30, 2017 are as follows (in thousands):   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"> <tr> <td width="74%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Capital Leases</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Operating Leases</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Total</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> 2017 </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">153</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">331</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">484</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> 2018 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">514</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,324</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,838</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> 2019 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">33</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,223</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,256</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> 2020 </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">419</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">419</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> 2021 </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">181</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">181</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Thereafter </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">938</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">938</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Total require payments </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">700</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">4,416</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">5,116</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Less amounts representing interest (3.5%) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(15</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Present value of minimum lease payments </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">685</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Less current maturities </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(584</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Long-term capital lease liability </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">101</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> </table> </div> <div> On June 28, 2017, the Company entered into a Third Amendment to the Chase Credit Agreement to make certain amendments to the Credit Facility, including but not limited to:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr style="PAGE-BREAK-INSIDE: avoid"> <td width="8%"> </td> <td valign="top" width="5%" align="left">(i)</td> <td valign="top" align="left">restates the chart within the definition of “Applicable Rate” in Section 1.01 of the Credit Agreement as follows:</td> </tr> </table>   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="55%" align="center" border="0"> <tr> <td width="72%"></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom" nowrap="nowrap" align="center"> Leverage Ratio </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">CBFR Spread</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Eurodollar Spread</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Commitment Fee Rate</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top" align="center"> Level I < 1.5:1.0 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">-1.00</td> <td valign="bottom" nowrap="nowrap">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2.00</td> <td valign="bottom" nowrap="nowrap">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0.25</td> <td valign="bottom" nowrap="nowrap">% </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top" align="center"> Level II < 2.0:1.0 to 1.0 but ³ 1.5:1.0 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">-0.75</td> <td valign="bottom" nowrap="nowrap">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2.25</td> <td valign="bottom" nowrap="nowrap">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0.25</td> <td valign="bottom" nowrap="nowrap">% </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top" align="center"> Level III < 2.5:1.0 to 1.0 but ³ 2.0:1.0 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">-0.50</td> <td valign="bottom" nowrap="nowrap">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2.50</td> <td valign="bottom" nowrap="nowrap">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0.25</td> <td valign="bottom" nowrap="nowrap">% </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top" align="center"> Level IV < 3.0:1.0 to 1.0 but ³ 2.5:1.0 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0.00</td> <td valign="bottom" nowrap="nowrap">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2.75</td> <td valign="bottom" nowrap="nowrap">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0.25</td> <td valign="bottom" nowrap="nowrap">% </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top" align="center"> Level V ³ 3.0:1.0 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0.25</td> <td valign="bottom" nowrap="nowrap">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3.00</td> <td valign="bottom" nowrap="nowrap">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0.25</td> <td valign="bottom" nowrap="nowrap">% </td> </tr> </table> </div>

600000

Setting the quarterly mandatory principal payment due on the Term Loan to $1.3 million due on the last business day of each fiscal quarter with any remaining unpaid and outstanding amount due at maturity

1.15 4.0 1.25 3.75 3.50 3.00 0.0300 0.0200

Amending the leverage ratio covenant to provide for the following schedule of maximum permitted ratios: (a) 2.75 to 1.0 at any time on or after December 31, 2015 but prior to March 31, 2017, (b) 2.50 to 1.0 at any time on or after March 31, 2017 but prior to March 31, 2018 or (c) 2.25 to 1.00 at any time on or after March 31, 2018.

0.0050

766650

577500

2.5 2.0 2.5 2.0 0.0025 -0.0100

0.0250

P30D

Amending the leverage ratio covenant to provide for the following schedule of maximum permitted ratios: (a) 2.75 to 1.0 at any time on or after December 31, 2015 but prior to March 31, 2018, (b) 2.50 to 1.0 at any time on or after March 31, 2018 but prior to March 31, 2019 or (c) 2.25 to 1.00 at any time on or after March 31, 2019.

2020-03-23

2016-11-08

2792000

254000

12313000

400000

0.423

0.01

34089000

18328000

433000

445591

183000

1016000

-4686000

3735000

32661000

1205000

250000

1428000

-995000

47370000

800000

21000

50000

200000

6997000

2511000

125000

45327000

3912000

44197000

53643000

6273000

7629000

23059794

22614203

7241000 4700000

100000

13900000 2.96

958000

4018000

100000

0.00

10389000

5267000

186000

375257

130000

384000

9813000

56000

576000

-390000

14640000

300000

-6000

1098000

17226000

2586000

2490000

22995643

22620386

2819000 1600000

100000

1384000

4452000

100000

-0.01

11041000

5561000

198000

327000

354000

10481000

-129000

560000

-362000

15322000

200000

-8000

1274000

17588000

2266000

2262000

22755976

2095000 1700000

700000

0001337013 us-gaap:StockOptionMember 2017-06-29 2017-09-30 0001337013 2017-06-29 2017-09-30 0001337013 us-gaap:StockOptionMemberus-gaap:MaximumMember 2016-07-01 2016-09-30 0001337013 2016-07-01 2016-09-30 0001337013 2017-01-01 2017-03-31 0001337013 2016-01-01 2016-12-31 0001337013 us-gaap:StockOptionMemberus-gaap:MaximumMember 2016-01-01 2016-09-30 0001337013 2016-01-01 2016-09-30 0001337013 infu:LitigationCaseOneMemberus-gaap:PendingLitigationMember 2017-01-01 2017-09-30 0001337013 infu:JpMorganChaseBankMember 2017-01-01 2017-09-30 0001337013 infu:SecondAmendedCreditAgreementMember 2017-01-01 2017-09-30 0001337013 infu:CbfrLoansMemberus-gaap:LondonInterbankOfferedRateLIBORMember 2017-01-01 2017-09-30 0001337013 infu:CbfrLoansMemberus-gaap:MinimumMemberus-gaap:LondonInterbankOfferedRateLIBORMember 2017-01-01 2017-09-30 0001337013 infu:CbfrLoansMemberus-gaap:MaximumMemberus-gaap:LondonInterbankOfferedRateLIBORMember 2017-01-01 2017-09-30 0001337013 infu:ThirdAmendedCreditAgreementMemberus-gaap:MinimumMemberinfu:LessThanTwoPointFiveButGreaterThanOrEqualToTwoPointZeroMember 2017-01-01 2017-09-30 0001337013 infu:ThirdAmendedCreditAgreementMemberus-gaap:MinimumMember 2017-01-01 2017-09-30 0001337013 infu:ThirdAmendedCreditAgreementMemberus-gaap:MaximumMemberinfu:LessThanTwoPointZeroMember 2017-01-01 2017-09-30 0001337013 infu:ThirdAmendedCreditAgreementMemberus-gaap:MaximumMemberinfu:GreaterThanOrEqualToTwoPointFiveMember 2017-01-01 2017-09-30 0001337013 infu:ThirdAmendedCreditAgreementMember 2017-01-01 2017-09-30 0001337013 infu:FirstAmendedCreditAgreementMember 2017-01-01 2017-09-30 0001337013 infu:EuroDollarLoanMemberus-gaap:MinimumMemberus-gaap:LondonInterbankOfferedRateLIBORMember 2017-01-01 2017-09-30 0001337013 infu:EuroDollarLoanMemberus-gaap:MaximumMemberus-gaap:LondonInterbankOfferedRateLIBORMember 2017-01-01 2017-09-30 0001337013 infu:AfterDecemberThirtyOneTwoThousandEighteenMemberinfu:ThirdAmendedCreditAgreementMemberus-gaap:MaximumMember 2017-01-01 2017-09-30 0001337013 infu:AfterJuneThirtyTwoThousandEighteenButPriorToDecemberThirtyOneTwoThousandEighteenMemberinfu:ThirdAmendedCreditAgreementMemberus-gaap:MaximumMember 2017-01-01 2017-09-30 0001337013 infu:AfterDecemberThirtyOneTwoThousandSeventeenButPriorToJuneThirtyTwoThousandEighteenMemberinfu:ThirdAmendedCreditAgreementMemberus-gaap:MaximumMember 2017-01-01 2017-09-30 0001337013 infu:AfterMarchThirtyOneTwoThousandEighteenMemberinfu:ThirdAmendedCreditAgreementMemberus-gaap:MinimumMember 2017-01-01 2017-09-30 0001337013 infu:PriorToDecemberThirtyOneTwoThousandSeventeenMemberinfu:ThirdAmendedCreditAgreementMemberus-gaap:MaximumMember 2017-01-01 2017-09-30 0001337013 infu:PriorToMarchThirtyOneTwoThousandEighteenMemberinfu:ThirdAmendedCreditAgreementMemberus-gaap:MinimumMember 2017-01-01 2017-09-30 0001337013 infu:TermLoanMember 2017-01-01 2017-09-30 0001337013 us-gaap:StockOptionMember 2017-01-01 2017-09-30 0001337013 2017-01-01 2017-09-30 0001337013 us-gaap:AccountingStandardsUpdate201609Memberus-gaap:AdjustmentsForNewAccountingPrincipleEarlyAdoptionMemberinfu:DeferredTaxAssetMember 2017-01-01 2017-01-01 0001337013 infu:LeverageRatioLevelFiveMemberinfu:ThirdAmendedCreditAgreementMemberinfu:CbfrSpreadMember 2017-06-28 2017-06-28 0001337013 infu:LeverageRatioLevelFiveMemberinfu:ThirdAmendedCreditAgreementMemberus-gaap:EurodollarMember 2017-06-28 2017-06-28 0001337013 infu:LeverageRatioLevelFiveMemberinfu:ThirdAmendedCreditAgreementMember 2017-06-28 2017-06-28 0001337013 infu:LeverageRatioLevelFourMemberinfu:ThirdAmendedCreditAgreementMemberinfu:CbfrSpreadMember 2017-06-28 2017-06-28 0001337013 infu:LeverageRatioLevelFourMemberinfu:ThirdAmendedCreditAgreementMemberus-gaap:EurodollarMember 2017-06-28 2017-06-28 0001337013 infu:LeverageRatioLevelFourMemberinfu:ThirdAmendedCreditAgreementMember 2017-06-28 2017-06-28 0001337013 infu:LeverageRatioLevelThreeMemberinfu:ThirdAmendedCreditAgreementMemberinfu:CbfrSpreadMember 2017-06-28 2017-06-28 0001337013 infu:LeverageRatioLevelThreeMemberinfu:ThirdAmendedCreditAgreementMemberus-gaap:EurodollarMember 2017-06-28 2017-06-28 0001337013 infu:LeverageRatioLevelThreeMemberinfu:ThirdAmendedCreditAgreementMember 2017-06-28 2017-06-28 0001337013 infu:LeverageRatioLevelTwoMemberinfu:ThirdAmendedCreditAgreementMemberinfu:CbfrSpreadMember 2017-06-28 2017-06-28 0001337013 infu:LeverageRatioLevelTwoMemberinfu:ThirdAmendedCreditAgreementMemberus-gaap:EurodollarMember 2017-06-28 2017-06-28 0001337013 infu:LeverageRatioLevelTwoMemberinfu:ThirdAmendedCreditAgreementMember 2017-06-28 2017-06-28 0001337013 infu:LeverageRatioLevelOneMemberinfu:ThirdAmendedCreditAgreementMemberinfu:CbfrSpreadMember 2017-06-28 2017-06-28 0001337013 infu:LeverageRatioLevelOneMemberinfu:ThirdAmendedCreditAgreementMemberus-gaap:EurodollarMember 2017-06-28 2017-06-28 0001337013 infu:LeverageRatioLevelOneMemberinfu:ThirdAmendedCreditAgreementMember 2017-06-28 2017-06-28 0001337013 infu:TermLoanMemberinfu:FirstAmendedCreditAgreementMember 2016-12-05 2016-12-05 0001337013 us-gaap:AccountingStandardsUpdate201609Memberus-gaap:AdjustmentsForNewAccountingPrincipleEarlyAdoptionMemberus-gaap:RetainedEarningsMember 2017-01-01 0001337013 us-gaap:LeaseholdImprovementsMember 2016-12-31 0001337013 us-gaap:FurnitureAndFixturesMember 2016-12-31 0001337013 us-gaap:AutomobilesMember 2016-12-31 0001337013 infu:TermLoansMember 2016-12-31 0001337013 us-gaap:TradeNamesMember 2016-12-31 0001337013 infu:PhysicianAndCustomerRelationshipsMember 2016-12-31 0001337013 us-gaap:TradeNamesMember 2016-12-31 0001337013 us-gaap:NoncompeteAgreementsMember 2016-12-31 0001337013 us-gaap:ComputerSoftwareIntangibleAssetMember 2016-12-31 0001337013 us-gaap:RevolvingCreditFacilityMember 2016-12-31 0001337013 2016-12-31 0001337013 2015-12-31 0001337013 infu:LiborPlusRateMember 2017-09-30 0001337013 us-gaap:LondonInterbankOfferedRateLIBORMember 2017-09-30 0001337013 us-gaap:LeaseholdImprovementsMember 2017-09-30 0001337013 us-gaap:FurnitureAndFixturesMember 2017-09-30 0001337013 us-gaap:AutomobilesMember 2017-09-30 0001337013 infu:TermLoansMember 2017-09-30 0001337013 us-gaap:CapitalLeaseObligationsMember 2017-09-30 0001337013 us-gaap:TradeNamesMember 2017-09-30 0001337013 infu:PhysicianAndCustomerRelationshipsMember 2017-09-30 0001337013 us-gaap:TradeNamesMember 2017-09-30 0001337013 us-gaap:NoncompeteAgreementsMember 2017-09-30 0001337013 us-gaap:ComputerSoftwareIntangibleAssetMember 2017-09-30 0001337013 infu:ThirdAmendedCreditAgreementMemberinfu:LessThanTwoPointZeroMember 2017-09-30 0001337013 infu:ThirdAmendedCreditAgreementMemberinfu:LessThanTwoPointFiveButGreaterThanOrEqualToTwoPointZeroMember 2017-09-30 0001337013 infu:ThirdAmendedCreditAgreementMemberinfu:GreaterThanOrEqualToTwoPointFiveMember 2017-09-30 0001337013 infu:ThirdAmendedCreditAgreementMember 2017-09-30 0001337013 us-gaap:RevolvingCreditFacilityMember 2017-09-30 0001337013 us-gaap:AccountingStandardsUpdate201517Memberus-gaap:AdjustmentsForNewAccountingPrincipleEarlyAdoptionMemberinfu:DeferredTaxAssetNonCurrentMember 2017-09-30 0001337013 2017-09-30 0001337013 2016-09-30 0001337013 infu:ThirdAmendedCreditAgreementMember 2017-06-28 0001337013 us-gaap:RevolvingCreditFacilityMemberinfu:ThirdAmendedCreditAgreementMemberinfu:JpMorganChaseBankMember 2017-06-28 0001337013 us-gaap:RevolvingCreditFacilityMemberinfu:ThirdAmendedCreditAgreementMember 2017-06-28 0001337013 infu:ThirdAmendedCreditAgreementMember 2017-06-27 0001337013 us-gaap:RevolvingCreditFacilityMemberinfu:ThirdAmendedCreditAgreementMemberinfu:JpMorganChaseBankMember 2017-06-27 0001337013 us-gaap:RevolvingCreditFacilityMemberinfu:ThirdAmendedCreditAgreementMember 2017-06-27 0001337013 infu:SecondAmendedCreditAgreementMemberus-gaap:MaximumMember 2017-03-22 0001337013 infu:TermLoanAMemberinfu:JpMorganChaseBankMember 2015-03-23 0001337013 infu:TermLoanAMember 2015-03-23 0001337013 infu:TermLoanBMemberinfu:JpMorganChaseBankMember 2015-03-23 0001337013 infu:TermLoanBMember 2015-03-23 0001337013 us-gaap:RevolvingCreditFacilityMemberinfu:JpMorganChaseBankMember 2015-03-23 0001337013 2017-11-06 0001337013 infu:FirstAmendedCreditAgreementMemberus-gaap:MaximumMember 2016-12-05 0001337013 infu:TermLoanMemberinfu:ThirdAmendedCreditAgreementMember 2016-12-05 0001337013 infu:TermLoanMemberinfu:FirstAmendedCreditAgreementMember 2016-12-05 iso4217:USD pure shares iso4217:USD shares

EX-101.SCH 7 infu-20170930.xsd XBRL TAXONOMY EXTENSION SCHEMA 101 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink 103 - Statement - Condensed Consolidated Balance Sheets link:calculationLink link:presentationLink link:definitionLink 104 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:calculationLink link:presentationLink link:definitionLink 105 - Statement - Condensed Consolidated Statements of Operations link:calculationLink link:presentationLink link:definitionLink 106 - Statement - Condensed Consolidated Statements of Cash Flows link:calculationLink link:presentationLink link:definitionLink 107 - Disclosure - Basis of Presentation, Nature of Operations and Summary of Significant Accounting Policies link:calculationLink link:presentationLink link:definitionLink 108 - Disclosure - Medical Equipment and Property link:calculationLink link:presentationLink link:definitionLink 109 - Disclosure - Property and Equipment link:calculationLink link:presentationLink link:definitionLink 110 - Disclosure - Intangible Assets link:calculationLink link:presentationLink link:definitionLink 111 - Disclosure - Debt link:calculationLink link:presentationLink link:definitionLink 112 - Disclosure - Income Taxes link:calculationLink link:presentationLink link:definitionLink 113 - Disclosure - Commitments, Contingencies and Litigation link:calculationLink link:presentationLink link:definitionLink 114 - Disclosure - (Loss) Earnings Per Share link:calculationLink link:presentationLink link:definitionLink 115 - Disclosure - Leases link:calculationLink link:presentationLink link:definitionLink 116 - Disclosure - Subsequent Events link:calculationLink link:presentationLink link:definitionLink 117 - Disclosure - Recent Accounting Pronouncements and Developments link:calculationLink link:presentationLink link:definitionLink 118 - Disclosure - Recent Accounting Pronouncements and Developments (Policies) link:calculationLink link:presentationLink link:definitionLink 119 - Disclosure - Medical Equipment and Property (Tables) link:calculationLink link:presentationLink link:definitionLink 120 - Disclosure - Property and Equipment (Tables) link:calculationLink link:presentationLink link:definitionLink 121 - Disclosure - Intangible Assets (Tables) link:calculationLink link:presentationLink link:definitionLink 122 - Disclosure - Debt (Tables) link:calculationLink link:presentationLink link:definitionLink 123 - Disclosure - (Loss) Earnings Per Share (Tables) link:calculationLink link:presentationLink link:definitionLink 124 - Disclosure - Leases (Tables) link:calculationLink link:presentationLink link:definitionLink 125 - Disclosure - Medical Equipment and Property - Summary of Medical Equipment (Detail) link:calculationLink link:presentationLink link:definitionLink 126 - Disclosure - Medical Equipment and Property - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 127 - Disclosure - Property and Equipment - Property and Equipment (Detail) link:calculationLink link:presentationLink link:definitionLink 128 - Disclosure - Property and Equipment - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 129 - Disclosure - Intangible Assets - Summary of Carrying Amount and Accumulated Amortization of Identifiable Intangible Assets (Detail) link:calculationLink link:presentationLink link:definitionLink 130 - Disclosure - Intangible Assets - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 131 - Disclosure - Intangible Assets - Schedule of Expected Annual Amortization Expense for Intangible Assets (Detail) link:calculationLink link:presentationLink link:definitionLink 132 - Disclosure - Debt - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 133 - Disclosure - Debt - Schedule of Applicable Rates and Commitment Fees Percentage (Detail) link:calculationLink link:presentationLink link:definitionLink 134 - Disclosure - Debt - Summary of Revolver Based upon Borrowers' Eligible Accounts Receivable and Inventory (Detail) link:calculationLink link:presentationLink link:definitionLink 135 - Disclosure - Debt - Summary of Future Maturities of Loans (Detail) link:calculationLink link:presentationLink link:definitionLink 136 - Disclosure - Debt - Summary of Company's Current and Long-Term Debt (Detail) link:calculationLink link:presentationLink link:definitionLink 137 - Disclosure - Income Taxes - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 138 - Disclosure - Commitments, Contingencies and Litigation - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 139 - Disclosure - (Loss) Earnings Per Share - Numerators and Denominators of Basic and Diluted Income per Share (Detail) link:calculationLink link:presentationLink link:definitionLink 140 - Disclosure - (Loss) Earnings Per Share - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 141 - Disclosure - Leases - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 142 - Disclosure - Leases - Schedule of Future Minimum Rental Payments Pursuant to Capital and Operating Leases (Detail) link:calculationLink link:presentationLink link:definitionLink 143 - Disclosure - Leases - Schedule of Future Minimum Rental Payments Pursuant to Capital and Operating Leases (Parenthetical) (Detail) link:calculationLink link:presentationLink link:definitionLink 144 - Disclosure - Recent Accounting Pronouncements and Developments - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 145 - Disclosure - Leases - Schedule of Future Minimum Rental Payments Pursuant to Capital and Operating Leases (Detail) (Alternate 1) link:calculationLink link:presentationLink link:definitionLink EX-101.CAL 8 infu-20170930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 9 infu-20170930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 10 infu-20170930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Accounting Changes and Error Corrections [Abstract] Accounting Changes and Error Corrections [Abstract] Accounting Policies [Abstract] Accounting Policies [Abstract] Accounting Standards Update 2015-17 [Member] ASU 2015-17 [Member] Accounting Standards Update 2016-09 [Member] ASU 2016-09 [Member] Accounts Payable, Current Accounts payable Accounts Receivable, Net, Current Accounts receivable, less allowance for doubtful accounts of $6,847 and $4,989 at September 30, 2017 and December 31, 2016, respectively Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Accumulated Depreciation Accumulated depreciation on pump equipment. Accumulated Depreciation On Pump Equipment Accumulated depreciation related to leased assets Additional Paid in Capital Additional paid-in capital Adjustments for New Accounting Principle, Early Adoption [Member] Adjustments for New Accounting Principle, Early Adoption [Member] Adjustments for New Accounting Pronouncements [Axis] Adjustments for New Accounting Pronouncements [Axis] After amendment ratio of indebtedness to fixed charges quarter one. After Amendment Ratio Of Indebtedness To Fixed Charges Quarter One After amendment, maximum leverage covenant ratio at any time on or after December 31, 2015 but prior to March 31, 2018 After amendment ratio of indebtedness to fixed charges quarter three. After Amendment Ratio Of Indebtedness To Fixed Charges Quarter Three After amendment, maximum leverage covenant ratio at any time on or after March 31, 2019 After amendment ratio of indebtedness to fixed charges quarter two. After Amendment Ratio Of Indebtedness To Fixed Charges Quarter Two After amendment, maximum leverage covenant ratio at any time on or after March 31, 2018 but prior to March 31, 2019 After amendment ratio of indebtedness to net capital quarter one. After Amendment Ratio Of Indebtedness To Net Capital Quarter One After amendment, maximum leverage covenant ratio at any time on or after December 31, 2015 but prior to March 31, 2017 After amendment ratio of indebtedness to net capital quarter three. After Amendment Ratio Of Indebtedness To Net Capital Quarter Three After amendment, maximum leverage covenant ratio at any time on or after March 31, 2018 After amendment ratio of indebtedness to net capital quarter two. After Amendment Ratio Of Indebtedness To Net Capital Quarter Two After amendment, maximum leverage covenant ratio at any time on or after March 31, 2017 but prior to March 31, 2018 After December 31, 2018. After December Thirty One Two Thousand Eighteen [Member] Leverage Ratio Less than 3.00 to 1.00 at any Time on or After December 31, 2018 [Member] After December 31,2017 but prior to June 30,2018. After December Thirty One Two Thousand Seventeen but Prior to June Thirty Two Thousand Eighteen [Member] Leverage Ratio Less than 3.75 to 1.0 at any Time on or After December 31, 2017 but Prior to June 30, 2018 [Member] After June 30, 2018 but prior to December 31, 2018. After June Thirty Two Thousand Eighteen but Prior to December Thirty One Two Thousand Eighteen [Member] Leverage Ratio Less than 3.50 to 1.0 at any Time on or After June 30, 2018 but Prior to December 31, 2018 [Member] After March 31, 2018. After March Thirty One Two Thousand Eighteen [Member] Leverage Ratio Greater than 1.25:1.0 at any Time on or After March 31, 2018 [Member] Allowance for Doubtful Accounts Receivable, Current Accounts receivable, allowance for doubtful accounts Amendment Flag Amendment Flag Amortization of Intangible Assets Amortization of intangible assets Amortization of intangibles Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Shares with anti-dilutive effect Antidilutive Securities [Axis] Antidilutive Securities [Axis] Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Applicable margin rate. Applicable Margin Rate Variable interest applicable margin rate Assets Total Assets Assets [Abstract] ASSETS Assets, Current Total Current Assets Assets, Current [Abstract] Current Assets: Automobiles [Member] Automobiles [Member] Basis of Presentation and Significant Accounting Policies [Text Block] Basis of Presentation, Nature of Operations and Summary of Significant Accounting Policies Capital and operating leases future minimum payments due. Capital And Operating Leases Future Minimum Payments Due Total Capital and operating leases require payments Capital and operating leases future minimum payments due in five years. Capital And Operating Leases Future Minimum Payments Due In Five Years Capital and operating leases, 2021 Capital and operating leases future minimum payments due in four years. Capital And Operating Leases Future Minimum Payments Due In Four Years Capital and operating leases, 2020 Capital and operating leases future minimum payments due in three years. Capital And Operating Leases Future Minimum Payments Due In Three Years Capital and operating leases, 2019 Capital and operating leases future minimum payments due in two years. Capital And Operating Leases Future Minimum Payments Due In Two Years Capital and operating leases, 2018 Capital and operating leases future minimum payments due thereafter. Capital And Operating Leases Future Minimum Payments Due Thereafter Capital and operating leases, Thereafter Capital and operating leases future minimum payments remainder of fiscal year. Capital And Operating Leases Future Minimum Payments Remainder of fiscal year Capital and operating leases, 2017 Capital Lease Obligations, Current Capital leases Less current maturities Capital Lease Obligations [Member] Capital Leases [Member] Capital Lease Obligations, Noncurrent Capital leases Long-term capital lease liability Capital Leases, Future Minimum Payments Due Total capital leases require payments Capital Leases, Future Minimum Payments Due in Five Years Capital leases, 2021 Capital Leases, Future Minimum Payments Due in Four Years Capital leases, 2020 Capital Leases, Future Minimum Payments Due in Three Years Capital leases, 2019 Capital Leases, Future Minimum Payments Due in Two Years Capital leases, 2018 Capital Leases, Future Minimum Payments Due Thereafter Capital leases, Thereafter Capital Leases, Future Minimum Payments, Interest Included in Payments Less amounts representing interest (3.5%) Capital Leases, Future Minimum Payments, Present Value of Net Minimum Payments Present value of minimum lease payments Present value of minimum lease payments Capital Leases, Future Minimum Payments, Remainder of Fiscal Year Capital leases, 2017 Capital Leases of Lessee, Contingent Rentals, Basis Spread on Variable Rate Capital lease interest rate Schedule of carrying amount and accumulated amortization of identifiable intangible assets. Carrying Amount And Accumulated Amortization Of Identifiable Intangible Assets [Table Text Block] Summary of Carrying Amount and Accumulated Amortization of Identifiable Intangible Assets Cash and Cash Equivalents, at Carrying Value Cash and cash equivalents, end of period Cash and cash equivalents, beginning of period Cash and cash equivalents Cash and Cash Equivalents, Period Increase (Decrease) Net change in cash and cash equivalents CBFR Loans [Member] CBFR Loans [Member] CBFR Loan [Member] CBFR Spread. CBFR Spread [Member] CBFR Spread [Member] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Text Block] Commitments, Contingencies and Litigation Common Stock, Par or Stated Value Per Share Common stock, par value Common Stock, Shares Authorized Common stock, shares authorized Common Stock, Shares, Issued Common stock, shares issued Common Stock, Shares, Outstanding Common stock, shares outstanding Common Stock, Value, Issued Common stock, $.0001 par value: authorized 200,000,000 shares; issued and outstanding 22,978,398 and 22,780,738, respectively, as of September 30, 2017 and 22,867,335 and 22,669,675, respectively, as of December 31, 2016 Computer Software, Intangible Asset [Member] Software [Member] Cost of Goods and Services Sold Cost of revenues - Product, service and supply costs Cost of Revenue [Abstract] Cost of revenues: Cost of revenues pump depreciation sales and disposals. Cost Of Revenues Pump Depreciation Sales And Disposals Cost of revenues - Pump depreciation and disposals Credit Facility [Axis] Credit Facility [Axis] Credit Facility [Domain] Credit Facility [Domain] Current Fiscal Year End Date Current Fiscal Year End Date Debt Disclosure [Abstract] Debt Disclosure [Abstract] Debt Disclosure [Text Block] Debt Debt Instrument [Axis] Debt Instrument [Axis] Debt Instrument, Basis Spread on Variable Rate CBFR/Eurodollar Spread Variable interest rate Debt Instrument, Face Amount Aggregate amount of term loan Debt Instrument, Frequency of Periodic Payment Frequency of period payment Debt Instrument, Interest Rate, Effective Percentage Actual interest rate Debt Instrument, Interest Rate, Increase (Decrease) Increase in basis points of interest rate under credit agreement Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Debt Instrument, Periodic Payment Periodic payment of debt Debt Instrument, Periodic Payment, Principal Debt instrument period payment, principal amount Debt, Weighted Average Interest Rate Weighted average interest rate under capital leases Deferred Tax Asset [Domain] Deferred Tax Asset [Domain] Deferred Tax Asset [Member] Deferred Tax Asset [Member] Deferred Tax Asset [Member] Deferred tax asset non current. Deferred Tax Asset Non Current [Member] Deferred Tax Asset Non Current [Member] Deferred Tax Assets, Net of Valuation Allowance, Current Deferred income taxes Deferred Tax Assets, Net of Valuation Allowance, Noncurrent Deferred income taxes Depreciation expense related to medical equipment. Depreciation Expense Related To Medical Equipment Depreciation expense for medical equipment Depreciation, Nonproduction Total depreciation expense recorded Document And Entity Information [Abstract] Document And Entity Information [Abstract] Document And Entity Information [Abstract] Document Fiscal Period Focus Document Fiscal Period Focus Document Fiscal Year Focus Document Fiscal Year Focus Document Period End Date Document Period End Date Document Type Document Type Earnings Per Share [Abstract] Earnings Per Share [Abstract] Earnings Per Share, Basic Basic Earnings Per Share, Basic and Diluted [Abstract] Net (loss) income per share: Earnings Per Share, Diluted Diluted Earnings Per Share [Text Block] (Loss) Earnings Per Share Effective Income Tax Rate Reconciliation, Percent Effective income tax rate Entity Central Index Key Entity Central Index Key Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Entity Filer Category Entity Filer Category Entity Registrant Name Entity Registrant Name Equity Component [Domain] Equity Component [Domain] Eurodollar loan. Euro Dollar Loan [Member] Eurodollar Loan [Member] Eurodollar [Member] Eurodollar Spread [Member] Finite-Lived Intangible Assets, Accumulated Amortization Amortizable intangible assets, Accumulated Amortization Finite-Lived Intangible Assets, Amortization Expense, after Year Five Amortization expense, 2022 and thereafter Finite-Lived Intangible Assets, Amortization Expense, Remainder of Fiscal Year Amortization expense, 2017 Finite-Lived Intangible Assets, Amortization Expense, Year Five Amortization expense, 2021 Finite-Lived Intangible Assets, Amortization Expense, Year Four Amortization expense, 2020 Finite-Lived Intangible Assets, Amortization Expense, Year Three Amortization expense, 2019 Finite-Lived Intangible Assets, Amortization Expense, Year Two Amortization expense, 2018 Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets, Gross Amortizable intangible assets, Gross Assets Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Net Amortizable intangible assets, Net First Amended Credit Agreement [Member] First Amended Credit Agreement [Member] First Amended Credit Agreement [Member] Fixed charges coverage ratio. Fixed Charges Coverage Ratio Fixed Charge Coverage Ratio Furniture and Fixtures [Member] Furniture, Fixtures, and Equipment [Member] General and Administrative Expense General and administrative Goodwill and Intangible Assets Disclosure [Abstract] Goodwill and Intangible Assets Disclosure [Abstract] Greater than or equal to 2.5. Greater Than Or Equal To Two Point Five [Member] Leverage Ratio Greater than or Equal to 2.5 to 1.0 [Member] Gross Profit Gross profit Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Income (loss) before income taxes Income Statement [Abstract] Income Statement [Abstract] Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Income Tax Disclosure [Text Block] Income Taxes Income Tax Expense (Benefit) Income tax expense (benefit) Income tax (expense) benefit Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements Dilutive effect of non-vested awards Indefinite lived and finite lived intangible assets [Line Items] Indefinite Lived And Finite Lived Intangible Assets [Line Items] Indefinite Lived And Finite Lived Intangible Assets [Line Items] Indefinite-lived Intangible Assets [Axis] Indefinite-lived Intangible Assets [Axis] Indefinite-Lived Intangible Assets (Excluding Goodwill) Nonamortizable intangible assets Indefinite-lived Intangible Assets, Major Class Name [Domain] Indefinite-lived Intangible Assets, Major Class Name [Domain] Intangible assets accumulated amortization. Intangible Assets Accumulated Amortization Total nonamortizable and amortizable intangible assets, Accumulated Amortization Intangible Assets Disclosure [Text Block] Intangible Assets Intangible Assets, Gross (Excluding Goodwill) Total nonamortizable and amortizable intangible assets, Gross Assets Intangible Assets, Net (Excluding Goodwill) Intangible assets, net Total nonamortizable and amortizable intangible assets, Net Interest Expense Interest expense Inventory, Net Inventory JP Morgan Chase Bank [Member] JP Morgan Chase Bank [Member] JP Morgan Chase Bank [Member] Landlord reserves. Landlord Reserves Landlord Reserves Leasehold Improvements [Member] Leasehold Improvements [Member] Leases [Abstract] Leases [Abstract] Leases. Leases [Line Items] Leases [Line Items] Leases of Lessee Disclosure [Text Block] Leases Leases [Table] Leases [Table] Leases [Table] Less than 2.5 but greater than or equal to 2.0. Less Than Two Point Five but Greater Than or Equal to Two Point Zero [Member] Leverage Ratio Less than 2.5 to 1.0 but Greater than or Equal to 2.0 to 1.0 [Member] Less than 2.0. Less Than Two Point Zero [Member] Leverage Ratio Less than 2.0 to 1.0 [Member] Letters of Credit Outstanding, Amount Letter of Credit Leverage ratio. Leverage Ratio Actual leverage ratio Leverage ratio level five. Leverage Ratio Level Five [Member] Leverage Ratio Level V Greater than or Equal to 3.0:1.0 [Member] Leverage ratio level four. Leverage Ratio Level Four [Member] Leverage Ratio Level IV Less than 3.0:1.0 to1.0 but Greater than or Equal to 2.5:1.0 [Member] Leverage ratio level one. Leverage Ratio Level One [Member] Leverage Ratio Level I Less than 1.5:1.0 [Member] Leverage ratio level three. Leverage Ratio Level Three [Member] Leverage Ratio Level III Less than 2.5:1.0 to 1.0 but Greater than or Equal to 2.0:1.0 [Member] Leverage ratio level two. Leverage Ratio Level Two [Member] Leverage Ratio Level II Less than 2.0:1.0 to 1.0 but Greater than or Equal to 1.5:1.0 [Member] Liabilities Total Liabilities Liabilities and Equity Total Liabilities and Stockholders' Equity Liabilities and Equity [Abstract] LIABILITIES AND STOCKHOLDERS' EQUITY Liabilities, Current Total Current Liabilities Liabilities, Current [Abstract] Current Liabilities: Liabilities, Noncurrent Total Long-Term Liabilities Libor plus rate. Libor Plus Rate [Member] Libor Plus [Member] Line credit facility additional borrowing capacity. Line Credit Facility Additional Borrowing Capacity Additional available balance Long-term Line of Credit Current borrowings under credit facility Outstanding Draws Line of Credit Facility [Abstract] Line of Credit Facility [Abstract] Lender Name [Axis] Lender Name [Axis] Line of Credit Facility, Commitment Fee Percentage Commitment Fee Rate Line of Credit Facility, Covenant Terms Amendment to Credit Agreement, description Line of Credit Facility, Current Borrowing Capacity Gross Availability Line of Credit Facility, Expiration Date Credit facility, maturity date Line of Credit Facility, Lender [Domain] Line of Credit Facility, Lender [Domain] Line of Credit Facility [Line Items] Line of Credit Facility [Line Items] Line of Credit Facility, Maximum Borrowing Capacity Line of credit facility Line of Credit Facility, Remaining Borrowing Capacity Availability on Revolver Line of Credit Facility [Table] Line of Credit Facility [Table] Litigation Case [Axis] Litigation Case [Axis] Putative securities class action complaint filed in the U.S. District Court for the Central District of California (the "Complaint") against the Company, Eric Steen, our CEO, and Jonathan Foster,our former CFO in connection with the Company's financial restatements. Litigation Case One [Member] The Complaint [Member] Litigation Case [Domain] Litigation Case [Domain] Litigation Status [Axis] Litigation Status [Axis] Litigation Status [Domain] Litigation Status [Domain] London Interbank Offered Rate (LIBOR) [Member] LIBOR [Member] Long-term Debt Total Long-term Debt, Current Maturities Current portion of long-term debt Long-term Debt, Maturities, Repayments of Principal in Year Five 2021 Long-term Debt, Maturities, Repayments of Principal in Year Four 2020 Long-term Debt, Maturities, Repayments of Principal in Year Three 2019 Long-term Debt, Maturities, Repayments of Principal in Year Two 2018 Long-term Debt, Maturities, Repayments of Principal, Remainder of Fiscal Year 2017 Long-term Debt, Excluding Current Maturities Long-Term Debt Long-term debt, net of current portion EX-101.PRE 11 infu-20170930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 12 g486354sp02.jpg GRAPHIC begin 644 g486354sp02.jpg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htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	9 Months Ended
Document and Entity Information - shares	Sep. 30, 2017	Nov. 06, 2017
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2017
Document Fiscal Year Focus	2017
Document Fiscal Period Focus	Q3
Trading Symbol	INFU
Entity Registrant Name	InfuSystem Holdings, Inc
Entity Central Index Key	0001337013
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		22,780,738

XML 14 R2.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2017	Dec. 31, 2016
Current Assets:
Cash and cash equivalents	$ 803	$ 3,398
Accounts receivable, less allowance for doubtful accounts of $6,847 and $4,989 at September 30, 2017 and December 31, 2016, respectively	10,971	11,581
Inventory	1,873	2,166
Other current assets	1,121	949
Deferred income taxes		2,675
Total Current Assets	14,768	20,769
Medical equipment held for sale or rental	1,200	1,642
Medical equipment in rental service, net of accumulated depreciation	24,301	28,036
Property & equipment, net of accumulated depreciation	1,711	1,997
Intangible assets, net	26,951	31,239
Deferred income taxes	16,334	12,436
Other assets	70	225
Total Assets	85,335	96,344
Current Liabilities:
Accounts payable	4,093	5,315
Capital leases	584	2,938
Current portion of long-term debt	2,849	5,314
Other current liabilities	2,427	2,872
Total Current Liabilities	9,953	16,439
Long-term debt, net of current portion	26,535	26,577
Capital leases	101	2,573
Other long-term liabilities		66
Total Long-Term Liabilities	26,636	29,216
Total Liabilities	36,589	45,655
Stockholders' Equity:
Preferred stock, $.0001 par value: authorized 1,000,000 shares; none issued
Common stock, $.0001 par value: authorized 200,000,000 shares; issued and outstanding 22,978,398 and 22,780,738, respectively, as of September 30, 2017 and 22,867,335 and 22,669,675, respectively, as of December 31, 2016	2	2
Additional paid-in capital	92,383	91,829
Retained deficit	(43,639)	(41,142)
Total Stockholders' Equity	48,746	50,689
Total Liabilities and Stockholders' Equity	$ 85,335	$ 96,344

XML 15 R3.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Sep. 30, 2017	Dec. 31, 2016
Statement of Financial Position [Abstract]
Accounts receivable, allowance for doubtful accounts	$ 6,847	$ 4,989
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	1,000,000	1,000,000
Preferred stock, shares issued	0	0
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	200,000,000	200,000,000
Common stock, shares issued	22,978,398	22,867,335
Common stock, shares outstanding	22,780,738	22,669,675

XML 16 R4.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Net revenues:
Rentals	$ 15,322	$ 14,640	$ 45,228	$ 47,370
Product Sales	2,266	2,586	6,956	6,273
Net revenues	17,588	17,226	52,184	53,643
Cost of revenues:
Cost of revenues - Product, service and supply costs	4,452	4,018	13,612	12,313
Cost of revenues - Pump depreciation and disposals	2,095	2,819	6,541	7,241
Gross profit	11,041	10,389	32,031	34,089
Selling, general and administrative expenses:
Provision for doubtful accounts	1,274	1,098	4,456	3,912
Amortization of intangibles	1,384	958	4,182	2,792
Selling and marketing	2,262	2,490	7,443	7,629
General and administrative	5,561	5,267	18,451	18,328
Total selling, general and administrative	10,481	9,813	34,532	32,661
Operating income (loss)	560	576	(2,501)	1,428
Other (expense) income:
Interest expense	(354)	(384)	(1,015)	(1,016)
Other (expense) income	(8)	(6)	(111)	21
Total other expense	(362)	(390)	(1,126)	(995)
Income (loss) before income taxes	198	186	(3,627)	433
Income tax (expense) benefit	(327)	(130)	914	(183)
Net (loss) income	$ (129)	$ 56	$ (2,713)	$ 250
Net (loss) income per share:
Basic	$ (0.01)	$ 0.00	$ (0.12)	$ 0.01
Diluted	$ (0.01)	$ 0.00	$ (0.12)	$ 0.01
Weighted average shares outstanding:
Basic	22,755,976	22,620,386	22,725,806	22,614,203
Diluted	22,755,976	22,995,643	22,725,806	23,059,794

XML 17 R5.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Statement of Cash Flows [Abstract]
NET CASH PROVIDED BY OPERATING ACTIVITIES	$ 4,102	$ 3,735
INVESTING ACTIVITIES
Acquisition of business		(200)
Purchase of medical equipment and property	(2,829)	(6,997)
Proceeds from sale of medical equipment and property	3,518	2,511
NET CASH PROVIDED BY (USED IN) INVESTING ACTIVITIES	689	(4,686)
FINANCING ACTIVITIES
Principal payments on revolving credit facility, term loans and capital lease obligations	(35,769)	(44,197)
Cash proceeds from revolving credit facility	28,317	45,327
Debt issuance costs	(38)
Common stock repurchased to satisfy statutory withholding on employee stock based compensation plans	(27)	(50)
Cash proceeds from stock plans	131	125
NET CASH (USED IN) PROVIDED BY FINANCING ACTIVITIES	(7,386)	1,205
Net change in cash and cash equivalents	(2,595)	254
Cash and cash equivalents, beginning of period	3,398	818
Cash and cash equivalents, end of period	$ 803	$ 1,072

XML 18 R6.htm IDEA: XBRL DOCUMENT

Basis of Presentation, Nature of Operations and Summary of Significant Accounting Policies

9 Months Ended

Sep. 30, 2017

Accounting Policies [Abstract]

Basis of Presentation, Nature of Operations and Summary of Significant Accounting Policies

1.	Basis of Presentation, Nature of Operations and Summary of Significant Accounting Policies

XML 19 R7.htm IDEA: XBRL DOCUMENT

Medical Equipment and Property

9 Months Ended

Sep. 30, 2017

Text Block [Abstract]

Medical Equipment and Property

2.	Medical Equipment and Property

Medical equipment consisted of the following as of September 30, 2017 and December 31, 2016 (in thousands):


	September 30, 2017			December 31, 2016
Medical Equipment held for sale or rental	$	1,200		$	1,642
Medical Equipment in rental service		58,681			59,034
Medical Equipment in rental service—pump reserve		(519	)		(551	)
Accumulated depreciation		(33,861	)		(30,447	)

Medical Equipment in rental service—net		24,301			28,036

Total	$	25,501		$	29,678

XML 20 R8.htm IDEA: XBRL DOCUMENT

Property and Equipment

9 Months Ended

Sep. 30, 2017

Property, Plant and Equipment [Abstract]

Property and Equipment

3.	Property and Equipment

Property and equipment is comprised of the following (in thousands):


	September 30, 2017							December 31, 2016
	Gross Assets		Accumulated Depreciation			Total		Gross Assets		Accumulated Depreciation			Total
Furniture, fixtures, and equipment	$	3,842	$	(3,253	)	$	589	$	3,809	$	(3,071	)	$	738
Automobiles		118		(82	)		36		129		(83	)		46
Leasehold improvements		2,177		(1,091	)		1,086		2,177		(964	)		1,213

Total	$	6,137	$	(4,426	)	$	1,711	$	6,115	$	(4,118	)	$	1,997

XML 21 R9.htm IDEA: XBRL DOCUMENT

Intangible Assets

9 Months Ended

Sep. 30, 2017

Goodwill and Intangible Assets Disclosure [Abstract]

Intangible Assets

4.	Intangible Assets

The carrying amount and accumulated amortization of intangible assets as of September 30, 2017 and December 31, 2016, are as follows (in thousands):


	September 30, 2017
	Gross Assets		Accumulated Amortization		Net
Nonamortizable intangible assets
Trade names	$	2,000	$	—	$	2,000
Amortizable intangible assets
Trade names		23		23		—
Physician and customer relationships		36,534		21,207		15,327
Non-competition agreements		1,136		1,120		16
Software		13,635		4,027		9,608

Total nonamortizable and amortizable intangible assets	$	53,328	$	26,377	$	26,951


	December 31, 2016
	Gross Assets		Accumulated Amortization		Net
Nonamortizable intangible assets
Trade names	$	2,000	$	—	$	2,000
Amortizable intangible assets
Trade names		23		23		—
Physician and customer relationships		36,534		19,427		17,107
Non-competition agreements		1,136		1,064		72
Software		13,745		1,685		12,060

Total nonamortizable and amortizable intangible assets	$	53,438	$	22,199	$	31,239


	10/1-12/31/2017		2018		2019		2020		2021		2022 and thereafter
Amortization expense	$	1,382	$	5,216	$	4,783	$	4,347	$	3,975	$	5,248

XML 22 R10.htm IDEA: XBRL DOCUMENT

Debt

9 Months Ended

Sep. 30, 2017

Debt Disclosure [Abstract]

Debt

Debt

On June 28, 2017, the Company entered into a Third Amendment to the Chase Credit Agreement to make certain amendments to the Credit Facility, including but not limited to:

(i)

restates the chart within the definition of “Applicable Rate” in Section 1.01 of the Credit Agreement as follows:


Leverage Ratio	CBFR Spread			Eurodollar Spread			Commitment Fee Rate
Level I < 1.5:1.0		-1.00	%		2.00	%		0.25	%
Level II < 2.0:1.0 to 1.0 but ³ 1.5:1.0		-0.75	%		2.25	%		0.25	%
Level III < 2.5:1.0 to 1.0 but ³ 2.0:1.0		-0.50	%		2.50	%		0.25	%
Level IV < 3.0:1.0 to 1.0 but ³ 2.5:1.0		0.00	%		2.75	%		0.25	%
Level V ³ 3.0:1.0		0.25	%		3.00	%		0.25	%

(ii)

(iii)

(iv)

add the following definition of “Excess Cash Flow” to Section 1.01 of the Credit Agreement as follows:

(v)

restate Section 2.08(b) of the Credit Agreement as follows:

(vi)

restate Section 2.09(d) of the Credit Agreement as follows:

(vii)

add a new Section 2.09(f) to the Credit Agreement as follows:

(viii)

amend Section 6.04(c) of the Credit Agreement by replacing the reference therein to “$5,000,000” with “$2,500,000.”;

(ix)

restate Sections 6.12(a) and (b) of the Credit Agreement as follows:

As of September 30, 2017, the Borrowers were in compliance with all such covenants.

The availability under the Revolver is based upon the Borrowers’ eligible accounts receivable and eligible inventory and is comprised as follows (in thousands):


	September 30, 2017			December 31, 2016
Revolver:
Gross Availability	$	9,810		$	10,000
Outstanding Draws		—			—
Letter of Credit		(750	)		—
Landlord Reserves		(45	)		(45	)

Availability on Revolver	$	9,015		$	9,955

The Company had approximate future maturities of loans as of September 30, 2017 as follows (in thousands):


	2017			2018			2019			2020			2021			Total
Term Loan	$	578		$	3,067		$	3,067		$	3,067		$	19,732		$	29,511
Unamortized value of the debt issuance costs (a)		(7	)		(30	)		(30	)		(30	)		(30	)		(127	)
Revolver		—			—			—			—			—			—

Total	$	571		$	3,037		$	3,037		$	3,037		$	19,702		$	29,384

(a)	Includes the reclassification of the debt issuance costs as a result of the Company adopting ASU 2015-03

The following is a breakdown of the Company’s current and long-term debt as of September 30, 2017 and December 31, 2016 (in thousands):


September 30, 2017										December 31, 2016
	Current Portion of Long-Term Debt			Long-Term Debt			Total				Current Portion of Long-Term Debt			Long-Term Debt			Total
Term Loan	$	2,877		$	26,634		$	29,511		Term Loans	$	5,336		$	26,664		$	32,000
Unamortized value of the debt issuance costs (a)	$	(28	)	$	(99	)		(127	)	Unamortized value of the debt issuance costs (a)	$	(22	)	$	(87	)		(109	)
Revolver		—			—			—		Revolver		—			—			—

Total	$	2,849		$	26,535		$	29,384		Total	$	5,314		$	26,577		$	31,891

(a)	Includes the reclassification of the debt issuance costs as a result of the Company adopting ASU 2015-03

XML 23 R11.htm IDEA: XBRL DOCUMENT

Income Taxes

9 Months Ended

Sep. 30, 2017

Income Tax Disclosure [Abstract]

Income Taxes

6.	Income Taxes

XML 24 R12.htm IDEA: XBRL DOCUMENT

Commitments, Contingencies and Litigation

9 Months Ended

Sep. 30, 2017

Commitments and Contingencies Disclosure [Abstract]

Commitments, Contingencies and Litigation

7.	Commitments, Contingencies and Litigation

XML 25 R13.htm IDEA: XBRL DOCUMENT

(Loss) Earnings Per Share

9 Months Ended

Sep. 30, 2017

Earnings Per Share [Abstract]

(Loss) Earnings Per Share

8.	(Loss) Earnings Per Share


	Three Months Ended September 30					Nine Months Ended September 30
	2017			2016		2017			2016
Numerator:
Net (loss) income (in thousands)	$	(129	)	$	56	$	(2,713	)	$	250
Denominator:
Weighted average common shares outstanding:
Basic		22,755,976			22,620,386		22,725,806			22,614,203
Dilutive effect of non-vested awards		—			375,257		—			445,591

Diluted		22,755,976			22,995,643		22,725,806			23,059,794
Net (loss) income per share:
Basic	$	(0.01	)	$	0.00	$	(0.12	)	$	0.01
Diluted	$	(0.01	)	$	0.00	$	(0.12	)	$	0.01

XML 26 R14.htm IDEA: XBRL DOCUMENT

Leases

9 Months Ended

Sep. 30, 2017

Leases [Abstract]

Leases

9.	Leases

Future minimum rental payments pursuant to leases that have an initial or remaining non-cancelable lease term in excess of one year as of September 30, 2017 are as follows (in thousands):


	Capital Leases			Operating Leases		Total
2017	$	153		$	331	$	484
2018		514			1,324		1,838
2019		33			1,223		1,256
2020		—			419		419
2021		—			181		181
Thereafter		—			938		938

Total require payments	$	700		$	4,416	$	5,116

Less amounts representing interest (3.5%)		(15	)

Present value of minimum lease payments		685
Less current maturities		(584	)

Long-term capital lease liability	$	101

XML 27 R15.htm IDEA: XBRL DOCUMENT

Subsequent Events

9 Months Ended

Sep. 30, 2017

Subsequent Events [Abstract]

Subsequent Events

10.

Subsequent Events

The Company has evaluated subsequent events through the date of issuance for the unaudited condensed consolidated financial statements as of September 30, 2017.

XML 28 R16.htm IDEA: XBRL DOCUMENT

Recent Accounting Pronouncements and Developments

9 Months Ended

Sep. 30, 2017

Accounting Changes and Error Corrections [Abstract]

Recent Accounting Pronouncements and Developments

11.

Recent Accounting Pronouncements and Developments

In June 2016, the FASB issued ASU No. 2016-13, “Financial Instruments (Topic 326) Credit Losses” (“ASU 2016-13”). ASU 2016-13 changes the impairment model for most financial assets and certain other instruments. Under the new standard, entities holding financial assets and net investment in leases that are not accounted for at fair value through net income are to be presented at the net amount expected to be collected. An allowance for credit losses will be a valuation account that will be deducted from the amortized cost basis of the financial asset to present the net carrying value at the amount expected to be collected on the financial asset. ASU 2016-13 is effective as of January 1, 2020. Early adoption is permitted. The Company is currently evaluating the impact of ASU 2016-13. The adoption of this standard is not expected to have a material impact on the Company’s consolidated financial position, results of operations, cash flows and/or disclosures.

XML 29 R17.htm IDEA: XBRL DOCUMENT

Recent Accounting Pronouncements and Developments (Policies)	9 Months Ended
	Sep. 30, 2017
Accounting Changes and Error Corrections [Abstract]
Recent Accounting Pronouncements and Developments	In May 2017, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2017-09, “Stock Compensation—Scope of Modification Accounting”, which provides guidance on which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic 718. The new standard is effective for fiscal years beginning after December 15, 2017 (i.e. a January 1, 2018 effective date). The Company believes the adoption will not have a material impact on its consolidated financial statements. In January 2017, the FASB issued ASU No. 2017-04, “Intangibles—Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment”, which changes the subsequent measurement of goodwill impairment by eliminating Step 2 from the impairment test. Under the new guidance, an entity will measure impairment using the difference between the carrying amount and the fair value of the reporting unit. The new standard is effective for fiscal years beginning after December 15, 2019 (i.e. a January 1, 2020 effective date), with early adoption permitted for goodwill impairment tests with measurement dates after January 1, 2017. The Company believes the adoption will not have a material impact on its consolidated financial statements. In May 2014, the FASB issued ASU 2014-09, “Revenue from Contracts with Customers (Topic 606)”, which supersedes the revenue recognition requirements in ASC 605, “Revenue Recognition”, and most industry-specific guidance. ASU 2014-09, along with amendments in 2015 and 2016, focuses on creating a single source of revenue guidance for revenue arising from contracts with customers. Under the new standard, recognition of revenue occurs when a customer obtains control of promised goods or services in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. Additionally, the new standard requires that enhanced disclosures about the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers, including revenue recognition policies to identify performance obligations, assets recognized from costs incurred to obtain and fulfill a contract, and significant judgments in measurement and recognition. The standard, as amended, will be effective for annual periods beginning after December 15, 2017, including interim periods within that reporting period. The Company is in the process of evaluating the impact of these changes, which includes a review of existing contracts with customers, an evaluation of the specific terms of those contracts and the appropriate treatment under the new standards, and a comparison of that new treatment to the Company’s existing accounting policies to identify differences. The Company expects that the disclosures in the notes to its consolidated financial statements related to revenue recognition will be significantly expanded under the new standard, specifically regarding quantitative and qualitative information about performance obligations. The Company anticipates the adoption of ASC 606 using the modified retrospective approach, under which the cumulative effect of the initial application of the new standard will be recognized as an adjustment to the opening balance of retained earnings in the first quarter of 2018. As the Company is still in the process of finalizing its evaluation of ASU 2014-09, along with the subsequent amendments, its initial assessment may change as it refines its systems, processes, controls and assumptions. In February 2016, the FASB issued ASU No. 2016-02, “Leases (Topic 842)” (“ASU 2016-02”). Under ASU 2016-02, an entity will be required to recognize right-of-use assets and lease liabilities on its balance sheet and disclose key information about leasing arrangements. ASU 2016-02 offers specific accounting guidance for a lessee, a lessor and sale and leaseback transactions. Lessees and lessors are required to disclose qualitative and quantitative information about leasing arrangements to enable a user of the financial statements to assess the amount, timing and uncertainty of cash flows arising from leases. For public companies, ASU 2016-02 is effective for annual reporting periods beginning after December 15, 2018, including interim periods within that reporting period, and requires a modified retrospective adoption, with early adoption permitted. The Company is currently evaluating the impact, if any, that the adoption of this guidance will have on its financial position, results of operations, cash flows and/or disclosures. In March 2016, the FASB issued ASU No. 2016-09, “Compensation— Stock Compensation (Topic 718)” (“ASU 2016-09”). The guidance changes how companies account for certain aspects of equity-based payments to employees. Entities will be required to recognize income tax effects of awards in the income statement when the awards vest or are settled. The guidance also allows an employer to repurchase more of an employee’s shares than it can under current guidance for tax withholding purposes providing for withholding at the employee’s maximum rate as opposed to the minimum rate without triggering liability accounting and to make a policy election to account for forfeitures as they occur. The updated guidance is effective for annual periods beginning after December 15, 2016. Effective January 1, 2017, the Company adopted the accounting guidance contained within ASU 2016-09. Thus, the Company recorded a $0.2 million deferred tax asset and a $0.2 million increase to retained earnings on January 1, 2017 to recognize the Company’s excess tax benefits that existed as of December 31, 2016 (modified retrospective application). In June 2016, the FASB issued ASU No. 2016-13, “Financial Instruments (Topic 326) Credit Losses” (“ASU 2016-13”). ASU 2016-13 changes the impairment model for most financial assets and certain other instruments. Under the new standard, entities holding financial assets and net investment in leases that are not accounted for at fair value through net income are to be presented at the net amount expected to be collected. An allowance for credit losses will be a valuation account that will be deducted from the amortized cost basis of the financial asset to present the net carrying value at the amount expected to be collected on the financial asset. ASU 2016-13 is effective as of January 1, 2020. Early adoption is permitted. The Company is currently evaluating the impact of ASU 2016-13. The adoption of this standard is not expected to have a material impact on the Company’s consolidated financial position, results of operations, cash flows and/or disclosures. In August 2016, the FASB issued ASU No. 2016-15, “Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments” (“ASU 2016-15”). The amendments in this ASU introduce clarifications to the presentation of certain cash receipts and cash payments in the statement of cash flows. The primary updates include additions and clarifications of the classification of cash flows related to certain debt repayment activities, contingent consideration payments related to business combinations, proceeds from insurance policies, distributions from equity method investees and cash flows related to securitized receivables. ASU 2016-15 is effective for annual periods beginning after December 15, 2017, including interim periods within those fiscal years. Early adoption is permitted, including in interim periods. ASU 2016-15 requires retrospective application to all prior periods presented upon adoption. The Company is currently evaluating the impact, if any, that the adoption of this guidance will have on its cash flows and/or disclosures, however, the Company does not anticipate that the adoption of this new standard will have a material impact on the Company’s financial position, results of operations or statements of cash flows upon adoption. In November 2015, the FASB issued ASU No. 2015-17, “Income Taxes (Topic 740): Balance Sheet Classification of Deferred Taxes” (“ASU 2015-17”), simplifying the balance sheet classification of deferred taxes by requiring all deferred taxes, along with any related valuation allowance, to be presented as noncurrent. ASU 2015-17 is effective for the Company beginning in the first quarter of 2017 and may be applied either prospectively or retrospectively. The Company has chosen to apply this guidance prospectively, thus prior periods were not retrospectively adjusted. The adoption of this guidance resulted in the balance sheet reclassification of $2.7 million of current deferred tax assets to noncurrent.

XML 30 R18.htm IDEA: XBRL DOCUMENT

Medical Equipment and Property (Tables)

9 Months Ended

Sep. 30, 2017

Text Block [Abstract]

Summary of Medical Equipment

Medical equipment consisted of the following as of September 30, 2017 and December 31, 2016 (in thousands):


	September 30, 2017			December 31, 2016
Medical Equipment held for sale or rental	$	1,200		$	1,642
Medical Equipment in rental service		58,681			59,034
Medical Equipment in rental service—pump reserve		(519	)		(551	)
Accumulated depreciation		(33,861	)		(30,447	)

Medical Equipment in rental service—net		24,301			28,036

Total	$	25,501		$	29,678

XML 31 R19.htm IDEA: XBRL DOCUMENT

Property and Equipment (Tables)

9 Months Ended

Sep. 30, 2017

Property, Plant and Equipment [Abstract]

Property and Equipment

Property and equipment is comprised of the following (in thousands):


	September 30, 2017							December 31, 2016
	Gross Assets		Accumulated Depreciation			Total		Gross Assets		Accumulated Depreciation			Total
Furniture, fixtures, and equipment	$	3,842	$	(3,253	)	$	589	$	3,809	$	(3,071	)	$	738
Automobiles		118		(82	)		36		129		(83	)		46
Leasehold improvements		2,177		(1,091	)		1,086		2,177		(964	)		1,213

Total	$	6,137	$	(4,426	)	$	1,711	$	6,115	$	(4,118	)	$	1,997

XML 32 R20.htm IDEA: XBRL DOCUMENT

Intangible Assets (Tables)

9 Months Ended

Sep. 30, 2017

Goodwill and Intangible Assets Disclosure [Abstract]

Summary of Carrying Amount and Accumulated Amortization of Identifiable Intangible Assets

The carrying amount and accumulated amortization of intangible assets as of September 30, 2017 and December 31, 2016, are as follows (in thousands):


	September 30, 2017
	Gross Assets		Accumulated Amortization		Net
Nonamortizable intangible assets
Trade names	$	2,000	$	—	$	2,000
Amortizable intangible assets
Trade names		23		23		—
Physician and customer relationships		36,534		21,207		15,327
Non-competition agreements		1,136		1,120		16
Software		13,635		4,027		9,608

Total nonamortizable and amortizable intangible assets	$	53,328	$	26,377	$	26,951


	December 31, 2016
	Gross Assets		Accumulated Amortization		Net
Nonamortizable intangible assets
Trade names	$	2,000	$	—	$	2,000
Amortizable intangible assets
Trade names		23		23		—
Physician and customer relationships		36,534		19,427		17,107
Non-competition agreements		1,136		1,064		72
Software		13,745		1,685		12,060

Total nonamortizable and amortizable intangible assets	$	53,438	$	22,199	$	31,239

Schedule of Expected Annual Amortization Expense for Intangible Assets

Expected annual amortization expense for intangible assets recorded as of September 30, 2017, is as follows (in thousands):


	10/1-12/31/2017		2018		2019		2020		2021		2022 and thereafter
Amortization expense	$	1,382	$	5,216	$	4,783	$	4,347	$	3,975	$	5,248

XML 33 R21.htm IDEA: XBRL DOCUMENT

Debt (Tables)

9 Months Ended

Sep. 30, 2017

Debt Disclosure [Abstract]

Schedule of Applicable Rates and Commitment Fees Percentage

On June 28, 2017, the Company entered into a Third Amendment to the Chase Credit Agreement to make certain amendments to the Credit Facility, including but not limited to:

(i)

restates the chart within the definition of “Applicable Rate” in Section 1.01 of the Credit Agreement as follows:


Leverage Ratio	CBFR Spread			Eurodollar Spread			Commitment Fee Rate
Level I < 1.5:1.0		-1.00	%		2.00	%		0.25	%
Level II < 2.0:1.0 to 1.0 but ³ 1.5:1.0		-0.75	%		2.25	%		0.25	%
Level III < 2.5:1.0 to 1.0 but ³ 2.0:1.0		-0.50	%		2.50	%		0.25	%
Level IV < 3.0:1.0 to 1.0 but ³ 2.5:1.0		0.00	%		2.75	%		0.25	%
Level V ³ 3.0:1.0		0.25	%		3.00	%		0.25	%

Summary of Revolver Based upon Borrowers' Eligible Accounts Receivable and Inventory

The availability under the Revolver is based upon the Borrowers’ eligible accounts receivable and eligible inventory and is comprised as follows (in thousands):


	September 30, 2017			December 31, 2016
Revolver:
Gross Availability	$	9,810		$	10,000
Outstanding Draws		—			—
Letter of Credit		(750	)		—
Landlord Reserves		(45	)		(45	)

Availability on Revolver	$	9,015		$	9,955

Summary of Future Maturities of Loans

The Company had approximate future maturities of loans as of September 30, 2017 as follows (in thousands):


	2017			2018			2019			2020			2021			Total
Term Loan	$	578		$	3,067		$	3,067		$	3,067		$	19,732		$	29,511
Unamortized value of the debt issuance costs (a)		(7	)		(30	)		(30	)		(30	)		(30	)		(127	)
Revolver		—			—			—			—			—			—

Total	$	571		$	3,037		$	3,037		$	3,037		$	19,702		$	29,384

(a)	Includes the reclassification of the debt issuance costs as a result of the Company adopting ASU 2015-03

Summary of Company's Current and Long-Term Debt

The following is a breakdown of the Company’s current and long-term debt as of September 30, 2017 and December 31, 2016 (in thousands):


September 30, 2017										December 31, 2016
	Current Portion of Long-Term Debt			Long-Term Debt			Total				Current Portion of Long-Term Debt			Long-Term Debt			Total
Term Loan	$	2,877		$	26,634		$	29,511		Term Loans	$	5,336		$	26,664		$	32,000
Unamortized value of the debt issuance costs (a)	$	(28	)	$	(99	)		(127	)	Unamortized value of the debt issuance costs (a)	$	(22	)	$	(87	)		(109	)
Revolver		—			—			—		Revolver		—			—			—

Total	$	2,849		$	26,535		$	29,384		Total	$	5,314		$	26,577		$	31,891

(a)	Includes the reclassification of the debt issuance costs as a result of the Company adopting ASU 2015-03

XML 34 R22.htm IDEA: XBRL DOCUMENT

(Loss) Earnings Per Share (Tables)

9 Months Ended

Sep. 30, 2017

Earnings Per Share [Abstract]

Numerators and Denominators of Basic and Diluted Income per Share

The following table reconciles the numerators and denominators of the basic and diluted (loss) income per share computations:


	Three Months Ended September 30					Nine Months Ended September 30
	2017			2016		2017			2016
Numerator:
Net (loss) income (in thousands)	$	(129	)	$	56	$	(2,713	)	$	250
Denominator:
Weighted average common shares outstanding:
Basic		22,755,976			22,620,386		22,725,806			22,614,203
Dilutive effect of non-vested awards		—			375,257		—			445,591

Diluted		22,755,976			22,995,643		22,725,806			23,059,794
Net (loss) income per share:
Basic	$	(0.01	)	$	0.00	$	(0.12	)	$	0.01
Diluted	$	(0.01	)	$	0.00	$	(0.12	)	$	0.01

XML 35 R23.htm IDEA: XBRL DOCUMENT

Leases (Tables)

9 Months Ended

Sep. 30, 2017

Leases [Abstract]

Schedule of Future Minimum Rental Payments Pursuant to Capital and Operating Leases

Future minimum rental payments pursuant to leases that have an initial or remaining non-cancelable lease term in excess of one year as of September 30, 2017 are as follows (in thousands):


	Capital Leases			Operating Leases		Total
2017	$	153		$	331	$	484
2018		514			1,324		1,838
2019		33			1,223		1,256
2020		—			419		419
2021		—			181		181
Thereafter		—			938		938

Total require payments	$	700		$	4,416	$	5,116

Less amounts representing interest (3.5%)		(15	)

Present value of minimum lease payments		685
Less current maturities		(584	)

Long-term capital lease liability	$	101

XML 36 R24.htm IDEA: XBRL DOCUMENT

Medical Equipment and Property - Summary of Medical Equipment (Detail) - USD ($) $ in Thousands	Sep. 30, 2017	Dec. 31, 2016
Medical Equipment And Property [Abstract]
Medical equipment held for sale or rental	$ 1,200	$ 1,642
Medical Equipment in rental service	58,681	59,034
Medical Equipment in rental service-pump reserve	(519)	(551)
Accumulated depreciation	(33,861)	(30,447)
Medical Equipment in rental service-net	24,301	28,036
Total	$ 25,501	$ 29,678

XML 37 R25.htm IDEA: XBRL DOCUMENT

Medical Equipment and Property - Additional Information (Detail) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Property, Plant and Equipment [Abstract]
Depreciation expense for medical equipment	$ 1.7	$ 1.6	$ 4.8	$ 4.7

XML 38 R26.htm IDEA: XBRL DOCUMENT

Property and Equipment - Property and Equipment (Detail) - USD ($) $ in Thousands	Sep. 30, 2017	Dec. 31, 2016
Property, Plant and Equipment [Line Items]
Gross Assets	$ 6,137	$ 6,115
Accumulated Depreciation	(4,426)	(4,118)
Total	1,711	1,997
Furniture, Fixtures, and Equipment [Member]
Property, Plant and Equipment [Line Items]
Gross Assets	3,842	3,809
Accumulated Depreciation	(3,253)	(3,071)
Total	589	738
Automobiles [Member]
Property, Plant and Equipment [Line Items]
Gross Assets	118	129
Accumulated Depreciation	(82)	(83)
Total	36	46
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Gross Assets	2,177	2,177
Accumulated Depreciation	(1,091)	(964)
Total	$ 1,086	$ 1,213

XML 39 R27.htm IDEA: XBRL DOCUMENT

Property and Equipment - Additional Information (Detail) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Property, Plant and Equipment [Abstract]
Total depreciation expense recorded	$ 0.1	$ 0.1	$ 0.4	$ 0.4

XML 40 R28.htm IDEA: XBRL DOCUMENT

Intangible Assets - Summary of Carrying Amount and Accumulated Amortization of Identifiable Intangible Assets (Detail) - USD ($) $ in Thousands	Sep. 30, 2017	Dec. 31, 2016
Indefinite Lived And Finite Lived Intangible Assets [Line Items]
Total nonamortizable and amortizable intangible assets, Gross Assets	$ 53,328	$ 53,438
Total nonamortizable and amortizable intangible assets, Accumulated Amortization	26,377	22,199
Total nonamortizable and amortizable intangible assets, Net	26,951	31,239
Trade Names [Member]
Indefinite Lived And Finite Lived Intangible Assets [Line Items]
Amortizable intangible assets, Gross Assets	23	23
Amortizable intangible assets, Accumulated Amortization	23	23
Physician and Customer Relationships [Member]
Indefinite Lived And Finite Lived Intangible Assets [Line Items]
Amortizable intangible assets, Gross Assets	36,534	36,534
Amortizable intangible assets, Accumulated Amortization	21,207	19,427
Amortizable intangible assets, Net	15,327	17,107
Non-Competition Agreements [Member]
Indefinite Lived And Finite Lived Intangible Assets [Line Items]
Amortizable intangible assets, Gross Assets	1,136	1,136
Amortizable intangible assets, Accumulated Amortization	1,120	1,064
Amortizable intangible assets, Net	16	72
Software [Member]
Indefinite Lived And Finite Lived Intangible Assets [Line Items]
Amortizable intangible assets, Gross Assets	13,635	13,745
Amortizable intangible assets, Accumulated Amortization	4,027	1,685
Amortizable intangible assets, Net	9,608	12,060
Trade Names [Member]
Indefinite Lived And Finite Lived Intangible Assets [Line Items]
Nonamortizable intangible assets	$ 2,000	$ 2,000

XML 41 R29.htm IDEA: XBRL DOCUMENT

Intangible Assets - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization of intangible assets	$ 1,384	$ 958	$ 4,182	$ 2,792

XML 42 R30.htm IDEA: XBRL DOCUMENT

Intangible Assets - Schedule of Expected Annual Amortization Expense for Intangible Assets (Detail) $ in Thousands	Sep. 30, 2017 USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization expense, 2017	$ 1,382
Amortization expense, 2018	5,216
Amortization expense, 2019	4,783
Amortization expense, 2020	4,347
Amortization expense, 2021	3,975
Amortization expense, 2022 and thereafter	$ 5,248

XML 43 R31.htm IDEA: XBRL DOCUMENT

Debt - Additional Information (Detail)		3 Months Ended	9 Months Ended
Debt - Additional Information (Detail)	Dec. 05, 2016 USD ($)	Mar. 31, 2017	Sep. 30, 2017 USD ($)	Jun. 28, 2017 USD ($)	Jun. 27, 2017 USD ($)	Mar. 22, 2017	Dec. 31, 2016 USD ($)	Mar. 23, 2015 USD ($)
Line of Credit Facility [Line Items]
Actual leverage ratio		2.96
Actual interest rate			3.99%
LIBOR [Member]
Line of Credit Facility [Line Items]
Actual interest rate			1.24%
Libor Plus [Member]
Line of Credit Facility [Line Items]
Actual interest rate			2.75%
First Amended Credit Agreement [Member]
Line of Credit Facility [Line Items]
Amendment to Credit Agreement, description			Amending the leverage ratio covenant to provide for the following schedule of maximum permitted ratios: (a) 2.75 to 1.0 at any time on or after December 31, 2015 but prior to March 31, 2017, (b) 2.50 to 1.0 at any time on or after March 31, 2017 but prior to March 31, 2018 or (c) 2.25 to 1.00 at any time on or after March 31, 2018.
Second Amended Credit Agreement [Member]
Line of Credit Facility [Line Items]
Amendment to Credit Agreement, description			Amending the leverage ratio covenant to provide for the following schedule of maximum permitted ratios: (a) 2.75 to 1.0 at any time on or after December 31, 2015 but prior to March 31, 2018, (b) 2.50 to 1.0 at any time on or after March 31, 2018 but prior to March 31, 2019 or (c) 2.25 to 1.00 at any time on or after March 31, 2019.
Third Amended Credit Agreement [Member]
Line of Credit Facility [Line Items]
Current borrowings under credit facility			$ 30,665,999.98
Debt instrument period payment, principal amount			577,500
Aggregate amount of term loan				$ 2,500,000	$ 5,000,000
Periodic payment of debt			$ 766,650
Increase in basis points of interest rate under credit agreement			0.50%
Third Amended Credit Agreement [Member] \| Leverage Ratio Greater than or Equal to 2.5 to 1.0 [Member]
Line of Credit Facility [Line Items]
Percentage of excess cashflow to prepay debt			75.00%
Third Amended Credit Agreement [Member] \| Leverage Ratio Less than 2.5 to 1.0 but Greater than or Equal to 2.0 to 1.0 [Member]
Line of Credit Facility [Line Items]
Percentage of excess cashflow to prepay debt			50.00%
Third Amended Credit Agreement [Member] \| Leverage Ratio Less than 2.0 to 1.0 [Member]
Line of Credit Facility [Line Items]
Percentage of excess cashflow to prepay debt			0.00%
CBFR Loan [Member] \| LIBOR [Member]
Line of Credit Facility [Line Items]
Number of LIBOR days			30 days
Variable interest rate			2.50%
JP Morgan Chase Bank [Member]
Line of Credit Facility [Line Items]
Credit facility, maturity date			Mar. 23, 2020
Term Loan A [Member]
Line of Credit Facility [Line Items]
Current borrowings under credit facility								$ 27,000,000
Term Loan A [Member] \| JP Morgan Chase Bank [Member]
Line of Credit Facility [Line Items]
Line of credit facility								27,000,000
Term Loan B [Member]
Line of Credit Facility [Line Items]
Current borrowings under credit facility								8,000,000
Term Loan B [Member] \| JP Morgan Chase Bank [Member]
Line of Credit Facility [Line Items]
Line of credit facility								8,000,000
Revolving Credit Facility [Member]
Line of Credit Facility [Line Items]
Current borrowings under credit facility			$ 0				$ 0
Revolving Credit Facility [Member] \| Third Amended Credit Agreement [Member]
Line of Credit Facility [Line Items]
Aggregate amount of term loan				12,500,000	25,000,000
Revolving Credit Facility [Member] \| JP Morgan Chase Bank [Member]
Line of Credit Facility [Line Items]
Line of credit facility								$ 10,000,000
Revolving Credit Facility [Member] \| JP Morgan Chase Bank [Member] \| Third Amended Credit Agreement [Member]
Line of Credit Facility [Line Items]
Aggregate amount of term loan				$ 5,000,000	$ 10,000,000
Term Loan [Member]
Line of Credit Facility [Line Items]
Frequency of period payment			Setting the quarterly mandatory principal payment due on the Term Loan to $1.3 million due on the last business day of each fiscal quarter with any remaining unpaid and outstanding amount due at maturity
Term Loan [Member] \| First Amended Credit Agreement [Member]
Line of Credit Facility [Line Items]
Current borrowings under credit facility	$ 32,000,000
Additional available balance	5,000,000
Debt instrument period payment, principal amount	1,300,000
Term Loan [Member] \| Third Amended Credit Agreement [Member]
Line of Credit Facility [Line Items]
Aggregate amount of term loan	$ 32,000,000
Maximum [Member] \| First Amended Credit Agreement [Member]
Line of Credit Facility [Line Items]
After amendment, maximum leverage covenant ratio at any time on or after December 31, 2015 but prior to March 31, 2017	2.75%
After amendment, maximum leverage covenant ratio at any time on or after March 31, 2017 but prior to March 31, 2018	2.50%
After amendment, maximum leverage covenant ratio at any time on or after March 31, 2018	2.25%
Maximum [Member] \| Second Amended Credit Agreement [Member]
Line of Credit Facility [Line Items]
After amendment, maximum leverage covenant ratio at any time on or after December 31, 2015 but prior to March 31, 2018						2.75%
After amendment, maximum leverage covenant ratio at any time on or after March 31, 2018 but prior to March 31, 2019						2.50%
After amendment, maximum leverage covenant ratio at any time on or after March 31, 2019						2.25%
Maximum [Member] \| Third Amended Credit Agreement [Member] \| Leverage Ratio Greater than or Equal to 2.5 to 1.0 [Member]
Line of Credit Facility [Line Items]
Actual leverage ratio			2.5
Maximum [Member] \| Third Amended Credit Agreement [Member] \| Leverage Ratio Less than 2.0 to 1.0 [Member]
Line of Credit Facility [Line Items]
Actual leverage ratio			2.0
Maximum [Member] \| Eurodollar Loan [Member] \| LIBOR [Member]
Line of Credit Facility [Line Items]
Variable interest applicable margin rate			3.00%
Maximum [Member] \| CBFR Loan [Member] \| LIBOR [Member]
Line of Credit Facility [Line Items]
Variable interest applicable margin rate			0.25%
Maximum [Member] \| Leverage Ratio Less than 4.0 to 1.0 at any Time on or After the Effective Date but Prior to December 31, 2017 [Member] \| Third Amended Credit Agreement [Member]
Line of Credit Facility [Line Items]
Actual leverage ratio			4.0
Maximum [Member] \| Leverage Ratio Less than 3.75 to 1.0 at any Time on or After December 31, 2017 but Prior to June 30, 2018 [Member] \| Third Amended Credit Agreement [Member]
Line of Credit Facility [Line Items]
Actual leverage ratio			3.75
Maximum [Member] \| Leverage Ratio Less than 3.50 to 1.0 at any Time on or After June 30, 2018 but Prior to December 31, 2018 [Member] \| Third Amended Credit Agreement [Member]
Line of Credit Facility [Line Items]
Actual leverage ratio			3.50
Maximum [Member] \| Leverage Ratio Less than 3.00 to 1.00 at any Time on or After December 31, 2018 [Member] \| Third Amended Credit Agreement [Member]
Line of Credit Facility [Line Items]
Actual leverage ratio			3.00
Minimum [Member] \| Third Amended Credit Agreement [Member]
Line of Credit Facility [Line Items]
Actual leverage ratio			2.5
Minimum [Member] \| Third Amended Credit Agreement [Member] \| Leverage Ratio Less than 2.5 to 1.0 but Greater than or Equal to 2.0 to 1.0 [Member]
Line of Credit Facility [Line Items]
Actual leverage ratio			2.0
Minimum [Member] \| Eurodollar Loan [Member] \| LIBOR [Member]
Line of Credit Facility [Line Items]
Variable interest applicable margin rate			2.00%
Minimum [Member] \| CBFR Loan [Member] \| LIBOR [Member]
Line of Credit Facility [Line Items]
Variable interest applicable margin rate			(1.00%)
Minimum [Member] \| Leverage Ratio Greater than 1.15:1.0 at any Time on or After the Effective Date but Prior to March 31, 2018 [Member] \| Third Amended Credit Agreement [Member]
Line of Credit Facility [Line Items]
Fixed Charge Coverage Ratio			1.15
Minimum [Member] \| Leverage Ratio Greater than 1.25:1.0 at any Time on or After March 31, 2018 [Member] \| Third Amended Credit Agreement [Member]
Line of Credit Facility [Line Items]
Fixed Charge Coverage Ratio			1.25

XML 44 R32.htm IDEA: XBRL DOCUMENT

Debt - Schedule of Applicable Rates and Commitment Fees Percentage (Detail) - Third Amended Credit Agreement [Member]	Jun. 28, 2017
Leverage Ratio Level I Less than 1.5:1.0 [Member]
Line of Credit Facility [Line Items]
Commitment Fee Rate	0.25%
Leverage Ratio Level II Less than 2.0:1.0 to 1.0 but Greater than or Equal to 1.5:1.0 [Member]
Line of Credit Facility [Line Items]
Commitment Fee Rate	0.25%
Leverage Ratio Level III Less than 2.5:1.0 to 1.0 but Greater than or Equal to 2.0:1.0 [Member]
Line of Credit Facility [Line Items]
Commitment Fee Rate	0.25%
Leverage Ratio Level IV Less than 3.0:1.0 to1.0 but Greater than or Equal to 2.5:1.0 [Member]
Line of Credit Facility [Line Items]
Commitment Fee Rate	0.25%
Leverage Ratio Level V Greater than or Equal to 3.0:1.0 [Member]
Line of Credit Facility [Line Items]
Commitment Fee Rate	0.25%
CBFR Spread [Member] \| Leverage Ratio Level I Less than 1.5:1.0 [Member]
Line of Credit Facility [Line Items]
CBFR/Eurodollar Spread	(1.00%)
CBFR Spread [Member] \| Leverage Ratio Level II Less than 2.0:1.0 to 1.0 but Greater than or Equal to 1.5:1.0 [Member]
Line of Credit Facility [Line Items]
CBFR/Eurodollar Spread	(0.75%)
CBFR Spread [Member] \| Leverage Ratio Level III Less than 2.5:1.0 to 1.0 but Greater than or Equal to 2.0:1.0 [Member]
Line of Credit Facility [Line Items]
CBFR/Eurodollar Spread	(0.50%)
CBFR Spread [Member] \| Leverage Ratio Level IV Less than 3.0:1.0 to1.0 but Greater than or Equal to 2.5:1.0 [Member]
Line of Credit Facility [Line Items]
CBFR/Eurodollar Spread	0.00%
CBFR Spread [Member] \| Leverage Ratio Level V Greater than or Equal to 3.0:1.0 [Member]
Line of Credit Facility [Line Items]
CBFR/Eurodollar Spread	0.25%
Eurodollar Spread [Member] \| Leverage Ratio Level I Less than 1.5:1.0 [Member]
Line of Credit Facility [Line Items]
CBFR/Eurodollar Spread	2.00%
Eurodollar Spread [Member] \| Leverage Ratio Level II Less than 2.0:1.0 to 1.0 but Greater than or Equal to 1.5:1.0 [Member]
Line of Credit Facility [Line Items]
CBFR/Eurodollar Spread	2.25%
Eurodollar Spread [Member] \| Leverage Ratio Level III Less than 2.5:1.0 to 1.0 but Greater than or Equal to 2.0:1.0 [Member]
Line of Credit Facility [Line Items]
CBFR/Eurodollar Spread	2.50%
Eurodollar Spread [Member] \| Leverage Ratio Level IV Less than 3.0:1.0 to1.0 but Greater than or Equal to 2.5:1.0 [Member]
Line of Credit Facility [Line Items]
CBFR/Eurodollar Spread	2.75%
Eurodollar Spread [Member] \| Leverage Ratio Level V Greater than or Equal to 3.0:1.0 [Member]
Line of Credit Facility [Line Items]
CBFR/Eurodollar Spread	3.00%

XML 45 R33.htm IDEA: XBRL DOCUMENT

Debt - Summary of Revolver Based upon Borrowers' Eligible Accounts Receivable and Inventory (Detail) - Revolving Credit Facility [Member] - USD ($) $ in Thousands	Sep. 30, 2017	Dec. 31, 2016
Line of Credit Facility [Line Items]
Gross Availability	$ 9,810	$ 10,000
Outstanding Draws	0	0
Letter of Credit	(750)
Landlord Reserves	(45)	(45)
Availability on Revolver	$ 9,015	$ 9,955

- Definition

The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.

+ References + Details

XML 46 R34.htm IDEA: XBRL DOCUMENT

Debt - Summary of Future Maturities of Loans (Detail) - USD ($) $ in Thousands	Sep. 30, 2017	Dec. 31, 2016
Line of Credit Facility [Line Items]
2017	$ 571
2018	3,037
2019	3,037
2020	3,037
2021	19,702
Total	29,384	$ 31,891
Unamortized value of the debt issuance costs, 2017	(7)
Unamortized value of the debt issuance costs, 2018	(30)
Unamortized value of the debt issuance costs, 2019	(30)
Unamortized value of the debt issuance costs, 2020	(30)
Unamortized value of the debt issuance costs, 2021	(30)
Unamortized value of the debt issuance costs, Total	(127)	(109)
Term Loan [Member]
Line of Credit Facility [Line Items]
2017	578
2018	3,067
2019	3,067
2020	3,067
2021	19,732
Total	$ 29,511	$ 32,000

XML 47 R35.htm IDEA: XBRL DOCUMENT

Debt - Summary of Company's Current and Long-Term Debt (Detail) - USD ($) $ in Thousands	Sep. 30, 2017	Dec. 31, 2016
Line of Credit Facility [Line Items]
Current portion of long-term debt	$ 2,849	$ 5,314
Long-Term Debt	26,535	26,577
Total	29,384	31,891
Unamortized value of the debt issuance costs, Current Portion of Long-Term Debt	(28)	(22)
Unamortized value of the debt issuance costs, Long-Term Debt	(99)	(87)
Unamortized value of the debt issuance costs, Total	(127)	(109)
Term Loan [Member]
Line of Credit Facility [Line Items]
Current portion of long-term debt	2,877	5,336
Long-Term Debt	26,634	26,664
Total	$ 29,511	$ 32,000

XML 48 R36.htm IDEA: XBRL DOCUMENT

Income Taxes - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Income Tax Disclosure [Abstract]
Income tax expense (benefit)	$ 327	$ 130	$ (914)	$ 183
Effective income tax rate			25.20%	42.30%

XML 49 R37.htm IDEA: XBRL DOCUMENT

Commitments, Contingencies and Litigation - Additional Information (Detail)	9 Months Ended
	Sep. 30, 2017
Pending Litigation [Member] \| The Complaint [Member]
Loss Contingencies [Line Items]
Lawsuit Filing Date	Nov. 08, 2016

XML 50 R38.htm IDEA: XBRL DOCUMENT

(Loss) Earnings Per Share - Numerators and Denominators of Basic and Diluted Income per Share (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Numerator:
Net (loss) income	$ (129)	$ 56	$ (2,713)	$ 250
Weighted average common shares outstanding:
Basic	22,755,976	22,620,386	22,725,806	22,614,203
Dilutive effect of non-vested awards		375,257		445,591
Diluted	22,755,976	22,995,643	22,725,806	23,059,794
Net (loss) income per share:
Basic	$ (0.01)	$ 0.00	$ (0.12)	$ 0.01
Diluted	$ (0.01)	$ 0.00	$ (0.12)	$ 0.01

XML 51 R39.htm IDEA: XBRL DOCUMENT

(Loss) Earnings Per Share - Additional Information (Detail) - Stock Options [Member] - shares	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Summary Of Significant Accounting Policies [Line Items]
Shares with anti-dilutive effect	700,000		600,000
Maximum [Member]
Summary Of Significant Accounting Policies [Line Items]
Shares with anti-dilutive effect		100,000		100,000

XML 52 R40.htm IDEA: XBRL DOCUMENT

Leases - Additional Information (Detail) - USD ($) $ in Millions	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016	Dec. 31, 2016
Leases [Line Items]
Pump equipment			$ 14.0		$ 13.9
Accumulated depreciation related to leased assets	$ 5.3		5.3		$ 3.9
Operating lease rental expenses	$ 0.2	$ 0.3	$ 0.7	$ 0.8
Capital Leases [Member]
Leases [Line Items]
Weighted average interest rate under capital leases	3.60%		3.60%

XML 53 R41.htm IDEA: XBRL DOCUMENT

Leases - Schedule of Future Minimum Rental Payments Pursuant to Capital and Operating Leases (Detail) - USD ($) $ in Thousands	Sep. 30, 2017	Dec. 31, 2016
Leases [Abstract]
Capital leases, 2017	$ 153
Capital leases, 2018	514
Capital leases, 2019	33
Capital leases, 2020	0
Capital leases, 2021	0
Capital leases, Thereafter	0
Total capital leases require payments	700
Less amounts representing interest (3.5%)	(15)
Present value of minimum lease payments	685
Present value of minimum lease payments	685
Less current maturities	(584)	$ (2,938)
Long-term capital lease liability	101	$ 2,573
Operating leases, 2017	331
Operating leases, 2018	1,324
Operating leases, 2019	1,223
Operating leases, 2020	419
Operating leases, 2021	181
Operating leases, Thereafter	938
Total operating leases require payments	4,416
Capital and operating leases, 2017	484
Capital and operating leases, 2018	1,838
Capital and operating leases, 2019	1,256
Capital and operating leases, 2020	419
Capital and operating leases, 2021	181
Capital and operating leases, Thereafter	938
Total Capital and operating leases require payments	$ 5,116

XML 54 R42.htm IDEA: XBRL DOCUMENT

Leases - Schedule of Future Minimum Rental Payments Pursuant to Capital and Operating Leases (Parenthetical) (Detail)	Sep. 30, 2017
Leases [Abstract]
Capital lease interest rate	3.50%

XML 55 R43.htm IDEA: XBRL DOCUMENT

Recent Accounting Pronouncements and Developments - Additional Information (Detail) - Adjustments for New Accounting Principle, Early Adoption [Member] - USD ($) $ in Millions	Jan. 01, 2017	Sep. 30, 2017
Retained Deficit [Member] \| ASU 2016-09 [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Impact of reclassification adjustment due to adoption of new accounting pronouncement	$ 0.2
Deferred Tax Asset [Member] \| ASU 2016-09 [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Impact of reclassification adjustment due to adoption of new accounting pronouncement	$ 0.2
Deferred Tax Asset Non Current [Member] \| ASU 2015-17 [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Impact of reclassification adjustment due to adoption of new accounting pronouncement		$ 2.7

EXCEL 56 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 57 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 58 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 60 FilingSummary.xml IDEA: XBRL DOCUMENT 3.8.0.1 html 97 200 1 false 49 0 false 4 false false R1.htm 101 - Document - Document and Entity Information Sheet http://www.infusystem.com/taxonomy/role/DocumentandEntityInformation Document and Entity Information Cover 1 false false R2.htm 103 - Statement - Condensed Consolidated Balance Sheets Sheet http://www.infusystem.com/taxonomy/role/StatementOfFinancialPositionClassified Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 104 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://www.infusystem.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 105 - Statement - Condensed Consolidated Statements of Operations Sheet http://www.infusystem.com/taxonomy/role/StatementOfIncome Condensed Consolidated Statements of Operations Statements 4 false false R5.htm 106 - Statement - Condensed Consolidated Statements of Cash Flows Sheet http://www.infusystem.com/taxonomy/role/StatementOfCashFlowsIndirect Condensed Consolidated Statements of Cash Flows Statements 5 false false R6.htm 107 - Disclosure - Basis of Presentation, Nature of Operations and Summary of Significant Accounting Policies Sheet http://www.infusystem.com/taxonomy/role/NotesToFinancialStatementsBasisOfPresentationAndSignificantAccountingPoliciesTextBlock Basis of Presentation, Nature of Operations and Summary of Significant Accounting Policies Notes 6 false false R7.htm 108 - Disclosure - Medical Equipment and Property Sheet http://www.infusystem.com/taxonomy/role/NotesToFinancialStatementsMedicalEquipmentAndPropertyTextBlock Medical Equipment and Property Notes 7 false false R8.htm 109 - Disclosure - Property and Equipment Sheet http://www.infusystem.com/taxonomy/role/NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlock Property and Equipment Notes 8 false false R9.htm 110 - Disclosure - Intangible Assets Sheet http://www.infusystem.com/taxonomy/role/NotesToFinancialStatementsIntangibleAssetsDisclosureTextBlock Intangible Assets Notes 9 false false R10.htm 111 - Disclosure - Debt Sheet http://www.infusystem.com/taxonomy/role/NotesToFinancialStatementsDebtDisclosureTextBlock Debt Notes 10 false false R11.htm 112 - Disclosure - Income Taxes Sheet http://www.infusystem.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlock Income Taxes Notes 11 false false R12.htm 113 - Disclosure - Commitments, Contingencies and Litigation Sheet http://www.infusystem.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock Commitments, Contingencies and Litigation Notes 12 false false R13.htm 114 - Disclosure - (Loss) Earnings Per Share Sheet http://www.infusystem.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlock (Loss) Earnings Per Share Notes 13 false false R14.htm 115 - Disclosure - Leases Sheet http://www.infusystem.com/taxonomy/role/NotesToFinancialStatementsLeasesOfLesseeDisclosureTextBlock Leases Notes 14 false false R15.htm 116 - Disclosure - Subsequent Events Sheet http://www.infusystem.com/taxonomy/role/NotesToFinancialStatementsSubsequentEventsTextBlock Subsequent Events Notes 15 false false R16.htm 117 - Disclosure - Recent Accounting Pronouncements and Developments Sheet http://www.infusystem.com/taxonomy/role/NotesToFinancialStatementsNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock Recent Accounting Pronouncements and Developments Notes 16 false false R17.htm 118 - Disclosure - Recent Accounting Pronouncements and Developments (Policies) Sheet http://www.infusystem.com/taxonomy/role/NotesToFinancialStatementsNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlockPolicies Recent Accounting Pronouncements and Developments (Policies) Policies http://www.infusystem.com/taxonomy/role/NotesToFinancialStatementsBasisOfPresentationAndSignificantAccountingPoliciesTextBlock 17 false false R18.htm 119 - Disclosure - Medical Equipment and Property (Tables) Sheet http://www.infusystem.com/taxonomy/role/NotesToFinancialStatementsMedicalEquipmentAndPropertyTextBlockTables Medical Equipment and Property (Tables) Tables http://www.infusystem.com/taxonomy/role/NotesToFinancialStatementsMedicalEquipmentAndPropertyTextBlock 18 false false R19.htm 120 - Disclosure - Property and Equipment (Tables) Sheet http://www.infusystem.com/taxonomy/role/NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlockTables Property and Equipment (Tables) Tables http://www.infusystem.com/taxonomy/role/NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlock 19 false false R20.htm 121 - Disclosure - Intangible Assets (Tables) Sheet http://www.infusystem.com/taxonomy/role/NotesToFinancialStatementsIntangibleAssetsDisclosureTextBlockTables Intangible Assets (Tables) Tables http://www.infusystem.com/taxonomy/role/NotesToFinancialStatementsIntangibleAssetsDisclosureTextBlock 20 false false R21.htm 122 - Disclosure - Debt (Tables) Sheet http://www.infusystem.com/taxonomy/role/NotesToFinancialStatementsDebtDisclosureTextBlockTables Debt (Tables) Tables http://www.infusystem.com/taxonomy/role/NotesToFinancialStatementsDebtDisclosureTextBlock 21 false false R22.htm 123 - Disclosure - (Loss) Earnings Per Share (Tables) Sheet http://www.infusystem.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlockTables (Loss) Earnings Per Share (Tables) Tables http://www.infusystem.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlock 22 false false R23.htm 124 - Disclosure - Leases (Tables) Sheet http://www.infusystem.com/taxonomy/role/NotesToFinancialStatementsLeasesOfLesseeDisclosureTextBlockTables Leases (Tables) Tables http://www.infusystem.com/taxonomy/role/NotesToFinancialStatementsLeasesOfLesseeDisclosureTextBlock 23 false false R24.htm 125 - Disclosure - Medical Equipment and Property - Summary of Medical Equipment (Detail) Sheet http://www.infusystem.com/taxonomy/role/DisclosureMedicalEquipmentAndPropertySummaryOfMedicalEquipment Medical Equipment and Property - Summary of Medical Equipment (Detail) Details 24 false false R25.htm 126 - Disclosure - Medical Equipment and Property - Additional Information (Detail) Sheet http://www.infusystem.com/taxonomy/role/DisclosureMedicalEquipmentAndPropertyAdditionalInformation Medical Equipment and Property - Additional Information (Detail) Details 25 false false R26.htm 127 - Disclosure - Property and Equipment - Property and Equipment (Detail) Sheet http://www.infusystem.com/taxonomy/role/DisclosurePropertyAndEquipmentPropertyAndEquipment Property and Equipment - Property and Equipment (Detail) Details 26 false false R27.htm 128 - Disclosure - Property and Equipment - Additional Information (Detail) Sheet http://www.infusystem.com/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformation Property and Equipment - Additional Information (Detail) Details 27 false false R28.htm 129 - Disclosure - Intangible Assets - Summary of Carrying Amount and Accumulated Amortization of Identifiable Intangible Assets (Detail) Sheet http://www.infusystem.com/taxonomy/role/DisclosureIntangibleAssetsSummaryOfCarryingAmountAndAccumulatedAmortizationOfIdentifiableIntangibleAssets Intangible Assets - Summary of Carrying Amount and Accumulated Amortization of Identifiable Intangible Assets (Detail) Details 28 false false R29.htm 130 - Disclosure - Intangible Assets - Additional Information (Detail) Sheet http://www.infusystem.com/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformation Intangible Assets - Additional Information (Detail) Details 29 false false R30.htm 131 - Disclosure - Intangible Assets - Schedule of Expected Annual Amortization Expense for Intangible Assets (Detail) Sheet http://www.infusystem.com/taxonomy/role/DisclosureIntangibleAssetsScheduleOfExpectedAnnualAmortizationExpenseForIntangibleAssets Intangible Assets - Schedule of Expected Annual Amortization Expense for Intangible Assets (Detail) Details 30 false false R31.htm 132 - Disclosure - Debt - Additional Information (Detail) Sheet http://www.infusystem.com/taxonomy/role/DisclosureDebtAdditionalInformation Debt - Additional Information (Detail) Details 31 false false R32.htm 133 - Disclosure - Debt - Schedule of Applicable Rates and Commitment Fees Percentage (Detail) Sheet http://www.infusystem.com/taxonomy/role/DisclosureDebtScheduleOfApplicableRatesAndCommitmentFeesPercentage Debt - Schedule of Applicable Rates and Commitment Fees Percentage (Detail) Details 32 false false R33.htm 134 - Disclosure - Debt - Summary of Revolver Based upon Borrowers' Eligible Accounts Receivable and Inventory (Detail) Sheet http://www.infusystem.com/taxonomy/role/DisclosureDebtSummaryOfRevolverBasedUponBorrowersEligibleAccountsReceivableAndInventory Debt - Summary of Revolver Based upon Borrowers' Eligible Accounts Receivable and Inventory (Detail) Details 33 false false R34.htm 135 - Disclosure - Debt - Summary of Future Maturities of Loans (Detail) Sheet http://www.infusystem.com/taxonomy/role/DisclosureDebtSummaryOfFutureMaturitiesOfLoans Debt - Summary of Future Maturities of Loans (Detail) Details 34 false false R35.htm 136 - Disclosure - Debt - Summary of Company's Current and Long-Term Debt (Detail) Sheet http://www.infusystem.com/taxonomy/role/DisclosureDebtSummaryOfCompanysCurrentAndLongTermDebt Debt - Summary of Company's Current and Long-Term Debt (Detail) Details 35 false false R36.htm 137 - Disclosure - Income Taxes - Additional Information (Detail) Sheet http://www.infusystem.com/taxonomy/role/DisclosureIncomeTaxesAdditionalInformation Income Taxes - Additional Information (Detail) Details 36 false false R37.htm 138 - Disclosure - Commitments, Contingencies and Litigation - Additional Information (Detail) Sheet http://www.infusystem.com/taxonomy/role/DisclosureCommitmentsContingenciesAndLitigationAdditionalInformation Commitments, Contingencies and Litigation - Additional Information (Detail) Details 37 false false R38.htm 139 - Disclosure - (Loss) Earnings Per Share - Numerators and Denominators of Basic and Diluted Income per Share (Detail) Sheet http://www.infusystem.com/taxonomy/role/DisclosureLossEarningsPerShareNumeratorsAndDenominatorsOfBasicAndDilutedIncomePerShare (Loss) Earnings Per Share - Numerators and Denominators of Basic and Diluted Income per Share (Detail) Details 38 false false R39.htm 140 - Disclosure - (Loss) Earnings Per Share - Additional Information (Detail) Sheet http://www.infusystem.com/taxonomy/role/DisclosureLossEarningsPerShareAdditionalInformation (Loss) Earnings Per Share - Additional Information (Detail) Details 39 false false R40.htm 141 - Disclosure - Leases - Additional Information (Detail) Sheet http://www.infusystem.com/taxonomy/role/DisclosureLeasesAdditionalInformation Leases - Additional Information (Detail) Details 40 false false R41.htm 142 - Disclosure - Leases - Schedule of Future Minimum Rental Payments Pursuant to Capital and Operating Leases (Detail) Sheet http://www.infusystem.com/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumRentalPaymentsPursuantToCapitalAndOperatingLeases Leases - Schedule of Future Minimum Rental Payments Pursuant to Capital and Operating Leases (Detail) Details 41 false false R42.htm 143 - Disclosure - Leases - Schedule of Future Minimum Rental Payments Pursuant to Capital and Operating Leases (Parenthetical) (Detail) Sheet http://www.infusystem.com/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumRentalPaymentsPursuantToCapitalAndOperatingLeasesParenthetical Leases - Schedule of Future Minimum Rental Payments Pursuant to Capital and Operating Leases (Parenthetical) (Detail) Details 42 false false R43.htm 144 - Disclosure - Recent Accounting Pronouncements and Developments - Additional Information (Detail) Sheet http://www.infusystem.com/taxonomy/role/DisclosureRecentAccountingPronouncementsAndDevelopmentsAdditionalInformation Recent Accounting Pronouncements and Developments - Additional Information (Detail) Details 43 false false All Reports Book All Reports infu-20170930.xml infu-20170930.xsd infu-20170930_cal.xml infu-20170930_def.xml infu-20170930_lab.xml infu-20170930_pre.xml http://xbrl.sec.gov/dei/2014-01-31 http://fasb.org/us-gaap/2017-01-31 true true ZIP 62 0001193125-17-339757-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-17-339757-xbrl.zip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
%T^E;XB@E4A."39D=6J1R_'[;E6SHVA"O9[9+2G?QSMN MB$.!H:NV="1G8&2 R[T?$=R M,$5G[O%09-)ZCX<]Y:"ET#1Y-M0R7'-&%"H*:*IH%)'P0E/ %VKCEJ2>9< JO4-HB< M.Y30JL Y>9L-*@N<.Q8W5H+($V.IX!PV5J"V"=C862B5WZ+T5*BQYF:E3I15 M;APTUJ"1)>6M!/#>;LA8@PPS":1G'?320<38+I:>$C!&ESU95Z&J,PP8:TZY M*%Y,EK8H5UUXL08G#M[,RH:R1ML>M-@1,)X&J<*+GFFL53R\#>*I@MQH4 T! M7A0V(&VUP%$:E)1"&CEHVP55(QBE00H)%B7;U3*!16F0<@(TTA2FH"@GV%&5 M"F;0-(%\?B1*@]+&7KFX-I$/ :*<)*/9'+G$X93,UZVQHVKZ%?^\FR1$JAT4:-LPS0+!%8CRLTGB9JC-RLP'(5W=9DFNA 0JNF MBI:M6(+$T7-,8SLV]>V[4TFBH[,>33&)Y+S6(>GUYSS:$X'2,Y#;2CGT1Q5 M)& C*<:AEAZH,X7;AGBGMX3U%?7 MSB;2'HT12-,>JK$JT3K3'LTMI302?):T1W.S$>3A;K;2'COH/UV@'^1I#UU5 M3?WM0/]YTQY-<$,[@!MG3'LT-C$(/Z2\(0J;:8_C/912:8\LAMG.DJ45'C5V M*BWEF+[FTYTPRY&33\=W!/GT8?AQ6$A^\II_(CH[(M^,?131-O=3]-O5I$;+)?MS_ ^N''5Y\6ZQMIBG [(X_(1O+K MAZT#_/3KASD%.:\^K##KUQGM?5V@-_&BA'9 )WP7)6QD3/R,Q;>+"Q&V%,O+ M3%&6R*-'A8M^_5!X^*\?[HY)@0&=3"G;6Z8J;8 MHY5CCR8"6!=[#BQ/Y^:\ ^:\G,[59[#6^D:TX!F4-95R MO#C7\:Q)P'4S)1:]1%2J M#590G'_-/H?1DQQ]%-Z 7QJ6QX\5315?M]@_4G#"AZYA'/_=OQ&&$U M(M?=7-NW7R]JZ M 4'' G1N&H7]<#+Q:+SC["XU#W96 M^@(56H>ZJ3&:Z=RIL.1$\Q+QO,Z)C/-XC]F(\SMK.CR5&OG[O'@>3QYM48AG9-K M8]M'DA\,_=D$K=Q^NA3*)*5FQII,PN\>'JG]VD=C%.%5Y<'[09O#%]:4]9^8 ML"S99?5-'0U/E/4MF[[%N\U3@/AWG=5:M)W.PLHIV>3#I 16J!6^[&:2<%&9 M<#^+D#>J5X$@J?L13=US-68;Y=<=M>VN M*JG=7]7#]"U+T5*+R%?U-W6X*ZMZ9W68K^J[U9BK+5_5JZG2-H!8MU;UAV]Y2B\B7]3=5 MN"O+>E=5F"_JN[68:RU?TBMI$NS\DG["YLYLV4.^I+^IPAU9TCNKPGQ)WZW% M7&OYDOZ&)FD XH\;N/EV].\Y%D=_O/*26E$6&PR;NO*/'\ (WFU1*GG3)^0(ZG M3580Q_/O3CT3\D.YB*9K"M5\!4*-4;<1JP^F.WF]FV!66,%H<5:K_?KP.EMO MRT..H'\.)Z/KZ2P*7[(I4)N@%@>$-2)*A!BB=1DD8(7SCP?Y"_ MNB4G=KMT'20G*TW":?CH3SHB'JAK@)S')$%@LBF>FS!X2K!'2+RXI3Q6',5N MB$)2-/B#1"X 9%04U]A1'OO83J$;_P6-K@/,DB,G(D7 MK[D*#Y$W0E^\:3/S=^]F==DAS+<^P@R75Z?I%MJ,GH=K.2E+Z$P1#OI5""%F&&3LE+)B>" M=DA>64\ %-V'X^2[%Z&U.SLANBQLJ"BZKC#JGF\+$RY#$"_AY,4/GE8O:KUD MSMY3H4F:5?9H5NNF>=D])4]4:AK>(#.::]^1>;[Q'\/H;I+&Y/LZ@W]9IX[& M1,%R1W%&&G"?1SX\.-LR0?'@;$ODQ*[!8RXXVZ1X>'"6,5'@+:XD,7JVZG91 M+'91WLQ/O E=K1%M'P7#N;DBG4OZC[6O1K!JMQ\AKJ7U2@7V;]RY$M^O%NU4GQ%QVP M6BQA,FJG66./9JU^.1=*D;GC<)@Z9K6]C8AFZ3ALVQ) *)DD3PB5-O4Z.,ZQ M:,5NY,8/T.UX9Z'SOV:?P^C)"YQG+T:V%_S5>6WEVGGQ-DWGRTUET>@-B88O M-RQ-Z+8N-^?75JZ=%V[39 A7EAM%QZ)LQV'?.T5UCS 7.G+ ]JHVR"*$-=:9 M8&V05YLE25 '[5W15F"65N<6$94JA-RX0G14 5HE" !E2>K(S+3YS#R10G14 M =HDB(6?W=*9V9"??3E350= TMC*FN@B 'AK46N5]K+MYK+-9LOW%=6[8;*\ MK5BTT6Q$&;;U8&U;**+9'JSG"#R<7R=X7UXF^O(>IQ-IX&<*X<>A H'^[8_[ M_D*D4^3%:80^Y;]]Q+_]^F'^9?8PQ&*-^[.OBYQ M?X&*;YCH;VO/&_DO6+^6O"/W?<&2B[PD7.I;&['KR- MHN4S-V_^]4-A[ O2,QWZ]']02P,$% @ 5S-M2Q2]HN9R$ S[< !$ M !I;F9U+3(P,3F>RXQDGY MS#KEL;VV)Y7-2PHB(0D5"E TK;VUV\W2(H4#YBDY SEY8M-$>A&=W^-JXGC MTT]/,X\\,*6Y%(>]X+R6'ORUW_Z.[DXJ+WTX_??O/I'_T^.3V_ M([\YS&.*^HS M[O"'_G#8W_UXO[=WL+M[L#_\/9U;SA>*3Z8^>>-\;S*34RD$\SRV(.>Q5&_) MY>7)#CGR/'*+F36Y92@H/C_HY4D\'>[NYP\-OGR] , MO6^_(6'>@Z>1\O@*!;Z):?8'7&@?A& I$H^+/RT4F#RB.DWQE".)Q!I^_/AQ M8%)3N0/=GU Z7^8?4STRN:.$@;'I[K"_/URE\A=SI@O)3$HQ'1?C8$4T?*$7 MVFUU^2I:W] M?A FIG([X)*^6JQFU\S9F3 8)2/$N1\&> MG&DQ"::48?7 M%],%:8AW7Z.3E#NZ&(RDU1!SU8R M!"+)\B-R^42%D+YIJLQO?#.?0[DR^@DOL&(>*.FQ>_!,@@]?;B]L:"9>RU^-,\.]9S ,X27\#LBCG+8".<*VF7A-Z!,)"NG MB][&@&P,ISL0V+C4]7C9Y=Q(;:0Y\:C6D65T-KF443.2;7.3P0TD@X5_I%CAMHP1[T!#!P.?-B3?^Q)Y\\4[B]4@-UC?L#1$M>.)W6@ M&/PP9:%;I$M[2ZZHC^DKE=V,KNZ"V8RJ!::D!"*)1"06J?.N1M[UF;G8!9[] M%? YO@#D;Y0$$/Q%/2^JQ,CN+?_,>DO$DRR9&I^(V7:(-T(\-M^-1PU*2^,F MIJ^'?"V&=@_XF/6 F'!4^5IR'NUF< M$Y8DY-E!W CB4S9J7(_+:.U0#K-0(IL.O885%.=0]_2I>ODL@+ MOVIT@ZN&>)[(V8S[YA'Z19@DX8B5"1RN-D6X)DL[YOM9S%/IN2NMB7TYMA_E=%N8WEU+K[TG,CP!#8CAVL#:"]9)1 MS6 *?/>#O>EB64]LQ_)#% M,&%$0DX=G(W@O&*/J3"6 II .&S9CTYA]L%@^)3.PX'%W*L;3=M(078GR475 M;IG#,E&QE8)-YWW*'I@GS?RY1,7U7U0 M>[E@[#T=>16]IP8[NV_DPG+VP"QY$W+MW.#E([0UW*$!6ZM;[.6B>,71VLX= M7CQL6\,+JG.S@Y^+^^5"N!WN+Q++K8&UG8,=WUP\$)EUD+Y0_*<&J,_QL,.: M"_F5QH(ZK%\X*%0#\ZJ\[-CGXH AVP[H2@N,EX:S#*NCY2K7XVR>: GR>CSL MZ.;"?\\,TOOIQ37YO&].F4]YMS9R?:XU%>*'?1)+@*U%+ ,)A5AM32(Q"'A6UY*LZV48Z:O4>I1GM&-?'%OL&HG- MP9=4W:/YW(.9']2&6^B$PT6#\2*_<\8PC(C?>>F$%:';B(\=_%P$,@(_7=>3 MPH@IS0PEDO((%DB2$CL/:> A\5#RECU([X&I8PIB?)E+<2R5DH],Z3./A^UY MN 1 XXH _H"H /H7 IYZ!)(HCQNJ4HG9.MX63G 6[P^XS;_$ P$\J65.1&()5H["Z1"X/F72)D M3!+.^-+P[C!> V-HG^=4+/2).;T%)Z674DSN&9X,,LI%O.J0VA'/Q3KSB$?\ MO],D*B%*;Y6LA^B21(5KXFDB!/8R1(TP) M)8G;IWFRGJ)SLG6=K%++4YW0ZA[O8R6 MP70@;A+$)'(4S>- LEDPNT7-O!NZ")B]=Y9#V/#+=,679LI;=+5>KE-L#1[E^Y"&K];5]= MO]G&]NS(\YF"^0D;OFQC!N4,G_&QDHWI+]R+DC=+$Y#A_X,/XA\\#/V6C8DY MY_P #_D^[&D^FWLPSP[?4>4@O?V$],$\7$;&F1[$;&,&.>K5(]F-4V?L%TD5 M;U!>S5?A;&"XD!0 MH/CIDLV6Z.W1$?,JJ@QY"U2^1 Y;HFVVFE=0&D@*E$X?@UFD^Z=!^J!T^+5Z MD/HG4%TJGXC"@]U+;E<@X04.E](QC"PD^*L?T_7Q57^XU]\?[CQI-Q*QC@2) MI>M)$-/5E*]$5:^(";#0][4=(7NKQQI^@&_JNL%S5V18Q2FBBW^L)TC! MA1O5)$D3+G^M)4OF%H]*8L0T^-!/B.L7GKT/I%+I2R+SM);R^9M%*DF0(HN> M^PF+^E+D+BJI)$1"%3ZN98C,O2>5!(AI\*&?$#"PEUH(1Q-_%&5(!P8F?N6#F92P(1(+2Y@_HFS MAAZA(^TKZOB'O3'US,#'9(0!$9?NO2$-.WT_3AJ%UR<<]AS%8*K?(X)['BZ1 M.NSY*L ./0">W ]0FI^5#.9QZ1Q*+5%^#+.S(WCAXLM;5 1O$7#9"+033)N= ML$\,3[E1$Z;_'5 %!->"I>W1G$=H(NB_4&\,>32SSU[WPPD+&Q&>3(ZM\' MM=6Z$.?\@?V'4:77L.D1C+T$'-J M7.9P],B.+\%^953HQ^^_XLAJ-%9FTV!NM)M+:=. %H6[FT,M=POE7DUJE>!2 M^V9#,1,!TQCP3H? [ZAG]A:=G^16B!Z%$F8-D"E[&G%X1UT-5\-Z+- R5,);$R+G_/: MXN0V>>HY5]HW<6'FGI@AQM$$IA2SHCI8(6^[5$L^\IS(!QC239@)?*^H5)HG M[65SW,#\U88:/T.?;+Y*4'&MH &@WKV$^77!@\TMU\4P8M:DURQ[$5#YQ7E*Y(L0WSDE_FGZ6:4 'U M4;-C*O[,.79ICC9Y\B45KB>5>\LT4P\L[:/YI&W )9P%%]6Y7$J+*E,HFYE& MYB2.WO[-TKK^P72!GP2"D;%7F=Q:8\N=;K"/ ]_6IO_.E,S5E37YM*I&952I MI&][E2D>BF3>MV?XL2(8_O *!QWV;*U%()14!JJ*0JEL[5;H6E0!*)6KW>J8 MSQP5%%K)UW*5'HN:,$NN5JG#1U+=>('&#]YY-8I2VR6^8.$$]IPZW./I2Q;" MPP%A*'!"YY#H+U84JT6W%6.[Y?%()S P*FPVRG*T"5';_1GY,%.EW"T:RE:Y MR;&:>BW^H)*5^E_,<\^EPOC\M0JW UMT+,S]8A5PERS[MUBC%I?MMY)>VT+E'+:A$7]..6"C=0UC1/E?@6-$@98:NB\IMA%X MJ.@654WJ%H!Z%> XWILQI&G=*&_:/P"%I\&8,Z.O0 IE/E6]"M5\0("IICV M,TLT-\$L;;.XS_MZ'65R\#G>S NJV%@-CWWY"-T@#>*S<,5*M?CY-Q=8XF: M=-'XH 4+_V^F"\VA019XZGR@?3ECRGP7!19ZRN?Y)1B5*=HTAJVP-GRY$#^O M<0/B%BI??VUY7<)6*9W>MJE7&^^"M&WXX)^<*[1R/P2N LNLE8=&!S^/N^;S M.-;3T5B5KBG;+-NV37U*#F,RWRKB]8:@5^D"Q0IFVPSC]AJNUM??[$>A]=BT M\BM2HE)V%%C!69XC:9T;,$="2U!M%4N5S&WJ)):W)-SQB>!C &;E1$ )K1\O M_CI;F[)%(:]JLN7$JKQ(;!>=4VND+>-JGV!?Z9Q588/!SY%QJ/JG18M(0W6J><4J]B_BT( MU=@UN9+"J:E\FF2[]/^5>@$+@R>Q3KCS0,,$53A\CJ?RXA8A7!11;(U:#%ZG M;62@UK.-8? J;9,]UZ0QA]=IG97#3AK2OS++/+??<0.\VF>Q3X/PL#9X_!]0 M2P,$% @ 5S-M2].Z6"I&$P 1",! !4 !I;F9U+3(P,36EG*LORM4G/.+%NI9QQ+(^G2M"\9FH0L M3"A" 4C9ZE_?!3]$4B+X"0J$DY<[2\+'_A; [F*Q6'SZY]O&[NT099@XGR^& MEU<7/>28Q,+.R^>++XO^:#%^>+CXY_=??_7I3_U^[VZRZ/UL(AM1PT6]I?%& M'++9]\:&;7JVX4(CO4?L_/IL,-3K]]:NN[T9#%Y?7R^M%3/)I4DV@Q5V#,?$ MAMUGB.ZPB=B@U^]''?P4D'+3^_;R^L/EMXE?YL1SK)O>A\178XJ"/BV@YJ9W M?37\KC\<]J\^+J^O;ZZN;CX,_YLL3;9[BE_6;N_/YE_\PKT[XCC(MM&^-XFH M^FOO\7%\V1O9=F_."[/>''%"D749MF5' (%U#OM\D4#Y]DSM2T)?!M=75Q\& M4<&+K[_J!85OWAA.57C]$!4?#G[^\7%AKM'&Z&.'N4!-JB)O+*OJ\./'CP/_ MUZ TPS?,;^61F#YS2A#8$Y;@G_I1L3[_JC^\[G\87KXQZ^)[WN$G2FPT1ZN> M3\.-N]^BSQ<,;[8VN@B_6U.T^GR!G977YUR_^OCABM?_YHZ8W@8Y -6Z=USL M[A^<%:$;G^J+'F_WR_PA13YO@^V9BS;^5'+#^3?@90>YS0V:$CN'FK\L7)AH MO(_IZC!A9H1AWL78-AC#*XRL&K27;/B<*&8&176&H4+K[AJYV#1L^;@>0(9M M4#/JPS:DTS8VV'IBDU?VX%B8(M-M1N9IN@(I&74 M?]9WC0"6[J1E8/*'KGPO$J$]<.7V@I]M-&(,N>RP(L8&I7LPV48;,)+X-!J9 MH NY188L^(ZZ^'\^,2#4+" 4)+ !C1PWUX@A;=/6(AOESXYR/;0Y,\ $M#P; M35?W;UO0"HM;$:L M+UOBW!)*R2ML&>]M'$P:T^12ALV1B?".$PMT/C@[((S0?7-N2*.D+19-/)<; M%@;\"S,2L>GJD1A.LQ5=JH.V ,$DVQK.GHT]2@,3Z9$X+TM$-[R8/%P%_4B5 MU7Q?L33>4"N:IZ!QB4#B]<_&!#2W\X)@M^>+AD?H^<7O4#[$!MU*!/](&+LW MJ /=<]&W6,.&]LG;<,<8H9R6.P3$PP:8?YRN0%!@DW^+;0]48#!,4;U&[)!* M2,L,DC\9ROX^V,?Z6.N\2%%N9# MC>[;YLBQ2ZWMZ5"FOPY@;F'PR_?:-G[NLVA[G$5]*,+6PGCF]]3^' Y=.>TO MV)R.VD:9\.;X+N6$0Z=MW!6[;IL3QVZ,=D"+>U&&KX656]17VUB#K>)T]8A M$:"V)W)Q;\KQMC#&9?ML&_O">V;H-P_^O.>G.RUM.<6]M(WO";WF> 7&:S!Y M$.B09!D,34#'+;%""D$Z<"WR'72.>P?"0BZ:>#H][;)JEDK*9/!A "_$IU;O.X7$+3TROLVP^^71GLV8_ ]5C_Q3"V M S[M!LAV6?2-/Q'[5\,P$/>;\.M?HC/GF;'GHB\\RHQZLHUG9'^^*"@\4$AW M?%;^A-QRU&=648+AX!&=&=AZ<$+_L8A\06DEE(^!VANWK-S<*1OS) ML#TD1%2FKA)4L&$ESL(%#9P+X+B8"EKOT K!^%M+XRU8I(4B/:]&5Q 4+H>" M2BIP''LE@:+[-]/V^!VO'PBQ7K$M4E.EJJK!% ;2 45"VA-%5-#XB(UG;/M! M<@(2DR444\B/+[G 6!/;XE&,(/CN+X)8N2-'I*G%UXPYM*8*M;Q!W4DQWE>94S).INT:TS)8CHZ!B>@NG=799 M9527%M6BTNHHKR),\FJH0#"CH6U:N('(*JF&8D$PA=CJRZVB L,$I;B7EV8<(Y.Z)IT@UJ1@W"GR>>V71Z@K#$@/%;'+RU M/G;1)JJ_HF1SXLF*.B,B)U*/4"#9SX7Q[=751>\5\300_F?XM*684,#R^>+Z MHNU]"5-SIBP-^].\"5K)B8$?_0F1'EQ&<,]N-[ %O.RW$ /;QZ M#Z"+7%0QW.%[@"NP>6.4U[JA/+)_DV!+NK#C9:S=$.> SS\1C#&_IP%/^S1C MC!_>$<:L77:,]&_O"&GN^4<,^>_Z0,[P9RF$KK62 Z7 M/0 0X$^BUD@2UT&=52H&K^?L+J%_CR.)X@6MD58J![DHD".&KI&:*@<]\U0G MQJNGCBJR0O+UE4:NG]R31-$P9^^?-')[E$9=(K I9H!&KI#2#,@]N8AUF$8. MD7(J._.\(\:KD0(KA_8.TBBI@XXK6]'M5Q$.@, M)]HMS$/Q>(M**PJY]MF6OZZ.2ZF@] FY\;01T)DNHX1*4,11%JZ E'S.BLLK M"1V+2 F)$/'YM)Q2:@OG159)I10'-\(#:@[VFO]EJ):+@!0WH"STL.H2**BD M*)QOA_GK/A-"[XCW[*X\.W(TB\/YQ%64A+]Q.RZ<#+XY*@Y%S"RJFN9RY"JC M%/E6!UB:/QKT5Y20A2*BQ164;N@SS-/4:=+QB&AYVE\ ,F^3)SCS[VL)N-X. M4A #T'$6G&%7D_)=9QDC6L9[G9EQ.>:"E@=[F?N4=/14B_S5\ERP),LR]M>" ML)V.BZ9""_DH7#B]0Q=$-KPGS$7[""TC'(2;ZZ-(^)R=AY;W'TKA+CHOT/+" M0RGD>3L)+6\^E$)=Z-_7\OY#CD7Y^^F)M9S)$S1 PCC^*1/G,ND/!_Z)#Z2I-*#K< MX<3YU@\,W.W^"^,O/H61%J =35 .001DQGY)?!K4I-$.\8%?N&&N9#Z4;;1# M?#C(6)E\*-NHDH.(\+4?V W,T=:CYIK'AJX2 72BXXCBBBKQ3%<\O/.!\2>, M3,0]DL)SE9P:*A$LR<@$44K1K<>PPQ,[,]^L*X AK-8)++ T+(^O@OPXK>)Z MB@[M3(0LWZL&DN*)R/%SJ\!O^I3#$A=7D0HDG M0Q20+@C/%X"ITH)2L[Z.>9GRWS=4U5KNA5IB6FD[3\MKN2TQK?0F0"=ZKB[1C[3\HT++?WR+3 IS[H7>/!_?S.IQ)9.X/?__?%*8#YJ M>3@@Q[>3-97$>U&!ZU7/B2234Z?;*D%@V^^/526VH,T2X9S=HQ^_N)7S".Z" M)@\+,*FSH(CR^=8H>)9:)PC!G\=GTU5JMH* MG:<1YL)B2F2\K(59-N5H@='0345X=B8=9K->!L/9^50B=ZT.$?5%DJ-N F,- M7%"UH==,95S'E=E-6S+.^:'^$A R:WK WS;R)[MC)4-$ MA0FC!:HR0=XJ;^C8 MZI@4[J:^.(["/WA(HL3>,%:>/S")<3T*Y+< '5YAGIKS)*A?@0B:8 =F\R/> M<2=9FAP!!H%@JM&0"I&;0V:>\BBLUC$L8@524$F*7Z'>3*I4M0NO?Y6I45D/=RC4@B:)DCHBI3 MJHG^ADZO#EF!FMBJYAI9'C^]Y%?/3#X>CN,9=G)4PDMI$T*S35.%<'C\3#<9 MS2F+F3O:;FULYPWA<2S8Y9N:"4(\N,_DKL 7U W"HQW,'.V(O4/T MUF#(^K(ESBVAE+SRI+8V#B;"R;L^ .[P\(V4,^%'P[%L$ SAB4+F,=Y)&24O M$R/7!=; QH\BF)-3SV6P7JS##E!@+1564_.:M8,BBD1T)XNHIG%BF#QW^C[, M_!_,4V#AV-C"+SDOGU=HHBL8YVAC8)XPN@G*G$849\&O/JCIUVR2$U=+F[PQ M"PKED%9'UTW9(E B6EK?,E='&7&B;01;RHR9>"X_B#3@7S_&CP?T\P!9%?(\ M\6R'2%HGBRC1.0D"8J8EP_EG%#LFWG*3^S_(H!-\$K;4K"T]4!./2D/-V](" M]1)ZES;806-ZX'XETE!#4QW''.@$D/W\&0\& IO3W1Q_=K,J>/'%,0(7!S]B MC2_AY">G+:@DY90DT8?_Z$_&):%BZ=ND)54H3J5IDY84HE+V#E$)PK_X5/*WCMG])$]*2I4/ .-PFE0K:XV)O?XY#GW][H!SWR[7JN< #*!=K@Z(G;\.3]A#JO\V&H!IV_(_3U:W!L.F_V&9[+H]=YR,3 MU5-A//JY'#?^#? PJQFGA(U'7X:YF4:4&C!(_H@)KU\T M;EB%^?1O?U4C:[2#(7SA0_G,_2;A> 48$K%, O!56^D0TA/B_"E;#:>@#:5J MH>; )BV&BAS3TFJ2P"89(D6S9TCR]4%'-9?_]$V7:8NO+H2Q<]C!&V\3Y"N) ML@3./,HM-G=)PKRXH%V/GO>1<@% V'J*MHBJNY-7P6LV(F5;6[E;G@ATA[CK M+O.B0Z/VE"$B'I6*Z-">*D2^/UXFI$2#RC"]$JF(HN;4X%FN$47&RD69@1]- MFE. IW1 BXQF55C$R<3J9<5ZM;J=1246^+6;Z3)6@2JHW4R'L0J51/UVNHPV M6WW4;:6S2(6*I6XKW40:O:<-6TK;L[B_+/JE-NR<)KO)@QE0"_^'1^U/R#WZ MO38G"AON)C^JW JHVYH*Y/6VE55K=QA9L0W2^F[SW'@+[)#6]Z)GQEMHB[2_ M4STWXGQ[I.U][%G1%MHD;>]RSX>VB@Z2L <^>R+IVL[.P[&Z%-="'#&H01BN M$L8="9F881J$YBID6$(/Q2S3(&)7'<:]B:$KPV6CXU MWS*KA'X%C2RIL[ HTY.@D35U#B9E651#C2RJL_ HPZH::F15M<^C3,MJ6,>R M>C>!S2,;N.$8+AJJN#J4M%"FSW9X38OE7^\NJ*0ZY"!!4N&E[^)ZJM%T-J#D M?9KI68M RX0@9V55YA5;W5*$R)7K,X.S8XU<_F:M\LLX_%4-QPW?V :9Q2* M>8X9W-7RK[CND$VVP<<.W2=Z(BYB2S+!CN&8V+ 7+JA*GTI^0\_/'N;/XF!Q M.=8"OSAX!3Q/H24VYG>1ET#++]Q&3+GSI-%XR MW>5[%>([RO_C!Z!T8'L)FCO*;9X40P<."^CL*%$0@UI,-<**2XHYQ>>,\,_>;!G_?\5;L.6Z-/Z#5G MJS!>\R0/(/Z29?QTHIM^7([MEL7J9H$I*9H0 -0-I6?OT> MD))(2@0(DJ LIV'2=O&Y7R'P+GAX."GO[TM@L$+HLPG^//1V8?3HP'"+O%\ M//]\]/7A>/@P&H^/_O;7/_[AIS\='P^N;AX&_W11@*@3HL&C\T8P6:P&5VCF M8S^$,0:W/O[MR6%H<#QX#L/EIY.3U]?7#]Z,N>2#2Q8GT-#!KN\$QPS1%]]% M[&1P?+P9_Y>$DD^#'SZ<7WSX(?.7*8FP]VEPD?G5B"(GGM,#8CX-SD_/?CP^ M.SL^_?AX?O[I]/33Q=F_LJW)>C#,JW)QI\('1^G&R:7CT MQS\,DL:?WIB?Z_!ZL6E^=O+/+[O;QX\>3^*_9 MUD"'%VZ;9\GZ_B3Y8]*:^9]8/._HKWS"GR@)T!3-!C'%G\+5$GT^8OYB&:"C]>^>*9I]/O+Q+#KFW^CTX\4I M[__G*^)&"X2!,=XU#OUP-<8S0A+]82W M/9$.=]*4V"GT_/4AA&7)YYC,MLOKGK!XFXP"AS%_YB.O!NV* Q\2Q;U#49W/ M4&'T\!F%ONL$^G&-0> M4#/JUV-HIVWDL.>;@+RR,?9\BMRP&9G[PS6F^,IG M;D!81-$7Y/$/=/U[Y"_Y=$/LW5.R1#1P<&\#OQDT;@NES)LBESDOW!B@4.M:)Z2P34"2?<_&Q'0W'B.P-N+1<,M MS#R/)]0/L<&T&L'?$L:N'8IA>B[Z'I[!H;V+%CR*1BBGY0H!\> \Q\G,Q 4 MOLM_ZP<1J,#D,VWZ-6*'5D):9I#^Q: ^BTYH",1^"YM7-JYV\E/-OA;I/O87 MT6+*=7AP[ZSB#78?418Y.'PD(V?IPQ]@Y4R6?&T!PY-Q-"#61HJU3,J'N^SA MF.8P7$HF-WM BR9&$$P'_C*&?[IQT"J12B\H(,OD1^T[2N)^=P1LY4>R MC81N W>,"V*0Q_<4,?[58J6%O0=_CL$%=IT<]00L;]!PC^@MO R(^UL-WK1$ M2-M]?:6*;N-#" M>J@Q?=L\[>\LFL,0MA:^IWRF]M?P.B[1 M_H:53-0VRDQH(HZ/9J(3;>.N.'7;G-CUR=L!+9[%&+X6=F[97&UC35S%R>P6 M@2) ;2_D\MF,XVWA&ZO.V3;VA^B)H=\C^.44S](VOCOT*HD*C)[! MY$&@0[)M?!@")FZ)%5H(Z@+7-K$#Z[BW)6S-18>ZJHP4Y$UN,C)YPN3W,7^= M(#@:K ?.0M_V\G%XXOF+DW6;$]ZA17I@*H1Y6NZQAV9.%(35J-OO?AA:R<+Q M<6U2D]YM4AK/<+Q BR=$*Y*9Z]HBC<\P!'6C)W2\Y4PU2HL&6-/K;7/&>UE[1\X-\PG>M,6\-4["?2FB"H M82JLM207'[*8)5NZ3,)O/%B2J]7#W"W,,WGPF0J/2T"M'/E+#* M8)).5N$ F8_&(+\K8TD[6H7G#HDDL;2+51CXBK]:NV#5H&1Z]@[1K^=&,*49 M0&(:>(:;6=9.8IT(PGJ$&26+:O)W0PNIMA 'A'J( MQA>DX7]'@R7U"077\O/1^=$@8H"!+!.#]0 \R*W!0[$ 5JYY)L21L4JX]U1# M%K;ZMM@@/SU=8T\B)9^X;X"\ST";\ M)ET4(OI 9N&KLP=1&CE2ZVLDBL=7 KKU7_B=J9W;W<5?1A3=JSZ097@O5U^< M?Q,:'R9)8F=51K ,H2R*5MK-,BPII^^_CO%:-2;SQ):Q<%91*+?)2":^Q@ZI-:5BU5$L1'K]Y@81+R?X,R'> MJY\&<*I!W1_&0JP59$J=D;XYQ)4EJ5 "U;'!*G4U\VT*+ KU_:;4V09%I2TL4HN&<(H5C<4D'+7OB_GG%?-=W>+QR%+&0+!"=HB!>S>S9 M7Q935ZFK%CK3*$4E[5]TG-5\/!,KYY$Z'N(R4;Y>]IJ9/8NKX1'FXJA558[Q MHRFU\[G#LL6*,SN%.&Q--RW+F?U=TH5P>P/@U81X%Z+Q&E:!3,L:#\P?A@6* M 57CY[-[1_D:8@7;?=',:.CA8;\FYM;W^6T^\]7,G/)0<)CWUFA&LW8LN3,/H-6IPZKOEW.[#-T6UXCQ9&AE"&FC%TU'[GF M&4$%1=QI7]D,>[KB,S<(S*OZS8:R$DL3F+3%!2LLE?W59GR1F.%3I0C6FD?G MUF> J;W!8!>-#=]*, M&_!""CD.#X2Q$= B;PN.^^)0/G*S_)^ 21BRN#_*& M>,T/.D?L'Y%#H<,$%YX8U!],RP%(O>D?84R-:)+A3.)Y)1K1P&"'P@(FZKJ@ M!DOF/4R"N^Y1?!(_AY!B[BI7GPUI]+'!^EL*5$:/K/^ MF?1QX0N8K,\-L*GVUT/Q]NDBF';N8_Z 42%E1>VT4#!ZFM'XG1PQ6W:;F$A, M&%$$]MN-X_H!V/22+,:"AN;IE>:J%3;M(,V&4I&Y<3_&+*1Q'2[)RBAH:)[> M^(F#AR5%CC?!OSC4WSQC=J:$0M+=/#98'BBY)*2$)=/< MII7 7474UF]PBT MF>>[Z\=+U+"(NYO'!MXYHHAQ&Q-=SV;@S?LO*/LRGP+ LC'L0CG&+N7W*,$@ MB?^_,L2] @<#)+:!3H MIUP3TS0JQ"F$S6VAG6L+S-]H1%18Z["\GRUHKM^6/DUJ)TF<:Y6>MB"ZY78& ME5K1I=UZA,609U!(5DF%4'D?6U!\<=[XPZUE&J36$+9@E-6A%+(E/I\&R-4)D\8RZG,M=%BU]U% M?*S)+#8"M[%"GE+D@E^P M>>7@!LQDBI9)9&$RXP05 :DV@!Z:RX\UMX? DAO-U4?127V#\]&*(YC8JU/^ MKI+$[$[_;HPZJ1S)MK">0D,VUQ2]D."%VQ-Y:T-*M;2/F3+9X";!AOJ*V1*Y M\=,W4@-8W+[3U.LJN_* 7,*+X58+V2KT,L+=S=L_&[9))%IQ6RT\Y2X\CZP/ MQ0S<;:)UWLOR>2_;F+=\6JVS@B:MO'#+.YE8M]D,!,F2W6MFFE:IZ"IHV#%Z MLS+6R.4S<50T5TV@,/_(^-47M0MD]2%VY1*8+#UL>Y%T3V5LD9W;6W>^$K++ M/607W?UFBB9U"K4G'W$?F'VW_RL!JQ.:V(+_KKL+N-U; "F'[*UDI,ZA%NX' MI RRM\Z1GB4D1F[OFS-5)(=R6# %WG%=4.VV2 K;5$TA-5-;G Z?U??B=$SS MEJB2N=T,9E=,[K*LV>U:5LA73 UQ^XIB5<:K$NU+;3O[2M54!JP0)$KQ]N # M%Z< IQ#MJU!5&>+>S;M4Q9A:L&HJYK8DTRWW?%5IMH]Y.:RD<'2"[HKZ*?]X M.TM:F&B=*A];*H!62N J^[C]K>6IE4WBE+(NU$_6PH*]/-0N%$MNA+P;Q9"5 M(=9)N3=>_[B-;ZQZF\QXB;?VP%ZF[YV_26;2PP? MCA5QV2.;2PP?D!5)-2N;BPNWQ@Q1*3R;"PL?DAGY;6*LJ+ ES-C=*+TQ(//W M5%. O340L\5@4KB]-0G%=N!9#^S .CX?+Z.BD# M>F/H%9;J2P.;?;'A=%P[2[G2 V.N>/G+"K>E\'M@OI7O_L(:8BD/#-ELI17K ME2\&YQ(ET_MEQD]PVD%8=,15M;1^1Z 6-TUX%51]VP\%ZZ!.RUY^LSHQBI MJ>VKIC6D%Z1S9H"8+>:%KY(^:0[5#DVC]F%%-XA%QD['/F8]>'9\P'(9)+ZB MG/.ZU$I9I1K(W@BB'+"X.F@J9M7.>XR^G)8^_9:&0#D8-L3>B"P6?AB?[R#$ M,O$?74^3)!$V^=LDN3;F'\YX?YRD#9K?G_FP]9F/;CU$P"^6>/'%$FF]J+UF M^LM3\Q\">9%T:?NV*")1,6O*V[=$T0178E':O"5ZXJR4*A1E.[1%TZNTZKJX MN2VE6'.61.EC-%5&L 7A;2_* A^B9.Y[H2Q1,].TUBZ4U:V23-UPMY6J'$C5 M:1=NYM1$F5&(7;A^4Q=EUA3IPDV;FCBS1FD7;M34A5ET F/L LT!"G%T0]"V M4J7!U&6@]YO0]N<-]OT6M-#9,WX;^N!Y5WU+'Q1F(O4M>=#*M,$V3R$M6+)Z MCN3VSY6Z<"U5[7!U/[Q=]9:IV;/&:+%PZ&HR2PK2(@KJ$GE?EP0G91409=>! M/_>!#T/7Y;?)V!2YR'_AG!EB;XQYH4]"5]4.(-^/ =L_!A2%LAWL!;!&IX@A M^H)V65;Q]RLB"FU K$4FNT"V=[RK %KD(73O:T;&"9.67\V._@\35EQ6U' M+.,F"N%77QSX+\R*8-/&99]-A"CZZW!TQQ"_)7C.BR06/&QG"G6YJ M^L 2WE;X'./_0P[E)]<*8-3'Z@9J$HE,8B![OH^FT)=JI(AI5TTL*_S!R_.$&$ MDBIYFZE&A(6L7,,V&A[]6[)ZIA%^/OF[14 M3[@PHF@^VTCM@5-).%0&LDM)5?+P:7J-;S>X6?4!&CO.G4=DL73PBJVS?X;8 MR]EMEAS<[@F2]^/G]^/G# 'KU:M ZJ:E:8KO"':5BG5%4 MD<.].I"H*-Q[>0"A'& R=23QK0:89+7]NQ]A.D @K2NU_AN'TA3/Q8R%TL88 M_HH>G3?$AI[G)T2-\8S0!:_7AH_,DI>64&(C,$U]/$?8]>.B_+?&[9[7NA?6$':R@7WJ.4=S8/-VK6^>516 _ M@_6,YU?Q$]0*" JZF\NVR(K(XA1*7.,Q M8/&Y1ZFAD0\M%*OU/I]X-&!0D?U@_.Q#/8(HM>%D^]N2\&&K2%-%7;4.L;'0 M#H=Y[5!>[H4_J?CP[%!T%RT0Y18H#_!<(>CFX_C'R8Q7%'?Y;_T@"I&7Q*TV M_0Q'J8J@6!.4&L)*\CC3_!?T@-SUC8[K-S>( /H-+#V>01>%,8&3V1X.6=E/ M/6.;<$<:4GZY*AY $C]I*\^8MH(76P\VV,5.IT M0+])]DOZ=V/4R:N&9EJ8H/ A).YODV5I*&6_G9:CAFW^]8,_Q_[,=QTNQ"5456@6 M>X$(,QZ;4%LD>\HK5ZPXJSNZ\.T*E%T6SXX]83SLN1<^:J*0MF'>2HJAAR&F MIDS4[&_:'YFJ:TYH9)9?U[Y"\7@BL1BCV-/.3C+/W0"6+>39Z"=>2S^&Z/6A\3*'@F MX?\B?_X,'!XF+Z..03U0Q,*I^$B_K)>>[+%X54I=MMTF&N<5NES9/]MPH>W] M\F![=$^6//[/3RWCCSX%6;-)]D>B(+2\CY85FA-^;)\40:.#VK^"W9MYASFS MR_IJOTJ8H"R C5N>#4"*5JMYM[HA)E6+QKASJF&%E@A!X]>\U,SZ JW>K4L^ M[U5D2JZ^*!KF5:_F&?;*'MQGY$4!VKYH M,NH@7?A4YPORZ#>!]1?AW"]"U0X/5T"/E![!U1[,.>6Z;21)=*HUA)@8S0Y0B[]%Y M&S*&0JEW+&C<4;IUE=;9'5U\T5#0LA4J[@A>5T-0IV>OCXDORSV8<,5C_00# M)=(/6]RVDU0;2I JEL%,7:17&*#G^.SX@AFMDJ-1HJ6JC& 7P@D=/?,SKS$N M^$:C)$KBOZ#KV0RYX626-)[@9 -.0"&'L=QC9Y4YHV_F#G%T@V:S(O[!7:7X MF#+,!#[T\+!D+KNXQJ101,=(^L;M$C=D%XZ;C6DD.1:%H+R1MTE'D.?)%C5]8=,.TFS(RN E[I,*,T% 7GGIKQ#W M(PE=>.%%ZI#GDN8$&KP+912K>[>YC,NZL5WCQZZ*XKR&:YSE3Q7NFA=Q2B+^ M8!RQ0NP+BRMH\^0DS*GJ$/4P#\D0NS5&A6Q.@+*1NV41(N/)5\JE)[2$-[(< M5?>@C,M-R0W/@; OA-LY1KC1;SB)\01XQFH,6.P)[_W M";1 M(DB3@FWE>172K>3]&/8IGOM 61(?L)_E"A1;R6E^T<)^[@JHM)*CV\=-[&=K MYJ$3D!*Y\I_V$[];EJ)S=%JY>I.;-Y/9+0(QANQ?!:7T6LGEA^B)H=\C[G6_ M\)]MY:XL^ 4"(PX9L<*84:\A;=P$(;2?3CC-3[ TX8?_!U!+ P04 " !7 M,VU+V_][.M=6 !)Y 0 %0 &EN9G4M,C Q-S Y,S!?;&%B+GAM;.V]Z7+D M.)8F^G_,YATP.7UO99IY1#CI>W97CWEHR5:/,J26E#E3DW:MC*+#)7;122^2 M+H7ZZ0< ]P4D0(( O.V6555$2.39>+X/^\$__8_O!Q>\P2!T?._//QB?IS\ MZ-G^SO%>_OS#;X^?MH\7-S<__(]__J__Y9_^VZ=/X/+Z$?QO&[HPL"((GJSO MONK1""3^ UBHX_?_GR_O[^>;3//GZ?3GF?%_BD_[QX_ >7F-P(_V3^1A<.E['G1=^ &N M4ZLFX/;VXC/8NBYXP ^'X %B0^'N/MJO\&!][G[X9ZSP MGP+?A0]P#X@-/T7I84W$W-=_ \,I)+! M\'L$O1WX'AUMM=!8$?7/A! &V< MF.'V.8P"RXY2_<3K/__02\27S$"/5,O_]T^QP6)C$"$JAK=J F$*#,0V*&>]%=BI0^BO'9%(GOAB^XB/ MC]&G4F+L __0,U]3B_P!X?RB%-?WONO8#F1'<>T%)9BM6L&5F,L:0E-Q&H%Q MH(=5Z#%Z*!]EM 1LQE1C5-0BZ!%U\G96L M_.^(.+'I^8:Q^A8=G&'1^Y+9W ME>"JQ2".!%R9BQK$,LD@%HV[[HM/J/?^1RQ>.>#$N1YC[_$W)A?E(XXA89O! MUQ4AW7"XG&YZXS!_5Q,<9@9Q)>.:"8=+--C6&(=]72_BL--%'7!82UA6')8C MI!"'X;WU83V[\.*$.KM>1V^R^K!\I%4LX,BOS:(\S@M!(FH"$F%*<33,,;/D MV#$6I0%H*-G5@)(F_U7"X@':T'G#%GV#$1LX&E]1 )$F.WB(>%X%2BYP I!( M30 CP,TR;(*"FRX,0V"YKO^.)X3!W@_ SC\]1_N3"ZST!7\/_F$Y6<]79'[D M'^:3S7H#K @$G 0<@>SZ22>\<8/7"+Y\4\-\M/E!*D,CWB*X0VZ'SK M2WK MFT!+_0:*H'LZG%P\M7L)C^AK.F0B'OW=A?@O6V^W/?A!Y/P'^?E]X!]A$'W< MHU2)$S/WT_.\= *:@?!)TR*_0/N7:LX7OHKS8DO]U^=\(^ M:5:3H0M#5 WCROHY(R\4E8 _L!H=J6!@*-@(@#$46F">EOC,2&^,J)@Q^AY] MZRT2O,/"'W!7_6Y_X^W@,^J_>S ,G_QKYSO<7;Q:P0L,_^UD!>B%.P]6$F.@ M,.DC^;Z6LN;R:F,8YBP9W&-EP$JU@0"KP]/@3D$A'O?ML4I@QSK!WV.EP/>@ M[$&_I.@8>70R;8"H W=[4%0(GGQ 5()$)TB4 J15Q?R I B9#?DS 0?KNW,X M'8 +WV!@O4!@^V_0L[+4LB)@>1\@<@X03R A^K2(B.I2R@(\GR)P#!ST!$J_ M7Q'?O::_6ZN;=QA*2?E4Q*"OI)!?GY!,@0P;BSL/CB6VS9;,Z/3$@,-)-3\4ZBDU'=?8'(A86="I^\^%PCF M8LCTW3\/*N6.CA B???/AT:Y(S0BB:Y;^JMG1[ Y'PVEU^03R2)7O&HZOA<0G1$I M!HK 2/M#&]@50/2!4IVIHH(1J$\6Y3 M8HL;@EO2+KY:'IA]GDXQ6QGXSX3FGG*:HZ2+TFV*0]B@3&><,9=#8X_H4WE8 M\]=3=(\;DR?_7T_H"?*H6+KKJ4H[6NSG!SN.EIN50://>L./5>,CP#KRJI1( M\?!O9A")X7TIALD[Y\?74J+NK1<+KS+2^:O@&R5'VYJ/1;3KM:CGL7USZ#9>&$TTBPW'N-\6W%M!YF9&M BL+ZOA.<9C>."R[3( MWN5Y/17\/(Z+1M5%[3ETG#@T,>,O^.H#LMR*R-'X;"Y^;F/&RIXO/;B/$_1E M1N.)M))CFVG)KFL_N$P*=M6+5774<^.2(?/8)H]A'&<5Y].TJU4J>):J2(\K ME@O!J:T!-V(DZ$7A.NK!*3VUV2?O2Z A!K2GE2:Y;.AV5KL5B"7/P,=47@MKL*.HI_KL2W35Z/!5;8O(!+Y2$]@=&R4L MXD7.SG%/N$KL([1/@1,Y,+SZ;KNG'=Q=(Z#T6UN<'3/F_6[<2EM.B2-B$R^X7H3+B)!80"&:OSN^C#8]^L [ST M#Y9373]@?DTYH^2V<.7\II46)@"+!7_$@K6BA][^MF&< ?[6"%\=[L*+FLWU-STE?_VLP@OEXP'JQ7J3'2C(YX$ $X5, MTD_9#7?&J#@3"\)+6DH.Q0UWB$#Z=RMPB#N.AQ3", )6X_=2M]S6@IE\68T6 M#26-9>O,I/P92-Y9*<-(F[<1IQ,+%XZ+LWJ)K28WDK=,A4IKBNAS9(KGPHCZ MKJN/RP])S]<>%P O-XMBWJJ_U7B((\DMCH]73X_JD[CUEN*ZE^J2NF-/0ND9 MZ2G-OY*^W*R*&3WR?@$V2N[G18&9$P':,'3;>G[-8^6IS43;U6=5I3H_]\T, MTVQ,>4W8?)ACA-3+^?^S-@#H)ODFYY4 XA3Y!__9<6'8?LU([3F90*@JY\F5 M1=J3R86HONUCH#LFCSO2\I^62*7<;_1<1=Y_M4(GO-O?HP^<3MQLO=VC\^(Y M>S3Z1$3_!Y]12;]C?)9!XF4B*8A=G)DJIFV/D0?7GTN:B37 M:!9TEJZ@2+2"/[!>0!0K@JK$6)G46.$YX>@40/SSNR,DA3^\,([@Z7"P@@_\ MFXY@JN0&$6 KTLC@KR)D!CJI*((T)Q_%>[G%UPN&UR?\M7YU/%RYY=[ZP%/# MX>6I<7J:7XCLN6MN"YGO;C1GTW52:BXM](-SVD_5Q+P(H!T:Q@25%BH,RN;,*'_4SC?"BQ@57ZLV,U MKLJ($B684*+,Y)T#4:;&LJ>VN5J9 H@2*3X;HNP9I.%$B8-T3D39,U!L1#D] M*Z*LLLH@HBS%5151DC+'(IFR(/ ,J#*WEB.[E]/Y<*XD!=O/A2Q[AVDP6Q+- MYT27O4/%Q)<*;P<20BY#"+,2666,^>X+YO?/ MABG[A6@X3Z(0G1-+]@L3&T>JJ[$N@$X&,60QJFKX\>D5!I#4Q!>2*05QVO-C M;BOS4N1FN9EN!O)CE*G5G1U[!V@8.^9JSX$;>P>)@1O;(Z$G0]8)I3]#5F*K M@"$?(#Z6M8/!W?[:"6W+Q7P]/&^:Q>K-F(TVL_<'IIOI>@!S!JEVO)=C3_23 M+J;6'"HB9/VY]($2,NU95438V'J>ZFZ:%$A#/?F5'F45&PX3VXF]=\^N\Q+O MXFH_9='QDL1-@^V6<&QUFZ77X*2Y2T2"@DS%I1R%>EI":8Q+L5YM8J\\B,R$ M.VE^&?.X%FT8 CO9@W_ >Q3)<6^56PW98%;<3,@0%XWXHG63?OL[ZMF"=[?[ M?%J=L:^1A>*M_"(=-6N.ZK&SGRD3&1"E>,<_Q:IO* !]VN#">^J!E1O#Q>-= MX)J 7+!6^.KM[^CM,7OE2^&?,BX/[WLOGU!8#]FMLL1+X#K6L^,ZT8>&3%*' M( .;5.*DFE%8-_WSO:N(609OWR8IN6A@%T0IVNQ@']/SPL;U$@[UV*K>*X%I MF!2Y,5TB+NE[UWN+T0VM/?84DZ[HBANX>$U7? HE9IM>P):T6[@R6%A 9K)=N AV9Z'U@/V/0K%=;4 M?<']Y>@';/Z]FJ2_N>Z%;&4[664%A8)M-5M6!Z=[#W /VJ J%]W->UC[2M$0 MV9S["U&O<[ELFI]CP+6:G9=R D+#M)(ME@.3O ^B^V^HE(AGZI[+OE)TPW./ M/7$X??EGQ)3M%903CD8TJ]T4.##1N3$]: N@+$S?) 6M;[SXYH4;+_U-[[1I M$:D5VNEV?'J,"S[A/6Y9 MB?4?9Y\7_\]/>C-%-WSX:*,CRGIR2%*MZW?+/<&[_3<857[?.^[3.'6DWU9SGD,E:85SP[:8T_PP#=:FY2/(\0ZR3R,KGPJ M(D*TZ1@EYPX$H8&/$_0]91#>[7'_&<(+G_29D;4/^+24&Y+ZJ8^H-VWM[KST MUJ*&"[1$255%#/RF\HQ2FGM?&/RQU@G(]8)$\03$%7YCW<#W0'9IE/S+K]3$ MK$X9^6!.U>U8@N%#99">P15T+C0(/I#2^!K?K;?;VO;I<'+QH+]RT_@.#[+W MQ(;JK>-/^(>T2NCCZ9%_^\+EF&():8!B]@F_5RI\H F9)T$,3:$'#@MF **MH"[/2A: W)S M0'HO%K$(**M3KTMLXTO5\V+TU3!;;6'VN\*L\!#K>)Q9.-4ZTN=3TP$-7Y$+ M^(^KOY^<-\O%G>1ME#I)QL[4?@C+NU([DPP&\>PCG4U3%@I?"2;(7PJR)\"* M/P=GE?OVK&'2AXKO25K=>': 1R27,/Z3 M*P\H(I03<[-='&DZ7ZP[^3E6 E(MX,=43^,:I(Q%@M%"098#\ J1_8H>)WO+ M[//!;WNB=\.X)81BQN//^^#6MRA'^AL?D3X*+NMG'A.8JZDQ2VHA?;U^ $3& MN"?UZ0//03X8,GWH&.4-#H@9OA<$NGFAKQUWI&17 *QK M^K'7R^5JMBH@+Q8B>ZYGF/5&Q7K5H!O@BLGCBC3<-:5_"7@UCY5T7_W#P8G( M&AMNG-,9PSBZ;8ME.L.0*X@[LD45(->A M_"[H,2-A"HR$M,YLG[0O]6:Y ZHMNKMNW.44HAN^>]P4.Y]M9KP 5WZ)[JC! MJ&)\4HD$CLVM$R5E8[1'=NN]MST"J0K;OO<8(1ONK> N>(SP4@:9#$.#ZL=7 M*Z#.-S&\*1G%'>9P9.MZMLBAZWN R)T )!GX 8AE)SMSD71 Q*L#K%B_S8+? M8>SW$?G]1EO@D(E)QE2M I$E0(K11PP)MZ?HU0^<_X"[[L]=>T,-VJIF<&2; MD5V)5T)9+!'D(I4C:Z"/#8@*8Q^M5A\5((N6AA1$-09&"R3=A.&)'47)TRH1 M%)O Q=4K.GHF():G"71Z.4>'C4/U31EDROG6"I=",+2 RMTI"B/4]T8=5-;O M67Q%)6@*=G!Q\JP-.06AFL"GOYMT#/GM7BH#4D,VMJ*I&AO%D&K=-%5]3 UT M>'>$K.?3)K@0,=JT,WV<:@#'/WR>3J=&/N#YN=!% \BRR33^7X*B?TR:HOA6 MCSP3@6E.-JOU9+99DU^A?Z[6T\EJMIX ]-H1VI'S!MV/";#(*81'A!(RA0]F MT_A03OK:>KF:S&:+])_(@T8>M[-ALK^3/]*Y"02IY4MO_J[K&_PBNQ_NE$X%Z M5/GGR=8*WAC#HP:$872W_\7W=WC*]!$&;XX-PT??I0_CJ"](A1O-"O9$6RS6 M&<;""',YD4=8/Y4(L$A5L!+DHEET,8!OT#LAQSZ!^\#?G>P(=4YCV<3Q\'0\ MNA_ 1H^KW;/6F9=EC+7&2AVP'N)P=R[#-STK'4X5 SC2K+#J%J=9(DJ#U?/A MCC7BYV?UX*#D5AT73>Z+V2M6%!_>GP['2UR#R';(6N*CY4(,QTLG//JAY39? MP,XI0OI.,S[[F"\I-!:;I9EL1*M2\Q%I ;N"&A!B/82?=ZDFV7O61HU#SAUW M&7>$ &L!136 Z"%G$C--*C:]C1H+:G-=RXI2/JC;,=>/!/(-=3VBJ:1!#^#. MB:XMFUP3M/WN4"MRU1^4V937M',T=W,C/09,I(!4#&K'D2!5;?A0CTP^CZ2U MXM2$*C7AS=ZK1\"ECPN[,'VSY%%E*(CU\V2-.:7@(!:E!1)Z>=6,A1:OU*"A MG%QT/!1BT!\1(;0_O_AO7W;0P6"8X[]@#,P+&$ _^FMRY6E>QN@*M4OUJD"M MCTK 0)M^CFQ9SM-^67*!;:%D%[C"73#I!7D$>F;V\6QL++ D&<9"9QQ4M Z7 M\#EB/GA >5AB"]%L 4\6K8P8'UB23B<&A'AF\GLFJZ5H3[1B6]$2"?4(Z=J\ M3WM:&49Z[$!'J6120*)\U[T8YS*)J]B6UJ7_*BU4Z MY72$2CT175LVC"ON,7WZPN/*B":W@:L3MZ$0"Q:7U&?4@49Z>T>PM'UY"<@% M-FEU5'\/D $'X/J6TE.?75E'AU E(!I !M]=#SW[XVX?%T=R[*0*.ML'IK^N M#E)4FSB2<#I?T2"6BL?IF"I(KPS0 G2B_"<@++D;UR],[PO1"(*=6=P"R?9P MJ8=H>C,4;FFO]OMX,SQX7=Q"766H5Z/,DO=L MV!90L',,8'^S#K!U1PGU<66@S6W@&9"M9Q2(8G&*]Y<(\J]I9IC!/S7(JB<> M'4>5B*A'39]AIC9CRP$#J@5M,EC',>0P/^-K.%.WDM$B;L!V&BPZ=F8B'4MZ MC@\K5MT'CF<[1ZO7A\Y?U@5BF45 M8YW3 B@G(!4*$JGEX9XZ,(ISEJ P<]-*W&P' M 1HKJ(CZ0VY8:2VTF$N$1%LKI[ M$X3X186QZDL4VI&3G?QL"<(H /[F>\FI"78HU]Y1#>JJ0>PYLUPOJO".4,Z0 MZVZ!YWO CN5*/EDNV$$:V)%8D)[WT0CX [VE40"KMTKH@(9#*C$T!DF'?G#X M#4:)98S]M>(;"GO$!3,X^H[K*;5;'$X O@G/WY,2A7%]@JWK^N\6RHU)FHMZ M])G[.U^&F^/9_@%B$E4]T.S,RK9^\0G _.ZDG:!;5*4 3U=/.**5??C] +X0,D%Z0_^;_"G6-;+KZY\]BP M2,C_OOP>,+MQS+5V-K,-RK.D-URHJ0-C!2"(-8#(!X=8![G-E2B1WD$>S7^C MYG^B "0:P),/$AT@4Z*DVSQ:#$QJ#NS]H/[Q%?:B^3%>Z%%SQD]-)R W$K'D M,:Y/66>%[N>E-OT4(]B;O.4T/R":"R-->BY.5:LNQCL"LB=\5W>YA%E.M[8? M[-1>+]&9?N66O2TP8AKUI&'<>KLK+W*BCQL/,=*!J*24UV!_3WHCSF 4 MX]>V2DV)ZPG%>S^NT<^JY1C:GY54W8IJ 'NKM#(V9@51216H6!P@\N27MQ+E MFMG'-1GUK3H3+2UPU1X)V8C %;;8\) _J00-F7JNA)DU8X%41-,""7W=:L1! MNUOR45!+KF8,E&,@#P$Q]NC%#IN?DYS])>4<23*?K2NYG["DNA*'(EPR>5V2 MF?6-"57-^;KW\C+^"8EM^3#DUY+S&^ODXKY5):VQ '6YW,-\D\E\F7E;3(MJ MNF8.JI@YN[("S_%>PO1RY8[JF]3')A%.0>V8O M]V3-F'6E77'"K#4@.F &5V2R&;]F_*Q"M! #N')I08-*7$'-U@,F??PB&*'Z MH H+I71J T+NLC8H(/=MN"=\"(&O(:&]K1HI=9,X?_.CZ8?A3NB?CB")!;F55>A\69Q)WHI$2+1WPF=C%^.W3IQ7B+S&! M*]VHW;I)BC(]H-7/MWA<0_=#%6HJJ=6&DJ+C.J"BJY8Z_7F%R.A1DH:D[JA-F6FNMMX=#"6[2PEXWI/E^LK[C8Z47OAH?:<[+Z2*O"SB% )K*8K>))Q/1>PKS&72R>;,G%"L #Q"GCN.F&G:1N\A)X_.E<@B=?P,:??8[W %R@# HL]\;;P>__$WXTS*DV/R=I M/KI1.4Q:MS;2F1YI%1"P@MNR\KO!_CBX$FZN#PC];M4'I.:X67= M'#V+Y6932O%<$"FGJ2K'!_EC\ODC+\N;$ZF*QG'__T4-S%'WT,=M]9R M3,W/RAR=-QG D32K=.][+ ADDA278A+AE\GME[2Q=5N*E8;1U# (.06#K[JZ M)%==W?J61R_R:!T+WTA M4]3DO2!GJFF?W+2H,O&[,JG4/#5YKR+MKQW/B>"M\P9W-Z@)\5Z<9Q?&52&V M-FI73N0X]O;@!Y'S'TTMS !!$J'#;QW'('DQ2[8&Q%H^$34@UY-52BFH D5= M:A X>DSB"XJ2]Y,;,].06#U"(@O _3%1A'C/\.I& @7[DA(-VSU*+7+J![W0 M([>Z)&I""QUFF M278U1J\0-?=8B:X\P0@;5L)@";'^S/$ \2A\!X.[?7YV4$C"-4O6EDD:S67' MR6:9WEW:CU$R];AN6^'TZ3E0BXC0M5*,L3H?3FD%5']NH<=8?XX1VC'1OT_2 MIY&=&4/(XZPZ(CW#T]X',F8T4$##0!I((WD>-/"$U(OK#L32M"8"8B)7BV<.9@*B M\URHH$^ VL<,F_/B@A(DAI%!'LLS88-W7UP>(5EZ,\&[SY7FL^$\\.Z?#0MP M!Z>= ]9GQ@$Y$ 8R0!)'S?#_]>-7Z]_]X,*UPG#[W:&='>.1H ?6JV;Q3'XM MIBP(!\\?@.@ 1 GX ZM1M$]@O$"8(@.A 8MZZM9M7 MBAZX;#*-9[IHSCBI7FQ.L";%V\7'C0A#$\L9$0UPW08%1IA30ZL9ZK]!6HVM MCI?TP#2RA*OIV;!!&(D=!ZSX)I*>8.5W=E'#IA!F5V H4M3((8XSO2\6H%+S"\\-]@ M8+W !PS,YL]'>U@^0U L84X@7*]GEC(#$@;L6!JP$W& U+.1?)I,E%]&[EN*L MY069O6RJ%1RSKN8RG7Y.I9'=W*D\Q2?2A+EHEER<9/Y-B+?9C99:'%;K3L=2 M][H]1"KP] OT$*I=9-!V=T"]?UP' 9=/2Q:H*-^ZZRV)R.HPA2/W5JMDJC@1 M2=*M+#1=K56#,+&NFE57K9)0E:AB3,HBM%ABHP1?OK][=UQL6'5$?>F$MNN' MI\Z;/?ADR,0>CV$O?O?0??V/8&Z?-3C&_*'H*RF<6:DFO\ MYRH>CR:2081$ S_ UZFCIB3R@?EY(7D\.HJ31M%)+!K_6#G>%;P<1/!0_@-A0*]B<*"['M! M/0.(LH*&B3$U2L38B&XPI_Q\.ETE>S22BOG)70XX#4%N$\B- L_$JD*%?3R) M4[8#I(:H ;\^D5T6(QM?QY2$+Z_-#Y7NU9( WR)CC?UIU#'@(^JLDT6RCG$_ M[6GIS%,S@2.WL]-126YGLI0/V<7X9O;P32YBJ>E61UMS,-0A!:&:>9:L[0WI MB&DT@RNS5B74X-MI-)KM$N>DV==)N1AJ3<0ZCNB1T01+77>KM;ZB%DW\]X_- MI\9BW@HGY9>L"?2S@B@=^HSMJ=Y#(C< [2-HL!Y/D5X)_B3GUXZ#'?W MU@?I3@WC@?)=%;3ZE]/2;*7H?N9R9S+?R@OJUD M]+BTKVQ+"8XY5G"D+'PBM%:@>+RS2.3L!\:5;Y MX)-+RW"%E4O&C8 Y. +R^D*]4KW<\>$/I8:HOOINNR=\U6JZ-;!?YM3%Z(/K MFFU<:3VK 9O6=/V8*0*I)F73.:,&A.#\F^]9;2>U-88W->"7EO+4 M:4 _@O.#&D]=BIWR97D;=EMBJ@-\O\&H+W@;7U4(W29[.,:CF_F<"EPD6F/8 M"G"\VG2F>/14%8 D M)GBNEZ.;-YUE6XZ3]TE3VY2[&#N=[CQIRG-3K_]1[$L@ 1!K T135[Q7AEJ/&J M?896C&MF+]>D3*]V@"B;3FT+A! TWZ)NK.L'NP<8PN --NY K3TC&[]5 YAG MYI>K*?J3 #>5 8)$B.3%EH$^&"4?4B&R.X9"/)DSNR(%BC0$9!AL]%=%G_ 6 M(A)X]=W=S>$8^&_QEO76XKAM;TCL,;:8P=[Y,LUT<3$3!XKR%)?'%>>CV=-' M6=U.AC0L]D*[ J,,26%'P8'*0[+Q$O*?N$?ILRA )%1>1V"0(R:S(U(SOY8V MM60/Q5>MC.7>MIT3JCXBO9-6UL_\L5>+N6$D?30B0G;';)#=);3=*CU,,\P1 MD\,1.?VRYI3/NV4-[JIK2^[VMS ,(63?3]+]GO06I\48CDFRM3DOP<+?@UBL M7EM)1+M< )#Z-HHA'>O-5EICO\EFO\0FJY3;E>8J]U 0F,(05S0N%C+^>HK::AW_ M'QCX]!G[80+E W: M3SULA?S%.)A&%?'QA6QGT\1>*'72)]*[\C*BX:118/4 M3:_42L>!*=55+]82SY_%VE6N,L@,6%.Y]7(V)?75B[%KJ,,^U:8.NQ#N*=#C MT&\Q"J'RL:5&5-@O49?3.L^IIK'>GE Y2C?>Z>UA%ZGH2Q8<3# (YJ*&^!'^ MHG?[^!+4NU,41I:'M\-M#_[)HT\@=[PF=8#?;@O/8'>U3K%%9.(!?G+;;4'L M!,2"5>U=$^WP//I4-]A7> MSCO$>J/>9BAI OM[0%J]K1WA/K%;^@P*F[>V6W;KSHJ'&/Z'VWY_6>OS2@%8 M,8:C%[1>KYKP2/+"!7LD4B4TA_G5@%1 )"J_D$R@D\U=6.SD[_1A\.SS]&=- MNK7=$&RF@::HC<4*Z.MSL4+^O :LD!G#E5B+-E9 (M6S0E^_6E@!B=2,%?HZ M26>%F]\+(]R4!R*?8>9LH2UEU/#91AGED(Y$&7<>5S\B?UP]862V<*6^$]'7*SI;((EZD45?%UNXHD 5AK[XKX&M!?[E((V$_B?T/!?^BR^H9X"" M-5RI-&_A@ C+5,X"_3VC\P"1J1<3]'>SA0MN;LKK;4G'@6G-35?F: !J"W=4 MPSH6>[RWKIC1']> .=[YUV'6ZUD;;[PKG1L'=>)G-JAQ*8G9"ZEY6HY3C081KHBG;^NIDI*?_L+ MQ5 ZO)"V"%9/DM)Z5\55Q7F\]7:/D6__#9^&0@R'.,.)/KJ_4O-K:C*^T1:N M-#)J,""E=&))RA$APK]FF! OB[+_U.*S ORT)B<%5/1HZ8BTKO-^K*]KA#S^ MHW7&>KUN0Z#Z,X/CN!QW]6ZV7V]N;YYNKA[!]MLE>'RZN_B?_W)W>WGU$C@ M^&^_W3S]16G(( TO=-U1]4 [E$.P?]SQ?UYFT"$CG*&[=^ M_A2:LT2 AKV_2D91@%$,@!X08&^3JB\HA42/(]V&,:-#0Z=69YB+I)UIP,G/ M>@&%L25IBH5BX'Q#[K(V'X5GU< E-X CC6;SID8D%Z6\'>GM57%DY'LOGYY@ M<-"P,:FG& 4>E4"(F5%WGOW@WCV%#U;4M@K7$CT&?2Z#6>V*VF"/S(I'ZB>SZ:#()[$I;@M"I0?C3?/7 MEHW1_['=H7\@8%CN5S\(_'?'>[FPCNB7M2F]'@+D(YG#.N:";[/EU%RG&/<@ ML.-3(OM$!; R'> Y50+L1(MT&A@O D86@>2<3*H"Y#I I@2D6I10QWA1B/?M MYPY;;Y;CDM+ISQ828"LI#=T?W 7>X8V9FAZT!]-S/]0>7N$1J?WE7"]'AW(Q M2[O)N"L9Q5U)A+'6TUDR1I*]O2F-'3-&#,')V\&@RI[*#M8-^%KD$%WAU!FX M#*QWQ;W^.BS*G?V*MZJQFW%,U\11RRN*L%VU@Z<>X+38BN8'3K.&5/W\D3 _ MS?Y^JD -+2%I*&J,CC:H*MRPSO*%\>.JT93>Z,Z:8=D94-*JQ!?C8B$Z(8?? M)Y/=)Z4H*218)T+2*.B"C@O_<' B/)"\AO >HDQ 0\H7VAT\/!(48XAB%L]" MV6S9VD!-0*X#("4@UZ(/[,2$(>[%EKW%4S*Z0;$CF[O0V18L?0#[!CW+B_ \ M.T^[5GY/.3@+QG#EXJH3DK%D0$3KA,/^'L>S+"@M=P1\D9^ZO7T)("F^/@$[ M&-J!HTCU* =F1T)U;;HJ4+;*^^'QURC,>[1!T7@R,9JF\J M!FG%'*ZVI'W&90)RV>"2TKU3TWP.ZS*&J^W+"QVN*D59TU4P M[!'2!5^_6M^=P^DP9$A(%:$8?32[>'I@^=Y72EN0*%&^7T9"($I095C^5XG. MKK3N FMKR'3![@/$S36R;@AZ6X0HQB_=,I[>W'S:@>!,C=88%A:,>$:V,*4# MT(CY ;[Y[AL,=(-Q=X9W ;DC;KI N>D&JN[G%0.4ZX(DTHBT3["JN?%)M(?M M/5IU=T(QIU\7I/K>&B4*/9'S0J:)+JP0MNZ0J3TH%2]5[1QIM%QFDRZI%(#% M*-X9,] CD\\C>7B@)509"(W>"SK-493=7NV4\JC\$QJ-=C ?[%E-9].DPN'] M":MY@R"$-I[4Q@4@;-<*0V#9)$]L_W!T+7Q5SMYQX0XX'HA>(?CM\^-G?(=G M%#AV!"Z0C^@!/R"_NT"V!Y:;_QI3L>4ZZ/>>8X$?\3,_7*1R?_@)6"_H+V$4 MOXQ^;GEX20&]"AXC"+T)P-6,+Z[N)J0VQ;_ZGD5*;5W[(<+-!/\2B3Y ],SU M'380Y9T'8_/?G>BU*/=/(?+#LSS;00:BCX.\CV\AEW[$1,0G;*0IU=55->"Y#>R-WLR8SBC-N.*U M$B&>-3?G6JR)M"<;O5FOQ$(M4AY1PW *F3JXA4>5("37S[/+)#^*F.50+$B3 M;FYOKZK(Z/1*/C+JR=6,BDH,=$ $8\M1>E@A*KC7GU'W@XH+3=J- 9[1L*%5 MN]&4:&WX4-UF^-[.]VX\] 6?+>]O=_L]#. .;W*_O?EZ]] XFN1[5R9^6 SB MZ:HL%MFY7"089))!(CHND/$CD?Z3HF'+F,XGI0;1ZTK'+[V2M00ZYM@HPN + MWO!]"9^IAV"+C\A%5*:7AZVS_EEVH!U+4+33N;\/>94GQ6E?RX]*=I<=5)W$ M'44Q&YY4E-+\9227LT539N?[^W^-M]>.5A.=H1D8Z%ZI=L/1#TA?R]\#-_-X M1\&R"D"TE8!'ZX-,X-[M[P/'LYVCY=YX?X%6@&]49/C$[+(4 M08S90(XLW:SFS2#,E>&]&:DZG+R90CS#CE62JT?50W2L\! 0FU/3T 6GW$E/ M0S)?Q,X#ZRC'A.4*EJ4UUI%ZGA8IV_@Q!.M(Y[E@G3\\*=:GYX7U0M(/PWH: ML;/ .KF[3%2RQ,)T1CNQD"N?!33M1.F9X+U/@!+ &YNS GPI\P4#^ MW1>6+4B4UG!_]SER>;6@#*:YP/[NGPO4N8.3 GU]7D#/\WT8S)-X:0[R>)OX M#@9W^VLGM"T7VSX\9YK%Z@G^1ENY:R?4(/VM" B;"E% MK,Z$(EK1TI,NZ'%431W=5WPT/ZP(YGVNPY@9:TJ7_>J[[9Y(<5P=)\=[^VIF MOCZ-NK#U!H-G7X(_AEG^>#OR\3Q(=C[;Y74 74BFXUX3>EA4$4*4F(.W";;M MRVMZ5#(95/7S-$C+6B'SF JP++5;\X8[9O9P3"8V:"E6149C&'3 1?ONO.:' M%6*#?^?SFM++C9-([08]$)I^9V?FAAJ12>E1>A&=4N&AP1+XUT5I1HOAP?,F+!;%4L*A 6%(8JO5,1?D9B=@I*>;(G/4R.7*45C-3>PIBB!LFJQNRLK\Q88JI M7O=62%&)7^'.L2WWZN\GYXCGVK?>[C[PCS"@7M;%_)KL8A,,-C%GR=I8;C9Q MX8E$+("I7%+;X9A('OL.KR8 M6+@&]#'<99/K"VM#)"THI?((+5BCT,B-%VMXA,&;8\-O,+K;;VT$X).+KXJ^ MA,< V@XSE'G$J:8=#EM9DW4Q7T^7"QH=.5Z2GB",5:8;2JQ<*]@5U"HFJO$" M1"&P&R^A+)"H!$@GN-N#@E905*L!M8T7) KEU;)HTI5&D(SZ31$!06U@8C ME-14;.*H>/ %*^I+@Z*",R=W$'"POPZDU\41K(37&D0I9$>N]>SS^>,7=2,R M8A5S"B[7TQ5[CS<$+UBZ9AS5QV-V1B+2]>NI]O*:,HE7^\[:DDX)J\P4DX=* M"J$\0!S&ZNX2KE=U(Y7$+N9T6ZV6,Y.#5H)8OF;$TL]K=FI)Y&O9M^GI^YQU M/'<\'8[I9]>6;BI(9B:<8O!&H1PT3&3YJ/@QU52";&!.HNE\M: .HCP8*>8' M?E3)#\JP.OSMJBT=V(8$*S]11)3OD'*][AUSI&9D[Y(J*.38LSZ;I M,G@L0/4.N0%NF*QN2-LAUY0PI1UR-6]5Y#7"U(45OMX'_INS@[NO'[^%<'?C M7<=W^7@O6SMRWLBYZ'CCZ@G][.X(XROM::=\!@J5B)QAEK+GZ'R:%I3!:RE8 M)4AU@NKRZ M!#???@+W#W>_WURB?WS]"[B^^;;]=G'S[1>PO7BZ^?WFZ>;J427PQ2"JR!0" M0GY^U$+9SBM8^-E0#?>.T?ELF5[S+8YRE&VH51I$TK?XST4S3?MP1XBQ1K1S MX[W!,!+(6?#=7T:HQGHBE'UQ[-N$$D/9K_7#33HT?3)\8: MT4YBH=@>#:M0]33#:"E7^\Q&+YEF53V:GIPR3L1,:H_F[O[J8:L_P7#BB(%8 M> *MB%!N/-L_P-OZEJGF9^3"/5?,,U^X+$QWQ!+ CUC&3V ;18'S?(IP%1,0 M^>#>PJO8RK#9VSTS=>]'E_CE$$'*1DV]_5@R^R&1&NJ(J""]XJYRX':/)QJ> M507D'AW5A6'R 5J'OOQ@CV.,GPZXD?"#G[4!14?_FN*W&I"\;VW;/Y$Z.TDE M;A>&5U;@?FQW_A&WO:WK^!P"I,*)U2H>-EYERY+O(!6, N:" M@GHF*ZQ]/5XT8>%-UX#*UW$1XN<-WBU MWT,[NMO'#]]Y>'-@]'$7H"[(-@QA%!KQF'EP8(M:& M]Y$W-;/XKNK4/A ;B$]4)R\AC,9&8D%X3!#;J1MSJ8I_/*=_.%IQT )HNU88 M.GO')K--P-K]^RF,R(?8GI>W(OYTL]$":7F)ATJ%+?YYM=X +V6LQS)K3:6K3!)2M.BLB%1K@_Y\Z MN7$N@"P9/J%>]!ANO5WL3]CH4$@K'BE4M!;DQVXO#Q1G1C?7A:168:*;1G>A MPLJ-"H-'>.P!VIBHVN-W"=^@ZY-358T=:/4(Q4Q/%%SHF'VBXP M&B;S#/B']]*@]7(NB'M4WITD,UIB*$?]?4Q"X"6":=3>[M1B];WO.O9'_/\# MQE;-8O3@DD;;N-I@EC'3!,0:P!_)GSJ/CD2$Y#_52*@5!HP$0 ^J$LS[>+O0 M$49P^Q+ V,+V+3GT%V3BF&H%S^ITAMA,&LC%*2[!(E6\W@#WM7W(_1":N>;^KQ<$#4;P4'QIKG*,)0)R_:( M)O)^4K0Q6I!_>9$FX$>O, P%J,8,>T)5P%,2R"$U%/[=L+XN]O?.L]^<&E] MA/C\Q9-_8;DV*46+K\F^\<(H(+7.?K<"!W=U;SS$@S",'NIWAXJ2*KM:VW"3 M6;-S.=N8JV5YGQ[DVD&J'J3ZP8/TNUW5 M1,VDY9FRRG7B.")F %^@AH2X9$%N[@^,Y^ P'WL>DLK=!S:UB+Z,Y'$JA MT'FVLNE)%7#H=8#/6&^J@"@=SE*,BMX^+TF<63D M?0]P5Z.G-\Y1DHG!>29(2YRGUG'EL]D;YTC=>>"\9USH.)^>!\ZK:=\/YZ7H M:8WS)Z153(->D*0CTG/S.%(:_:?12;12^ Y\JTAG?OF%#@W>ZV9B"O9WT/D%%WO,;(BLO>4_/ !OD&/=2&M38 ZZ+=8Q3,P75!G MX9/%Z4S#)/X-2)1H@6QQ04@./N!;;'5:-6-(WA:P=H5' W3BD"<[4.J7^K*] MHPZ#94-X&H_%C 8[+#/=*349[Z9<3J -\K2IF4SOPX8M>\(48:XY)5M@UA < M)<_OC($2L""L^J 4%N ,]<8]9O*^$@EZ4<"KW= M*J!!*Q34DXH"A(KGRK!PZUC/CAO?HM*-AH:G9>.A;@)'ZBSFJR(B"K)T:!X& MN];01KBY3.40H>=:#2244*B#B>^]/,'@@ ^+L#4DPZ71#)Z\6LQ+D$'R M/J%T/I!C5)HT)D*<+(#'S9S4"CZM.5B'$#THRF#$>Z:ZXR798!)P^G@Q7:Z+ M>%)PQIH)4J)<+:#JQV08K\.55&S96,.4R%/7,F#5<8L5X\O:P(S_UB>4@QMF MN"F_XFH4[UL0J/0"++[,98>B\BNRT@6O:S]X@$>4)*]6"._V%_[AX'N/$;W* M%L.+$J'8;0U'(B[2*;GLP-7>#T NE]Q$020#(EHL_C:QMQY\L2*X:T.@>*?G MV.O$M1 + $$FF)1R"%$*A_L/]$LK.J&4_ #O3O3ZZKL[S%'H+7@XNOX'A,GK MS^1%4BW'"^,2ZD=DBM+^*7O*%W',&&R5&+[;D_( 87BR4! N_#"B[?-L>T,! M:AO,X,C3PG(G6 5U=N-F&L-39: .T^\'4"\X&8&VHQP1L]X7N] 'N'+S#$I_V)Q5820&:8X!' M3=&'5OBCI6PK !L#I@2!T,-=]5O$<2]6Y_W'M*=EHJW9!)Z13;HHD(@"N2S% M-5;%^&;V\$T:>MK3K829EF (*1%Y#P-,:C[D"S-B0J VT@'V2 F9(SEF M:O CN-JCY%J.8P;!J 3A;@]B%0#K %@)0%I K@8_@A4I*,\X9B#,UFP@R8!Z M,7$ND"105J&Q%^2S8HS\,13#4Z\?H6,[EH?OISJ%D7^ P0-T"?##5^?87!^= MZU7IW,1F%W-%T)5A;#8)*Z6B28_13H2#H"A]W&:>3D:C>&V4O=[B._!2KQ_D M>=U!/Z.X;M8_> _7Y3 /'XASSN$(G)+Q Y(%@P#NR)3WO170TQNYWRSU! MQ)B/KU9 VR'!^++,T06311P=\FP;:R8Y7B.: "0E026\+M*7KU ^<_X([IZ]=>4H;" MJB5<^6=2T!<+!;E4'1 WT--FI(6QIU:KIVH01TM,.M(:(Z0+PO#B%1>ZDA<4 M(RNV@B/7UHME.ZIBB?H@JI>'K6ARJ!ZJ1%(Y ;M05(B*>@21=I/ID\9/*L,, M4<]%S#2P$$D3C<#2Q[5FE/S#Y^ET:N2=O)\+S0\P)NB7^'\)F/X1>+X'M8-4 M*2/I6,J#)F:R)W#\X,F_A#89USV].D'T<>?!IW?_Z=4_A6B,^XC/MT<0-B_5 M])4B?0J(VT2.68/\.0<(-ZU MB(*XQ:6?T',07.WW,%YUO\0W,#V?(D!/*PUFFGHS2#[IU.^[B"3 7Y&[KTV* MKYR75R;R8Y6@B/@8S>-)^-6F0GI$!TY-7)U1#>&-XZ;1X":-Z5)%&A#=.,%H M(KE? FC%_(5XSOAL+'X>PG)9'I$RG]I0'"='5.F-YVNH&2#Y-H2[\!HY_I N M+H:-VQ&87I$Z9*+;P3[ 6"Y6BQ3JL3R DP#\F(L$_OXG!4OJ(_A)4$PV#AQ+ MS@;PS7??\%8>&PTYG CL+1L?ZE6["8XA-_)QS@0K/QXOVF5S MJ,L2D<:6L!70,41+*_Q]_7A"NK??G986J_--'3"8F\-#^58K" K@$_P>?75;2E?PB- !H0UV M<>3L,CO/V]IZY$K 'U@-('IT0^WP4)3@6XZ!EE!MR6LFS-(BIA5X6X_9M[^D M T Y3YRC/&1K/4/!FP@>N!&5 MOZ@#JC)KN+)MS30ZQ+(!$:Y;"]?7:Y8!8H?7RA%82UPF%)8CIA42Z3> M+ZB M _JX;L58&E.V%DW9]1\"_2SW(/]?ZW#\QWRY8 (\2$X_6[9].IQ<CJ3,4*K-I# M(V:W_.EPS ;UD>7E(>D[WFO6L":'(O-?#%;)-O:D9#"-BPTK)*]I7V@%T;F M12Y%_@!8B"MF_8.HVPU.PT"^X;O16Q4-V@,*;ML>@?SW$INJ3"D[9:^,35)$ MD;RL=$6_K_DFB_FRFI=:8A3;DK*'RO*VM31H\0G9NX>[*"CSTG<)MOAIS"?>.[=#6 MY1A>E KS+FO8LQJU($:*[E@J2,6"'PN"02)9T8U^PETV2R[O8AEJX<>:FV74 M,<5%!["U=QR;'U8(*MZ^V&JYI@));4%Y(9Z5\9+DEA;5Y-OSK TLRKNA27_A M@G07KI/>0@=.VMZ1"I<60SAR:S5?I*A)>T^Q1)"*5(X><8Z:_1V5AR:&I"R# MJBL^*K"%#[6&#[@\S0G^XON[AEGQUDO.-?KS,K%!,X(CBS:S9$$G%38! M!7&*%WA$.6CV"+5I[W =E.3-MV+5Z^[!TY(HWGJ%>X0FD\ MB],XUH^7D^S, K"'D"R36)D1X$"L(!O"Y!; M ) )Y.*GW @06T$NH"N$;9N$3?EV>=71-*M)6 C=@Q7!>+6N'.(0Y#? *=OM M- :K91NEA'\0-9V@U E<7K"5QYE>D=H5HMO!TUE8;"ITX<<73RJ'_0B.QD@^ M'5 [\8']1)E[M+R//X7@XA0$:<$^LF4!+TQ3JX7*ZR9UIV>YI]01*K482U=4 MTCNOOEJA8R-"N'3<4P1WG/#CDZ8$F5PF\N3RL@&TV3IB=C/LP@Q;,%J'L;X.R.&^I+Z/D'QXM_@.)6C]&-A[J9$!S;;MB33P&]T-/,#OPA M5TD<_O[:\9P(WCIO<'>#NE3>BX,,C*N!7)^B4P"W!S^(G/\@0YBK[T?HA9"+ M382H4$ Q(NSF@51:/['(.[$%GX@)(+'7%3A+B7/!+RS!P)T:!N[DB$^:S06JV,Y<:(9X^0A!.>SMCE->H0 MR/8Q*1UB8AO3\%X0F?)H_\++160V@U MF&<2R8(-,TW"/I9@\K_Q\-;@K%E")K0T4L2<]J3L(4\=L?,;RXJ7Y7PS-1L6 M 9Q,(W!)KQ.CH?0#)^\:641OTM,>2.QZ7\G488=1 M')O'%D;#9"$63V; 2YN+D0;MAN2B0U%= XAW)L, SP,BJ)^.:)3]U0\"_QU9 M^"=PY3H)\)."'.@%&SIO)$BXW;GQ\.V6?J#T?A]N,#3/"[)$6BW6?[50#Y!8 ME9\?[+%TQRA&"?+9;.,YR#:=U@D@UU(^I:OITM\H0:E203H.JX1&\?5#?9._ M&>(<@10\2/HUOATMKQG&,??5\:ZZP4^[80=W,6CBNU+ "%6U7A^ MF?4MZ>U]ITG,32 6)V'0HG@D>]T0SO.5EZTP^90 MA^6T]NF5$46LMRD&SZN AE:>T/>Y,NU(+W!X,A;CY!7HP(&NGVQW> M$X'/)N);OA/SN@[-\@F1CR]&R]A3,AEF* MQDLA&E8Y&C!6H_C@;J^\;P S3S"5 !SU:DD#C3OYT0<^\>![>,=$2V7A]G=D MPK?-$(X&9&,D!^)C.2 7I+0:L4CW3%[WI"&-)0%+P.J,BE(TOK/#UVO7? MPZYFL>T5%2AJL(.#Y.=9-S.51Q:0D41 1*IOWL3Y:?;W4SJN6A*R$5:TZ"A& MU;7C69[M6.Z]'SIX(H8=7?17U:",:@]'%LZF36C+)(-4M$ZH$^5W'7WHWJSTH-?^KVGG2Q4RW!A6D_ DDXXAM% 7.\RDB M2_&1#^ZM@+(Z/1P8G<7SAKJ97ST+FIQ5"Q!:II71T1@!/:#1V5FCOJ 4*GTZ M*%DE57;(:-!)$^2Y2?-<[6Q>9SZV TF#'AZ(>W^MA;WKS\F&3U$Y1^XL M-LO2#%PL1G'1[J$.Y6!(_&FOX2\5#4W)5 -!S75R0*Q,/6-A1COS#[>2<-(1]*5H-(6#QT0TWGN@?J\ M0LSTV+2_6:]75-"H/ZP@R,%FW.@$EO:C!JUA$+.O,-X[?;=_=%X\9^_8>!MC M?#S+\5[N?=>Q'1C>.AZ\B>"A.G/52X3T'8=\]C&GV'(Z,]*#!OD.]#!7DEZ@ MC;?9'!,ULD\=C.J[4?3];@\*2D"N!:1JP!]8$2":E.Q.'#48IN!@R-FYV _^ M^3;&'B&5R%OT^A H/B*;62KZF??BFU-SE98 2^_5!9:B0Q7#G# R)[ , ML%5Y6F*8)R:/)U(@2T% !LLF?X5"[VLW]+XJAMY7SF]MF+/IM ]\JV_*H9> M/R<,J4ZP0:^?)R:/)U*A][4#>E_'@EXW\A0#CY=C5YOEJM+D2>X/#[*\ C8- MH-;+#9/=#:DXZX#96"AKOM*[\1%5...\['JYF9K&I@*TD>_O[D1ZAC@0G1[IH#W973_K&",6\1F<*DI(T,K!W\AL#3W)6E M/B:SA:SH9FY0%E,C+?I$9 B1/'&O('>F#S>2&L=*4E4:AR;_.Z?\2&T/[_X M;U]VT,')/L=_P3D^+^0X^A%1ZW@OCQ^'9[_Z2>J_EY#5-:4<"6"NUWDZX]6A M6(+<1![J@,GFP-BY2TT.G+3-/BKA9Z3@;K_=^=T;J!L?EE58F]:$%1@XC?/BJ_!@CMVWZ(;^DC%JI$&5O"%O'&$#,A\PKM>I*;@YL&?FPORIY? M8+**->,6B_5\E:PY%1.NG&-)R2=@Q\(E3S>,X3 ;I:372H])+=1IAU'K VS M3D/-J,SEZT1$O;UFY**QO!9"1_V=[\%(9T$_=60S,E EE*))Z'<P])2DD* XSF7-WAJ([K]-5EKH-:0N.J3[@ M>. #:01[I%)=7VJ\N-0(C:C"&\#+S$;4@4P?N/$ U@BP2M4<-V)T>C">.34- M'7BN!WDTL1YO<%5Q($HP06F")9T!!R(CN+)Y,9P#D4K].9 _+H,Y$*D\%P[L M$9U^'#@])PXLD,<0#DR#JX@#GY \01W!6)3^+$CLY$KHA@DT3AJ,L$[M>;!/ M9(82(=%Y)DS8*SZ]J-#8G!$5ECAD !?FX55%AN^^H$1!@LZ "-]]KF1>#Z?! M=U]_$N2.RF *?/?/A0#Y8]./_M;G1'\Y:PPAOR2TTJGO >(='#L8X%+7H6VY MV)JAZ=(L5&=*;+28*]F7O>DQ2'7C1_=$.^%+C;E21+CZ\F:F&S\::R=$JCV) M"@E:/T)=G06AMG)1+W*EAUS%KB]L+F&KK>OZ[]C:KQ^7< ^# .Z>K._;,(11 M2S%_YMQ4(^%_0>7E%??_M&PRL%_CMA$\,H,ZFXY[03Q]?+?3Y[TY1&%D>/F5# M^9R\4B1BA],TCC2<+Y,N7*H")#I K 0/5V+YH*!@ A+5:H W;C@(*D?UK^L0 MP[C^+3O\DT4S/5%;Y* ^@=*(H&H&=M0.X1:CGJ*HMG$D[3H]6-V/HY17*1DY M-&8I-%82&ML_'-!H-(SCXN=:&B\8&AP$I/795QH&HSD.C %03'J=3,# >NV! MU)GVOEJA8P_,FEB&AH1'#&//9<.8+7JQ'=&C-\'U"05!-=4WW6!;RN0^F,U# MI#-@DY;UT@EMUP]/05S@7U#OI4.XAA!OMYBC'5LL^V ?/$"88AM#*0D3+=($?HW^A?ZR[,50O2/_PM02P,$ M% @ 5S-M2S/P>JXF*P @CH# !4 !I;F9U+3(P,3G\Y)4Q>V^S.ZFNV:2DF5KX\1M>6WW))N7*9J$).Q0 MA 8D;6M^?0!2$DD15Q(4*(@O,VT;EW,^XG)N..?'_WA;AF]_^(O9G]Y_^OS^3Z6_/* T"KZ>?2[]:HQ! M/F= R/EZ]NG#QS^??_QX_N'+TZ=/7S]\^/KYX_^56Z/5&L/Y(CG[9_]?LL9G M5RB*0!B"]=ED2]6_GMW>CM^?C<+P[($VCL\> "44!.\W8X5;!@EV4?S3NQ*7 M;\\X?(_P_.+3AP^?+[8-W_WA'\[RQE_?8ECI\/IYV_SCQ?]^NWWT%V#IG<,H M3@@UE8YT,%;7CU^^?+G(_IJWCN'7.!OE%OD9. H$GG%;T)_.M\W.Z:_./WXZ M__SQ_5LK$+S;_&Z!P>RG=S":I><4 M]0]?/G^@_?_I"OGIDJZ;*+B.$IBL;Z(9PLN,ZG=G=-SO#S<5\ND8\3I.P#); M2LEF 5[0MA?"X2[:$OM >O[R2-8XH'-,9[L%3$+T&M]$ <3 3]J1 M61^N-<57,/9#%*<8? ,!_4#7OZ5P1:<;1<$]1BN D_5CNEQZ>#V=[;=ILG7; M37@8AD=!D"UB+VQY3C6?S""CNXG(:;F=G_6[5@PJ3](Q8^8_G?HL!EF[H9?; M'#Z'8!3'((EW.V+L8;PF,MMH280DNHQ&/KD+TY <$@'Y'4[@[QDQY% +"*'D M!/;((/O#M0*D:]HZA-'\ZE";H #E:K4)R<1"0'L@NBLF>&J/E$B;T$)H M$-\#[%-!>-Y$ C(PJ6G&MT?) WA!(=%6+XDR$GQ?H>@288Q>B1"^$,(37[=$P1DE7$$W2A H6'ODO69$@GLYND1>UV]%* M$W3%$%ED*R]:Q^,4XUQ$ND71_ G@)6UFCB_)/$;/:JI7/'EOH).;1S*X04:* M_1^/$;FYHSD@VEYV--R2F>?9A.99;#&M0>9O41Q?>S@BT].C[W%!%-J[=$DM M8PA36JX (9XHP/3'Z8P<%-"GOX5A2J[ _#-M^[6"PR@A'0-D?C&HSV*2-4". M_0XVKVA.MM@]RF.4R]*GM#86T'R![)RIBNZ MM@C@^3@&.#9&2F]!JIJ[^H.883-<0285>\@MF@M!9#JB+T?DGWYFM,I/I1<0 MHE7^H_&=9&!Z,W:_.T1DY2>TLX3N#'5SVG1"Z'N$$BJP[U6H1T3R M)C?<$WA++D/D_]H FXX(Z1HE@8FL&S24)NP#UT]4IVAR^AJ9MFL$MO/>AUY& MQXZF8H]W\_VU)NX3"AVLAP;3=XW(OGVHZ^6@,E\/>.[@XZO/VC7_5 'O^COS MYK#$6P??4SQ3]VMX8Y?H?L,*)NJ:RY)I(K./EJP37?.M.7772.SKY-TPS9_% M&G\=[%S97%WSFJN*T]DM(!SSF\'WUAUSJYY?TR?8_!;2OYY35T5 M':F<_%FZYN\.O JL N,%$7D N4/*;2 9@DS<$11&"#H&U+:V@]ZAMR-L@^*J M9 BAP:P5.$DG$ 4TQB__+:7/4(AB-CN9G]!4F3*D@9P(5S_A9L8L6C,&_OLY M>KD( +P@7_4'^@_Z>7\X__!Q$ZOY3^17OXS(U$'FK@V]^7:XT'L&X4_OZG^_ MZ)R>C:MM0@X[+_P;\/!U%%R1+\L@C=M4C\KZPJ>_^67[64:,SS)ZCA/LT2"] M"E'J_;K'<4M&C@Z1$B *)N1W,0-(?MM#TTF_HAJ51!Z M_\&:P99['8'HX^H1BAZ3,A9G\G/\31-:( ] M?>7 )U;4Z5"43V ($BLK'D6O<(AM=KJ4+0]@#FD1UR4W'E+UEID-NN>NB?L MT6_TN%X^HY!!5O7O.WK*M_X(5VGSL+\=B/RS=N57GTQL6ERL,M?:N;^ X4Y: MF&&TU+D[ME0@QNX^0S@ .'NT\_'#AW=GA($9(+=D<)OSRB4PHRX!. 992]H3 M(DPH^.G=IW=G:4R80ZO<'W9<\.S)-P4^GP9\!'=;@=/G 2>AG%(@]<. E$3R M++#ZXX 5XUXJ\/G3@ ]?JBA@^O, DT#D+G#ZMP$GL7&A@.K+ !57U]BA1(3+ M 25%7;( K6N1_,>+?3-EY\9+Q3?*C16\F1<_9Y"D\?G<\U94R_OS!0B3>/N; MS'174ONK$)+;\^LT$7Q^[,:62/3LERK;2Q3J42J/MM;5"] MV1>95WCZ'&X>M4C EG3J$1]W*/*;L%+J9X>;>$'=BN1_-!3RQ0LS1V.R?>+\ MLQ>F^Y90O;Y6N"I$&B$#^\ULT'JU$:B>O+=\LTHO3%&/OG @W0Z23C;XV \/ M)11=O_EA2@7AOR 4O,*0)P0H=;7#T^9Y+J&(2WNIB0T:;Z'W#,/LZ2V'Q'(+ MRQ32=R3TP%B@,*!OH\G!E^S[L92[]9$7B4"AW-TR;^(CE-&P'_2JH]\'F:Y$ MCO3 9[>U0G7I%;QDF3!:VJ98#C2[L9&PHOWG5/\)PF""\",1_:8X?ZK)BBI2 MZ=8)?3=1/OICGI>1W'#362E9SQ588>##S>-,.=TZP]E8)]-D ;"*$LMH:)E> MZ;)FM[5&M?)5PVMMCW*=PT34PP8']UO[LU2Y8[6T0S'GQ2%?(A=VL<'# T@\ M&(%@^VRCHJUYJ.@:!_2ZB6W; MU,4FL=<6GC6W0F_DP*B+D@5&;H7<-,1(2YPML',K'$=]XXFOW@(?M^)PU/%1 M,W@6.+D5AZ..D\S 72#D5OB-.D(<16X'S">W(FYT[_XR$DW":!!U'!X!$APC M9AD018>CJR\!M/$2!]2X^B! &Z:JG\O5^']M6%@&05=#_K7!$7K>70WVUS^ M>*NGB5;1_XM,USU:ADKDSBL$ #=/ZE:X<2S2!68-CO$7@)^1RZ@I!*(5 +IY MU+>!3^@+*8!S\_0W=,JQ(1LN!@%D9:":V)WA5>\_KW'U;68SE&0A^ZZ^T&R&%C.LS-67F=7=U+.;XJ0N710(NFD\U9.LF %G.X@^NWE<:1HB:J^M"GS< M]-[HX<-]3US Y.I9I0.32I!A@=AP-K%#_@J$FIC\=.2$WN9KJ%: LO% .PS1 M*Z&.5G^]0NES,DO#NA]7\LQ<:PS+CVP)XE.M>4,[/:*K4Q?[C!,U-H=C9/E^*6T/2 MJ2]\"#>(H(/3SQ:.2*_5O&M=CRMK"J/JT>5ZP)D9_.I'I.L1:29QVQ[)K@>J M-<5,2?!V/7[- 'BB7>KFDQECH-6WJ)O^4F. L7-J=NXWM6NCR0L76K' +!%. MX.\9?Y2.ZCLGGLE%W,F.5AP3'.E;K,QKDS_[BQ]1R%?IN1WLT?\ 7D"4 HF* MPFYK)"U(9>CX/EVNRD\EZ9/3K( ZC%/FJ"BWL).BC]Z2MX2("9$]\C*W*5D(TQ7 ><#5)9@A M#'9E@$%\_4:0)5($$4GP^H9 A M.3%XK>U13A#>;)%+LH/X*Y77VE*RS.R#BT^$_58V*+T#2;'@.716VUBADHC0 M^?:CFXF2(D:6W]Y*8JDM*1LB>#C7VUFE5KHN6"VM4IP75=X[PK)?;D13&2/R M :PE)M/= I)._>-#:8@\Q.P M,9O:IEF-W)Y0*G-'(#;X M_!\ YPNJTK\0$N?@+ET^ SR=;=1DU: 1W5%ZQ&F-.,DWU1ZFS[R*;%EZ8]CT M)PCMH54' M_PZWH,@Q2D9C9=UT,7-.VHY=7&,1R['K1@$+&=:=?UH 6)K:T2 MGLX3"5W/3*F!$>>L84TN3ZS!KEBOL2XY1!.8TA-(9E/9<7NW2@#FU M?I1%?MO:2KE<=Y\TBM8_IY&H.ELPOZ'K =G/D ME$!S,P&=Q!7%U 04_.K.YT51AXWM2G6]H$U#@/:P:2).',&>:^2$W"O6(@@Q M<#W57'O\9$\>6F6B.PJ9K#V&HE UU/4M4=/&C3>+H?=*4#(B*-LE]"N_S=' MTV"')AKJOE^S40;F_J_##B'E1]L<+CVSW4>-M'+1)$2O1%D(( 8$/1OOZM2J M*#&C9=3Z6GDMV#57OWSJ$5_W@"ST@*B(]PH76[XL3P^E = M]/AP:+8^= ?O$2X[@=CD^E =U,I+"V]-Y8QX@O #6*787]#D^[-20@G>>PMY M1YO\$-$1/"-K'>Q:>$P*V57LY!K MK(-F+S&.R77?'=#BP]OUQQH=XBH2N)J]Z!@6K*IDWNSUQX"O2')P/9-E=XBV MMC[-[IJ1AR MT2I\>95]"T(93DX0O%\^M4QXD,-W'2G+HQ;BHZY@[( MED4!.?((#\GZ,5TN/;R>SO;;Z$50<7)\"R;F6+F5NQG)0;X_T7^",)@@G G8 M^(%^EU"%/E:W3NB[B?+1-[F'R/4UG55*TNYZVGJ"DNQ!-/.R]1?Q= 8FM5GK)U[A/JJQ(R" .:$ MWD0SA)?Y\C$AG)37X^;YUP/(5NH3JFE,#*E%J[^ET+ ,0NK7I9 6\(JCD.3] M;!H-E+G:[2R]#WTX,Y MP4"6;5&7EZ)CK_CAEP41=ND5#W3%7Z&E!_?-KSH]K<34^PL0I)L0&0Z%WG/( MK22BVOUH!%Q]8 KYULV\*AI7Q%X0EGROG"QVM4-<";J: =?-/&7-4#.GY+B? MT-+PNCRP::UGF-4O_S)H(HW-50]62\@8*KFK/JN62 G5:=>KW^C*KDI'65FH MV0+XP57QI!,$2U?(#L #(-@[XZ\!1XL9':\L#=VA:+5Y"U$+%9*W[Y7.?3I. M%X4/>2).EOVLL+N(S&W$*I'PTPS0DC:PEU@V(%3"&:3G6BW)K(W<:FBY2LD7 M>$2SY-6KL2BTC:OUM>*G@$3H!;?PA3X1J(+,^3(\_X7^0#WC]W+]S?L[PN/0 MBV.!/5UGA)YQ*+*L2[OUC)<"Z3MO*;;IZH[2,T[Y=G=))QM\T"3]KS"D.8GW M22IN!XE$H#>&D7C=&W+IS0HT,Q, %UN>8Z?-2#:^U1ZI#<]#W5%ZR.GUFQ^F M-+GP=N4U8[4^3 ]YU3@WFXQD:#&G@X-0>DT[1PM? VJM@ZW4G$;,Y%J M+,WZZG8V7K(3>+6,HUMHG=OR1J%M=RG&MNZ.Q1ICA6?:BI1E'IA&:Y-]I4)PGT(91695.I$CV;DV_P->'@" M:YD538S8LW [!KT/@$JN 2U+/B'+P LI[4:08(_G,?/!_M2#A_1>;X)F,-LD[O91TC%X3K$1L'1GFW%5T/X+"!:WZX MNQ[;80'97%P80CW, PNKJ9[=LA1; G9/V3ML-EA68[SU*F,.98V/-BN,,Y@]7AJO+N90YOBX G[FGWU: M0)RLR?")IDULLTN:>7U!/ZKY2T MR)J:Y:_A5.9P$,Y6$&7@,YN?R1P*WXCPM6C!FVI_,Q2O5B'TJ?^43#N'$=GV M[&..U/G&;Y%7B1X8+;?Q(9]:TRD4IA,/!^&1,P4O%=F-+1/K_ =+K.I M#9JIF*QL+.0TMD7W340(2+/,/?RUP6AHG]Y++X;Q(]&#O& :_>SA+",.W=\? ME;@0=+?/&UG4($\%I,1+J7D/:,?@MQ1$_GHZRXO 0G]3+UZ-%WYW^[S=$#F% M*-Y4R@37LQG(2K(3,GVJBL]Y7B"],?K%9;V"KR:+M0'L\R?-\,!M;I_V)ENJ M?_MHCR(B]D8^7-4*L&IV-B+77:<87:$P]#+1C2_<,=L9H6 "<9QD"BT(-$47_^6>N$3(FK' M/8+D%B%G*A\LQ9Y&J/ROU3>R8;R(X!"#2R_ZE4\6KZD1.FZI)80P7.:3:)PB M*/X/8,2GMMV G?"D1[!Y:B3[H=K S)SP&>'[,(WI52M@G=',T/P1V-,<=_Z" M2X0Q>H71?.RMR!^3-9LRG0&LE'PB%$YG.8V<^ZG2Q#:-"KH^MWE?:*>W1>1% MR1/ W#I!\GY]X>;Z;05Q7LQ!H)ZJ].P+1[=4SL!"&5K:K3>\2.I1B?OTA8MO MWAMSCY%GW/X1)(>>_%B$J+7"1$L,5CENOAT1@EB,:(W M@!F:YM1D"50?Q23U+?PRFF.8&.O/GC17%2DL_B[->J$YTBYA14*P0L* M7^A=7;W)A30+^]@IXDB$=K)8OT?Q"OAP!D$@%"WY[7(R&-F.H^?:B2M)&9D2&ZRE<1'$HNU0-M5-MA\HG M-Z/NM5"YK*'R^337BJ*T5L T+)ZH#HI;*0NU0&FBR>Z ^^$T-UVW8NA4B@)N;C'6Q\^XX5MMJ>)3K=YT<@;WUQ V) M+FXZ-U48)E*B-/6L#OQ(+]?S:AF!KQ:,Z7K6K%:HN9_Z2AF>)O'NKJ>WTEY; MJL_ 7$]?U1(XT1M;5PN1&;T%]AX8N%ISK-DAUSAADJOUQ0X'XUX>3S<5SP/ MN)>VT['*8IT!R@F-0>'Q?@#(H'2WXNY=)ZY?-'D858 W*!K";"(%4">N2K!WI3A%4P'>H$#PK5 ],25!/:6%>4K+*!KH!:0<_,9.0Z>-/%>@>#I: /]L:=I&"+$:5W'Z-.#$"8#<(O1Y0(C_\G@+T@\#2,QGKEM\_CC@(Q<; M#EGSV@Y:M0P9M7N^%CSE,A+59^QE+/:2$Q7RH)N&%AD:U21(12BKF]*Q-(/( M3M%531I;K!\W[4_JB+5,'%LL/3<]7LV!9*/DYG$E3$-3D1KY<+I^P?%2GO#D MQ5/$A9]<03'E8G&NNVD:%X/%SQE='$!=.XRM5[1\]!<@2$.B5Q2> 0I%/(J" M,5HN89*YB &(2P9&4R6C<@.PN&94I8W](DQ#T:@N:!Z*+_6U^-)QE8>A;Q># M[.VB,.MCK9GYD@?TAU!<>$/8OBN*4,J&1MZ^(XJFD19$1?..Z,D"ZG0H*G?H MBJ97824/?O.^)"N7E $4=ND+#Q5I2%KF3&>$OG!XN^^"5N"IZ-,7+@Z1&']( M.6H&ZJ[4JXFH33A^EO=A@B59 G7'^0V1:@L ;K^]K8A1F4]PO4W MMDTA8CG0''U2.V1 LY"HZH3>%0^)!Y6AJBEQ+8.PA_0Y#4P"IYA&IU%TJ+.A M:EH(\0,?3^KH:A2I/D1@#Z&A0[Q(FQ"(NB?>]9PK:D$T=6?BX5*HV(\+29=+ M#Z^GL[Q."\!$6 3!]Q6*\LQNA)GK$,XA07'D^S1Y0/P ? !?**ZC*+B):"T) MA-=ZP2)#R,8QA6SP,\,S@@08C@9L MK^EIFL0)H0M&\VWV#;;/2M;-MN--P==FG<:=QI9B>CFTJ0S.':(O/-;4V*-T MXSX >K01?-M\*\$@?>'S>.JX=UA?U[I5?W"^=EG#SU''T% 56:R87(\O#EL,""XHEC?HFA.:R_D M65'9!)>;V*:QV' /VY2N9.OM"I;<1'\#'J;A;PK,J(]U'%RCE&<*:3;647"] M24)NANU\L./@FV:Q-\0U&:KG/.?2;$ SHT[(Y>6%E.[V_+.'M85%LB'ZB4PF MWR-OB7 "?P=!%I<6QZD7^>#Z M;06BF'>&23H9P:\TQ\]>F((\2?IVJC&*DUA^P[89R187]1NSS4B6N&#=@*V& MLL5'[49K,=#!>5"YH0P-.O@=CM"Z(C;@M9:$AICYYI"6CI]3#)XW#.->42A' M7\!V#V0NG+C^3O8 .&:BZBFZ/)1Q;!LNX9 KVY3RC;J0+,'IP., M@OM8YUG% "3W/M9ZAC'@R+V/M0K9.HFCJGFP6W\&[VW=QN8VI?;>0!X>M *7R5AIFR9*V'&:@Y3,D:);9'A# MI@,;>S?J^%&=1$[;;JOE6QWLMB=RU@]VV\%N:\ENVWE&<*MVVYN(_!4\>6\@ M'@5D#V6$W40SA)?9Q#:,M=>S&? 3^%(01_, CE&4P"B%T7RZ C@CCF=XT1C MAGEA1Y6R15K4PRH'F_O[$D1@QDTTQFMM\UA0^ ;ETY/+L.L:JB9..EOW<#JK MU1.VR$$>YSC,0>3#K'[K+3EOY_G7[,O96Z(V*S!;(ECYM-(;PXY#:@O\V(N% M)OQZ0S,Y,2OCBDLL^>QDI?O=2T#S0KHEUI;,?A%%:YP2O9AHQ='\BES$2APPNMG@Y1YD.;^* M52W,8\EK;35+8Y.[M*JSLY>A\SH[]WJNFGYXE]%IX2.P:G#%#/=?GO$O>_8: MJEZPI[."6()%&2'N,>R\RU$JP_"/:M;-Z[JE0"PSB3;=J?@U&@!4W'_N%YQ2 MAT>P,T\FSR(%X=K#-'EI? _PXX( ?)?>!L0Y,B M)]O6EAPI."L>ZX546R0W(J4H'B4)AL]I0D_ )[3%&P3W^?O]$<8>.?LRS9+O M..P5FUCG4K)OF&WM4'U_P X7]"MFA?")I?%,WV0OUG^ M^?HH)5OG\*,[2H\XK1$G^73:P_295]$=I3=&G[G<+,-2? ,5"PU]9\G@-H5G MF315%I\YIY?K^JD.1*:6F^LV$AU,E<5/UVV3FG*X%$/W\U\91&RG&KB>ZTHH MHW*O _=K@C65#9M<#[7MJ9.?Z;0@-:$(NUX5N\.ERU<"VY74[O^+#+.:19-3 M@B7Y.!USSC)=]R8 &URF2V% 6;6-E7+.5+01K+#B[]:H$Y>6+K6P0>%C@OQ?IRMIZ&"] MG9$0[UTVK$EF!<1J=[.'> F+0O1\FOG- &O7[QEU!A'G^NFZ-IM6<:CYL[6'X :>M3KGK7FHH,!B$67RG.AI6:0+YT:#H;7]H&IV:'R.G$H (O-I(W M@J.*$)3391K2W#Y7@'#DP_P(B.[3Y>KZMQ2NEIQ$@HH];:BE8V\%J56<8C=] M#C>!WNR,F&I];'!!TZGL&;AO(K)R09P\\!\:RGI9>3.9+V*QD7>OD9DWX-F8 M0@/ ?A.#\W(5^/*?^Y"L=DBPVQW=FW0^J[48)#U4AT&E# MAL*NDISEKL8(\D2:$TZD*8*$O9J&-)DR2<[5.UM-@BTC)-%?#Q=7VP/3QZ._ M $$:@NELDB;DM]]@1&WK#UD-(Y1BHQSMQK/%4597U21+I0&M M\?2*C'*T'[#-]@>V8[%%;\DG7K$A[0. MF+R?;6Y4+UN]OKWEBG\--QZFS[QR+NC&P_285^[5W7R%-P_@XD>W]OC(1TX &/RM]_ M^=131%3$Y;:CN>G1[\3[JBDY=F.?.2AG M\G-HCL629-=VH8-R*Y4FN[8:'8Y;G;O2@$VI5Q$LK24*5^,Y3$*W=WBX&O)A M'K+2#>-J"(AQT$IBB*MQ(>8Q*T15UW-'&<*L+!ZXGE;*$&1M<\#T/]^.":!$ MYKUFR;:.JO:V 03EQK!VR;1.8QTJ6/Y:YL]R[>!C.:T+A'2T W=W+,8"T#=8?CIU'2 ]D'6!7:GYCLP$71? MH'=J;@0#CS *\$Y-93#P)J< []14A_8/,0KL3DU_:/J0K4"LB>Z@(Z4X].KP M/OM0"Y! (JG8R+5>L;!.9[<@C@'8579-L$T^MG#D+YI%B09 M:COJT84L]FH'&_NVAPL:L;JE'X /*OGD,&F61GY>U"2KX_L"0I1G ^EAE83Q M@N80I(1>8XSP&)%OY&?&:^6Z"0I#6,EXOR/PD5;J\' 0?U\%9&V2]G_\^&=A MPC:UOGWCZD\?OC3FJNAKA:O@[VF<9'MD@O =>"UO*!CY:'_Y/W-B(722),L,9I;.1!\O[8S'4D:MD)%7FI];%2N?NWE-S,-+TOB@@EPL_*;FNG_C/K1(C5#QB- 7K 7^D$J% H M.%%T1N@7AU.,+C?-,9/ %7,]F1$:9SO+&TRA?G%-R>";9[HH_:B-C M;N8C0G3+S79%_)7JK%F2Y4RT-8JA9*Y^H18+6;GE9(TU-^XQH<'*96MF3"N5 ME4!"+C80;//U"+)4]S'!AX",H=^]'O29UBT.US'&KL\7U_'^-U,@RONQ]XSIL M8KUTY]'@:8VNOXIH"$]=G76]A+90#ZY4;.$(!ZX_2=)7N2L5AIJ:!UU_'== MTQ=W:.\-6 MHM$[6S*N,T UM:PMP)\&@!4!UI)GMO!^'N!M#:_R3>I^J0DE.V@958[RY[K M++*T5@Y-M8@5UY._F("K%+;4+L]$_^'2M8E7"Y2QS5:'VY$60A+O4 +B)S2! M$0$+>N'N&,N#-*>S^_)'C )Q)5U"RV6(_%_M!B=NR5$.1:QUL.'.:84WF\-6 M0_;#[3"#>.MGMV^!2/8JR*CUSZ) M5WL_&-M-"6Y,QUA V-Z?R MERO+C'H #7M6"E*3RV_8N1K<--ZO+N[286_>D FC.22;+O?H]^0:_0M"P2L, MZ;MS/H62C:DWAHU-J@(^FS>5GC:W::/O5]ZR2M ,>Y:'C4$=^GT<(@8#\#B?P]XS]Z>PF %DX"IU[GT:YOMG)/#9V]6F<75M-%AAUN0-?C]EK?0&87^.%"\WIU M55V!Y[Y89JJD2,Y?3F,[V0O8$*H0WH_C3XQ\U7?.X?5$)3T.'O:,)(??1%+/ MQA@MES +BYP 0&_'U2J$/D7HFX?G,)H@?)UB%* P]##Y^_AYAG6\'P;&MRF? M36?T,VC)6\PN=GD@.XY^"K+C83+Q?!C"1"%P0;V_7>Z^>42*R"@BE*)H_@3P MLL%74QRFWU=!![O;=5%7_7[5V%"NOR5I IKJ/G4]FK0)=F*C^WB:PN ?X<>%9WLK[ MQ$AV+;>YE12:7"#5B._'MI-]@?;)H@],?)J4 M'89I0A^(:5EW]$8[ENW8&*T3W:S5D@@]$69;%: X.)TB\$2DB_KUNYR& M_# M=F(C8^\.['Y325UKE0I!V53; D$3A+F5@72<:T9FZ.?FZP3+$]VFC^ES#'Y+ MR3^O7^C/5F^[?6(D6Y3;W(IPR@52C?A^;#K9%Z@(F'R.3W0SB3)'1<$F03(S M$T]?,C.X6S;*R+=A\VYDZ'YDQ%L#V^'0: S>-FO&<'@<_/#(H%_G_VUQ M4+"'&UL4$L! A0#% M @ 5S-M2[[PX1W1&0 G*4! !4 ( !1KT &EN9G4M,C Q M-S Y,S!?9&5F+GAM;%!+ 0(4 Q0 ( %&UL4$L%!@ & 8 B@$ *U9 0 $! end

Large Accelerated Filer

Accelerated Filer

Non-Accelerated Filer

☐ (Do not check if smaller reporting company)

Smaller reporting company

Emerging growth company